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ABSTRACT 
Loss of glucose-stimulated insulin secretion (GSIS) from the pancreatic beta-cells is one of 
the earliest detectable defects in the pathogenesis of type 2 diabetes. However, despite its 
relevance, the mechanisms that govern GSIS are still not completely understood. 
ARNT/HIF-1β is a member of the bHLH-PAS family of transcription factors, with a 
prominent role in the transcriptional regulation of enzymes required for the metabolism of 
xenobiotics as well as regulation of genes that are critical for cellular responses to hypoxia. 
Recent research has uncovered a previously unknown function for ARNT/HIF-1β in the 
pancreatic beta-cells, where the gene was found to be 90% down-regulated in human type 2 
diabetic islets and loss of ARNT/HIF-1β protein leads to defective GSIS in pancreatic beta-
cells of mice. The main focus of this thesis was to understand the mechanisms by which 
ARNT/HIF-1β maintains normal GSIS from pancreatic beta-cells and understand how loss of 
ARNT/HIF-1β leads to beta-cell dysfunction and type 2 diabetes in mice. ARNT/HIF-1β was 
found to positively regulate GSIS in both INS-1 derived 832/13 cell line and mice islets. In 
the 832/13 cells, loss of ARNT/HIF-1β leads to a reduction in glycolysis without affecting 
the glucose oxidation and the ATP/ADP ratio suggesting that the regulation of GSIS takes 
place in a manner that is independent of the KATP channels. In order to further assess the 
mechanism of lowered GSIS in the absence of ARNT/HIF-1β in the 832/13 cells, a 
metabolite profiling was performed which revealed a significant reduction in the metabolite 
levels of glycolysis and the TCA cycle intermediates and glucose-induced fatty acid 
production, suggesting the involvement of ARNT/HIF-1β in regulating glucose-stimulated 
anaplerosis, which is believed to play a key role in the regulation of GSIS from the 
pancreatic beta-cells. The changes in metabolite levels in the absence of ARNT/HIF-1β were 
associated with corresponding changes in the gene expression pattern of key enzymes 
regulating glycolysis, the TCA cycle and fatty acid synthesis in beta-cells. In an attempt to 
understand how loss of ARNT/HIF-1β leads to beta-cell dysfunction and type 2 diabetes in 
mice, a pancreatic beta-cell specific ARNT/HIF-1β knock out mouse (β-ARNT KO) was 
generated using the Cre-loxP technology. Functional characterization of islets from both 
male and female β-ARNT KO mice revealed a significant impairment in GSIS, which was 
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attributed due to a small, but significant reduction in rise in intracellular calcium upon 
glucose stimulation. Further analysis revealed reduced secretory response to glucose in the 
presence of KCl and diazoxide indicating a defect in the amplifying pathway of GSIS in β-
ARNT KO islets. Expression of pyruvate carboxylase (PC) was significantly reduced in β-
ARNT KO islets suggesting possible impairments in anaplerosis and consistent with this, 
defect in GSIS in β-ARNT KO islets could be almost completely rescued by treatment with 
membrane permeable TCA intermediates. Surprisingly, both male and female β-ARNT KO 
mice have normal glucose homeostasis. In an attempt to assess how β-ARNT KO mice 
maintained normal blood glucose levels, indirect calorimetry was used to understand changes 
in whole-body energy expenditure. This investigation revealed that β-ARNT KO mice 
exhibited a small but significant increase in respiratory exchange ratio (RER), suggesting a 
preference in utilizing carbohydrates as a fuel source, possibly leading to improved glucose 
uptake from the blood stream. Response to exogenous insulin was completely normal in β-
ARNT KO mice suggesting intact functioning of the skeletal muscles. To conclude, based on 
our in vitro data, we believe that ARNT/HIF-1β plays an indispensable role in maintaining 
normal beta-cell secretory function, however, results from β-ARNT KO mice indicates that 
these mice are protected from the adverse effects of hyperglycemia. Although loss of 
ARNT/HIF-1β alone is not sufficient for the genesis of type 2 diabetes, it creates a perfect 
storm in the pancreatic beta-cells that may eventually lead to an imbalance in the whole body 
glucose homeostasis. Our study provides significant information to the scientific community 
that engages in assessing the pharmacological potential of gene targets for the treatment of 
type 2 diabetes. 
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Chapter 1 
Introduction 
1.1 Rationale 
Diabetes mellitus, a disease originally described as a condition producing excessive thirst 
(polydipsia), excessive hunger (polyphagia) and excessive urination (polyuria), has been 
affecting human lives for thousands of years and was one of the first diseases recorded in the 
ancient literature, dating as far back as 1500 BC in the Egyptian manuscripts (1,2). Around 
the same time, physicians in India reported that urine from people presented with the above 
clinical symptoms attracted ants and flies and named the condition as “madhumeha” or 
“honey urine”. Although diabetes mellitus has been recognized as an illness for centuries and 
physicians in different parts of the world have been treating the disease with various 
efficacies, the prognosis for the disease in those days were shockingly grim and the disease 
was generally considered as a death sentence. In 1889, Joseph Von Mering, a German 
physician and Oskar Minkowski, a Russian scientist, discovered the role of pancreas in 
diabetes, when they observed that pancreatectomized dogs displayed all clinical symptoms of 
diabetes mellitus and died shortly after the pancreatectomy. However, it was not until early 
1900s that an effective and life saving treatment for diabetes mellitus was discovered with 
the advent of the hormone insulin from the pancreas by Canadians Dr. Frederick Banting and 
Dr. Charles Best. Ever since that historic moment in 1922, scientists across the globe have 
been working relentlessly to understand the causes and the pathophysiological abnormalities 
associated with diabetes mellitus, generating a wealth of knowledge in the field. This new 
found knowledge about the disease has led to the discovery of many new treatments options 
for diabetes mellitus in the 20th century and has improved the quality of life of thousands of 
diabetics, who otherwise had a very grim prognosis.  
Despite the commendable advancements made in diabetes research in the last century and a 
half, the complex and multifaceted nature of the disease has made it nearly impossible for 
scientists to understand the exact nature of the causes and consequences of the disease. 
Although scientific discoveries have led to effective strategies for the prevention of diabetes, 
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pathway to cure still remains an elusive dream. The clinical presentation of diabetes has also 
tremendously changed from a century ago to now, from severe insulin deficiency being one 
of the critical symptoms, to the current clinical presentation, where insulin resistance 
associated with impaired insulin secretion plagues the vast majority of diabetics. The fact that 
these clinical symptoms are a consequence of over-eating and obesity has made diabetes 
mellitus a global epidemic and one of the leading causes of reduced quality of life and life 
expectancy in the 21st century.  
In the past century or so, dramatic advancements have been made in the understanding of 
metabolic regulation of insulin secretion and maintenance of normal glucose homeostasis in 
humans. The fact that impaired insulin secretion is one of the most clinically relevant 
abnormalities presented in the current generation of diabetics and the ballooning population 
of diabetics across the globe, makes the research in unraveling the mechanisms that regulate 
insulin secretion from pancreatic beta-cells more relevant than ever before. Although, the 
basic mechanisms that govern insulin release have been well studied and some of the key 
metabolic pathways involved in the secretion of insulin have been discovered, the exact 
nature of these pathways and the identity of the metabolic signals that control insulin 
secretion is still not completely understood. Therefore, a complete understanding of these 
intricate processes is critical in finding better treatment options for the prevention or cure of 
diabetes. My thesis is an attempt to broaden our understanding of the metabolic control of 
insulin release from the pancreatic beta-cells and how it helps sustain normal glucose 
homeostasis in mice. Insulin secretion can be regulated through different ways in our body 
and it is a well-known fact that dietary carbohydrates, specifically glucose, are one of the 
major regulators of insulin. It is therefore necessary that we gain a better understanding of the 
mechanisms that govern glucose-stimulated insulin secretion (GSIS) and the key regulators 
that play a critical role in governing these mechanisms. Specifically, my thesis will examine 
the role of transcription factor, aryl hydrocarbon receptor nuclear translocator 
(ARNT)/hypoxia inducible factor-1β (HIF-1β) in the regulation of GSIS and maintenance of 
normal glucose homeostasis in mice. However, before I delve into the details of my research 
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topic, the following parts of this chapter will focus on providing the required background 
information on research in diabetes.  
1.2 Pancreatic Islets of Langerhans and Insulin 
The pancreas is a soft, elongated, lobular organ that is located on the posterior abdominal 
wall, close to the stomach (3). It has both an exocrine part and an endocrine part. The 
exocrine part of the pancreas, known as the acinar tissue, is formed of zymogenic cells and 
secretes digestive enzymes. The endocrine part of the pancreas known as the pancreatic islets 
or the islets of Langerhans, synthesizes and secretes hormones. Human pancreas has roughly 
one million pancreatic islets (4). Each islet is a heterogeneous population of 5 kinds of cells 
namely, alpha-cells, beta-cells, delta-cells, epsilon-cells and pancreatic polypeptide cells 
(PP).  Alpha-cells secrete the hormone glucagon, beta-cells secrete insulin, delta-cells secrete 
somatostatin, epsilon-cells secrete ghrelin and PP cells secrete pancreatic polypeptide. 
Among the different kinds of cells, beta-cells are the most prominent cells as they occupy 60-
70% of the islet volume. Interestingly, different types of cells in the islets are distributed in 
an orderly fashion, although the pattern of distribution is different in rodents and humans 
(5,6). In humans, beta-cells are scattered across the islet, whereas in rodents, beta-cells form 
the core of the islet, surrounded by a ring of alpha, delta and PP cells. Human pancreas is 
abundantly innervated and rich in blood supply and the islets were thought to be innervated 
by both sympathetic and parasympathetic nerves. However, recent studies demonstrate that 
human islets are scarcely innervated and the innervation pattern is quite different from that 
observed in mouse islets, which were found to be abundantly innervated (7). Compared to 
mouse islets, the axonal density and axon contact points are relatively sparse in human islets. 
In human islets, a few parasympathetic cholinergic axons penetrate the islet and the invading 
sympathetic fibers preferentially innervate smooth muscle cells of blood vessels located 
within the islet. Thus, contrary to the age-old belief that the autonomic nervous system 
regulates hormone secretion directly from the endocrine pancreas, recent discoveries by 
Rodriguez et al (7) suggest that sympathetic nerves may regulate hormone secretion in 
human islets by controlling the local blood flow within the endocrine pancreas. These unique 
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differences between the human and rodent islets make one wonder about the functional 
implications it can have on the islet cell function.  
Islets of Langerhans were first described by Paul Langerhans in 1869 (8), however, the 
hormone insulin was not discovered until 1921 when Nobel laureate Dr. Fredrick Banting 
along with Dr. Charles Best from the University of Toronto established that pancreatic islets 
secreted a hormone, which when delivered systemically, was capable of curbing 
hyperglycemia in diabetic dogs and can be used for the treatment of type 1 diabetes (9-12)  
Insulin, often called the “miracle drug” of the 20th century, soon became the elixir of life for 
children and adults dying from diabetes. Decades after the initial discovery, the amino acid 
structure of insulin was characterized by Frederick Sanger in 1951, for which he was 
awarded the Nobel Prize in Chemistry in 1958 (13,14). Compared to other macromolecules, 
insulin is a small protein made up of 51 amino acids and consists of two polypeptide chains, 
named subunit A and B held together by disulphide bonds. Insulin serves several important 
functions in vertebrates (15).  It is the master regulator of glucose and lipid homeostasis and 
is secreted primarily in response to a post-prandial hike in blood glucose concentration. In 
addition to glucose, other fuel molecules such as amino acids, hormones and some neural 
stimuli can also stimulate the secretion of insulin from the beta-cells of pancreas. The 
physiological role of insulin in maintaining whole body glucose homeostasis is associated 
with its ability to promote the uptake and storage of glucose by the peripheral tissues namely, 
the skeletal muscles, the liver and the adipose tissue. Insulin also inhibits the production of 
glucose through glycogenolysis from the liver in its attempt to maintain circulating glucose 
levels in the normal physiological range. In addition to its role in maintaining glucose 
homeostasis, insulin also serves as an anabolic hormone by promoting the uptake of amino 
acids, contributing to DNA replication and protein synthesis. 
1.3 Diabetes Mellitus 
Diabetes mellitus  (DM) is a metabolic syndrome characterized by chronic hyperglycemia 
resulting from impaired insulin secretion from the pancreatic beta-cells or defective insulin 
action on the peripheral tissues such as the skeletal muscles or a combination of these 
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abnormalities (16). Chronic hyperglycemia can have serious impact on different organs of 
our body leading to both microvascular and macrovascular complications. Some of the 
devastating side effects of prolonged hyperglycemia are hypertension, high cholesterol and 
high triglyceride levels leading to cardiovascular diseases and stroke, diabetic retinopathy 
leading to complete loss of vision, diabetic nephropathy leading to kidney failure, peripheral 
neuropathy leading to foot ulcers, amputations and sexual dysfunction. With an estimated 
347 million people afflicted world wide, the World Health Organization (WHO) predicts that 
complications from diabetes will be the 7th leading cause of death by the year 2030 
compared to its. Aside from the obvious personal cost to people with diabetes, which 
includes reduced life span, the financial burden associated with treatment of diabetes to 
patients as well as governments across the globe is humungous. According to the Canadian 
Diabetes Association, by 2020, diabetes will cost the Canadian healthcare system an 
estimated $16.9 billion a year. From a clinical standpoint, DM can be classified into three 
main categories namely, type 1, type 2 and gestational diabetes. The pathophysiology of type 
1 and type 2 diabetes are described in detail in section 1.3.1 and 1.3.2. Gestational diabetes, 
characterized by the classical hyperglycemia, is first diagnosed during pregnancy. Unlike the 
other two forms of diabetes, gestational hyperglycemia is a temporary phenomenon and most 
women are relieved of symptoms at the end of their pregnancy. However, women with 
gestational diabetes are at greater risk to develop type 2 diabetes at a later stage of their life 
(17). 
1.3.1 Type 1 diabetes (T1D) 
T1D, also known as juvenile diabetes or insulin dependent diabetes mellitus, is caused by the 
autoimmune destruction of the pancreatic beta-cells (18). Representing 10% of the diabetic 
population, T1D leads to a complete lack of insulin production, leading to chronic 
hyperglycemia in patients. One of the hallmark features of T1D is the infiltration of the islets 
by cells of the immune system, leading to inflammation and a condition known as insulitis. 
Markers of the autoimmune destruction of the beta-cells include autoantibodies to insulin, 
glutamate decarboxylase 65 (GAD65), and autoantibodies to the tyrosine phosphatases IA-2 
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and IA-2β (19,20). In 2008, Ludviggson et al showed that subcutaneous injection of GAD-
alum, an adjuvant-formulated vaccine incorporating human recombinant GAD65, preserved 
insulin production for up to 30 months in type 1 diabetics, who were screened positive for 
GAD autoantibody (21). Although administration of GAD-alum slowed down the loss of 
residual beta-cells, it did not change insulin dependency for these patients. Usually, 85-90% 
of the type 1 diabetics will have the presence of one or more of these autoantibodies when 
fasting hyperglycemia is initially detected. The risk of developing T1D is strongly related to 
the number of autoantibody markers, where the presence of two or more autoantibodies gives 
a higher probability of developing the disease than the presence of a single autoantibody. In 
T1D, it is generally believed that the rate of beta-cell destruction is quite varied, where 
infants and children are observed to have a rapid rate of destruction compared to adults. 
Although, it is most commonly diagnosed in children, T1D can occur at any age of human 
life.  
Despite the significant advancements made in T1D research in the last several decades, the 
exact mechanisms underlying the initiation and progression of beta-cell destruction are still 
very poorly understood (22-24). Most of our knowledge on the pathogenesis of T1D comes 
from studies conducted in animal models of T1D namely, non-obese diabetic (NOD) mice 
and the biobreeding-diabetes prone (BB-DP) rats. Even though we do not know what triggers 
the infiltration of islets by the immune cells, it is generally believed that beta-cell 
autoantigens, macrophages, dendritic cells, B lymphocytes and T lymphocytes are all 
involved in beta-cell autoimmune destruction. One of the major obstacles to unveiling the 
molecular and cellular basis of disease progression in T1D is the lack of availability of 
pancreatic specimens in which islets are undergoing autoimmune destruction. Currently, the 
only effective treatment option with guaranteed results for T1D is daily doses of insulin 
injections to keep the blood glucose level in a normal and healthy range. However, a method 
that has also gained a lot of momentum in the last decade or so is the process of islet 
transplantation for people suffering from T1D (25). Several islet cell transplantation clinical 
trials are underway across the globe. Although the process has a promising future, as with 
any organ transplantation procedures, the related complications such as immunogenicity, 
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decline in graft function and continued dependence on exogenous insulin injections for 
maintaining normoglycemia, all point to a procedure that requires a substantial amount of 
improvement before it becomes a mainstream treatment option for type 1 diabetics.   
1.3.2 Type 2 diabetes (T2D) 
T2D, also known as the non-insulin dependent diabetes mellitus or adult on-set diabetes, is 
characterized by hyperglycemia due to insulin deficiency or peripheral insulin resistance or 
both (26). Representing 90% of the diabetic population, T2D has now become a global 
epidemic, affecting millions of people world-wide. Pancreatic beta-cell dysfunction is one of 
the hallmark features of T2D (27). A decline in beta-cell function as determined by changes 
in glucose tolerance from normal to glucose intolerant and loss of glucose-stimulated insulin 
secretion, particularly the first phase of insulin release, are some of the earliest events in the 
progression of the disease (28). The failure of beta-cells to secrete a sufficient amount of 
insulin could be attributed to several factors, the two most prominent being, abnormalities in 
beta-cell glucose metabolism and a decrease in beta-cell mass (29,30). Under normal 
conditions, pancreatic beta-cells have an incredible capacity to increase their mass to adapt to 
changing insulin demands of the body such as in pregnancy or weight gain. Beta-cell 
replication, neogenesis and hypertrophy are the factors that contribute to increase in beta-cell 
mass in humans and rodents (31). In pre-diabetics or people diagnosed with T2D, beta-cells 
fail to increase their mass and compensate for the increased insulin demands. This leads to 
progressive elevation in plasma glucose levels, culminating in overt diabetes. Persistent 
hyperglycemia also leads to further decrease in beta-cell mass due to a phenomenon called 
glucotoxicity. Glucotoxicity often leads to beta-cell apoptosis as observed in the pancreas of 
type 2 diabetic patients, where neogenesis or beta-cell replication failed to compensate for 
the loss of cells. 
Another hallmark feature of T2D is insulin resistance. Insulin resistance is a condition in 
which the peripheral tissues, namely skeletal muscles, liver and adipose tissue, which are 
highly insulin responsive under normal conditions, become resistant to insulin, leading to 
delayed clearance of glucose from the circulation. Insulin normally regulates fuel 
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homeostasis by promoting the uptake of glucose by the peripheral tissues, inhibiting the 
release of stored lipids from the adipose tissue and inhibiting hepatic glucose production (32-
36). One of the main factors contributing to insulin resistance is obesity. Obesity due to 
oversupply of nutrients and physical inactivity is strongly correlated to T2D. Under normal 
circumstances, excessive circulating glucose is taken up mainly (80%) by the skeletal 
muscles and stored as glycogen. It is therefore widely accepted that skeletal muscles are one 
of the major sites of insulin resistance in T2D, although liver and adipose tissue could also 
become equally resistant to insulin. Insulin stimulated glucose uptake by skeletal muscles 
and adipose tissue is a well-studied signal transduction pathway in humans and rodents. In 
healthy individuals, in response to rise in circulating glucose, insulin is secreted and released 
into the blood stream from the pancreatic beta-cells. Binding of insulin to its receptor on the 
muscle plasma membrane, signals the translocation of the muscle glucose transporter, GLUT 
4, to the surface of the plasma membrane, facilitating the uptake and transport of glucose into 
the muscle cells. However, a number of studies have reported that the insulin-signalling 
cascade that is critical for the transport of glucose into the muscles cells is impaired under 
insulin-resistant state. In addition, fatty acids are also known to cause insulin resistance in 
humans and rodents, although the mechanism underlying lipid-mediated insulin resistance is 
not completely understood.  Fatty acids are generally stored as triglycerides in the adipose 
tissue. However, in obese individuals, due to oversupply of nutrients, triglycerides 
accumulate ectopically in tissues such as the muscles, the liver and the heart. In skeletal 
muscles, excessive accumulation of triglycerides interferes with insulin signalling and 
translocation of GLUT 4 to the plasma membrane, thereby impairing the intracellular 
transport of glucose and rendering the muscles resistant to insulin. Fatty liver, a condition 
that is often diagnosed in insulin-resistant individuals, the liver becomes largely resistant to 
the actions of insulin, leading to its inability to inhibit gluconeogenesis.  In addition, adipose 
tissue also releases hormones and cytokines, which are also believed to contribute to insulin 
resistance in animals (26). It is therefore widely accepted that perturbations in both lipid and 
glucose homeostasis along with beta-cell dysfunction leads to chronic hyperglycemia 
manifesting in T2D. 
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Despite the remarkable advancements made in understanding the molecular, genetic and 
biochemical factors that cause beta-cell failure and insulin resistance in T2D, the underlying 
mechanisms are still not completely understood. It is generally accepted that T2D is a 
polygenic disorder in which a complex interplay of genetic and environmental factors 
contribute to the pathophysiological abnormalities presented such as reduction in beta-cell 
mass, insulin secretion, insulin action and obesity. Through traditional linkage analysis and 
genome wide association studies (GWAS), approximately 25 genetic loci harbouring 
common variants that were related to T2D were discovered (37). Unlike T1D, where the 
genetic risk is mostly associated with the human leucocyte antigen (HLA) region of the 
major histocompatibility complex (MHC) on chromosome 6, the genetic component of T2D 
risk is not concentrated in one specific region and the pathophysiological abnormalities 
appear to be the result of the interaction of multiple genes scattered all across the genome 
(38). The role of environmental factors such as obesity, sedentary life style, small or large 
birth weight and stress, on the development of diabetes has been well studied and well 
established. However, it is important to understand that even with the same environmental 
exposures, some people are more susceptible to developing diabetes than others, and this 
increased risk appears to be genetic in nature. 
Type 2 diabetes management, like the disease itself, is multifactorial.  Obesity and sedentary 
life style being the root cause of T2D, life style interventions designed to impact physical 
activity and food intake are critical to diabetes management. From time and time, research 
has shown that maintaining an appropriate and stable body weight and body mass index 
(BMI) is critical to improve glycemic control and decrease cardiovascular diseases. Even a 
modest weight loss of 5 -10 % has shown to improve glycemic control dramatically in obese 
people with T2D (39,40). In addition to life style changes, pharmacological interventions are 
used to manage hyperglycemia in type 2 diabetic patients (41,42). Medications to improve 
insulin secretion, such as sulfonylureass and meglitinides, those that improve insulin 
sensitivity such as metformin and thiozolidinedions and those that can slow down intestinal 
carbohydrate metabolism such as the α-glucosidase inhibitors are some of the different 
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classes of drugs that are used for the management of hyperglycemia in T2D. However, due to 
progressive beta-cell dysfunction that is characteristic of T2D, insulin replacement therapy is 
ultimately required to sustain glucose homeostasis in type 2 diabetic patients.  
1.4 Maintenance of Glucose and Energy Homeostasis 
Regulation of glucose and energy homeostasis requires the release of appropriate peptide 
signals from the pancreatic islets, the adipose tissue, the stomach and the gut. These peptide 
signals interact with the brain and ensure a perfect regulation of energy homeostasis and the 
brain in turn influences the secretion of these peptides. The human body requires the blood 
glucose level to be maintained in a narrow physiological range of 70 - 100 mg/dL (equivalent 
to 3.8 - 5.5 mM). The tight regulation of glucose homeostasis is achieved not only by the 
actions of insulin, but by the opposing actions of both insulin and glucagon. In response to 
the postprandial rise in circulating glucose, insulin dampens the rise by promoting the uptake 
of glucose through peripheral tissues and by suppressing the production of glucose from the 
liver. On the other hand, glucagon prevents a critical drop in the blood sugar level 
(hypoglyceamia) in between meals or during fasting by promoting glycogenolysis in the liver 
and mobilizing glucose from stores inside our body (43,44). Thus, the interplay between 
insulin and glucagon keeps the blood glucose concentration constant throughout the day.  
Although insulin is the major regulator of energy reserves in our body by promoting the 
uptake and storage of glucose in the form of glycogen and triglycerides, as mentioned in the 
beginning, the brain, the gut and the adipose tissue also play a critical role in maintaining 
glucose and energy homeostasis. The key to maintaining energy homeostasis is the 
underlying basic principle that food intake should match energy expenditure. Any deviation 
from this basic concept, such as an imbalance between intake and energy expenditure, results 
in either weight gain or weight loss in humans and rodents (45). The ability of the brain to 
regulate energy homeostasis depends on its capacity to sense insulin and leptin (46,47). 
Leptin is a hormone that is secreted by the adipocytes and acts on the brain to regulate food 
intake and body weight. Both insulin and leptin are commonly known as adiposity signals 
because they are secreted in direct response to the body fat. The brain has both insulin and 
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leptin receptors located in several regions, however, they are most abundantly present in the 
hypothalamus. In response to the postprandial increases in insulin and leptin levels in the 
brain, the brain sends signals to the liver via the autonomic nervous system to reduce the 
hepatic glucose production. The importance of insulin and leptin signalling in the brain was 
supported by several studies. Administering insulin or leptin directly to the brain reduces 
food intake and weight gain, whereas reductions in either insulin or leptin within the brain, 
have an opposite effect (48). The brain also signals the gut to secrete duodenal peptides such 
as, cholecystokinin (CCK) and peptide YY to decrease food intake. Peptide hormones such 
as those secreted from the intestinal cells like glucagon-like-peptide 1 (GLP-1) and glucose-
dependent insulinotropic peptide (GIP), commonly known as the incretins, in addition to 
coordinating digestion and absorption of nutrients, also augment the post-prandial increase in 
insulin secretion and decreases food intake. The gut hormones are generally secreted 
proportional to the quantity and quality of calories consumed and function as satiety signals 
to the brain to limit meal size. Ghrelin, secreted from the P/D1 cells of the fundus of the 
stomach and the epsilon cells of the pancreas is the only hunger-stimulating hormone, 
stimulating feeding and secretion of growth hormones. Ghrelin stimulates appetite and 
induces a positive energy balance leading to body weight gain. Leptin and ghrelin are 
complementary in their action, reflecting acute and chronic changes in energy balance 
(49,50).  Thus, in general, if the brain senses a caloric shortage or surplus, it generates 
responses that alter food intake, nutrient storage and physiological functions such as hepatic 
glucose production, adiposity and thermogenesis. Maintenance of glucose, lipid and energy 
homeostasis in our body is largely dependent on the ability of brain to interpret and integrate 
neuronal and hormonal inputs. Disruption or failure of any of the key components of brain-
gut-endocrine-adipose tissue axis will lead to pathophysiological abnormalities resulting in 
metabolic disorders such as obesity and type 2 diabetes (Figure 1). 
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Figure 1: Role of the brain and the peripheral hormones in the regulation of food intake and energy 
expenditure: The brain integrates both the neuronal and hormonal inputs to determine food intake and energy 
expenditure. Adiposity signals (long term) such as insulin (pancreas) and leptin (adipose tissue) interact with the 
arcuate nucleus of hypothalamus decreasing food intake and increasing energy expenditure. Satiety signals 
(short term) such as the GLP-1, GIP, Cholecystokinin, Peptide YY (Small and large intestine) generated during 
meals, provide the brain with information such as mechanical (e.g., stomach stretch, volume) and chemical 
properties of the ingested food, nutritional status and inhibiting food intake. Ghrelin is the only hunger-
stimulating hormone, stimulating food intake and secretion of growth hormones.  
 
1.5 Glucose-Stimulated Insulin Secretion (GSIS) - The KATP CHANNEL 
Dependent Model 
Pancreatic beta-cells secrete the hormone insulin in direct proportion to the concentration of 
glucose in the circulation. The understanding that beta-cells are inherently designed for the 
secretion of insulin and that metabolism of glucose generates signals necessary for insulin 
secretion came from three critical studies which showed that 1) beta-cells only respond to 
glucose and not to its non-metabolizable counterpart, 2-deoxyglucose 2) beta-cells express 
non-insulin dependent glucose transporter 2 (GLUT 2), whereas tissues such as the liver and 
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the skeletal muscles, expresses insulin-dependent glucose transporter 3 (GLUT 3). In beta-
cells, glucokinase (GK), the glucose phosphorylating enzyme, is expressed in the 
physiological concentration of glucose unlike in other tissues such as liver where, the 
expression is induced only after feeding (51-53). These early discoveries provided ample 
evidence to show that beta-cells are specialized to secrete insulin for the maintenance of 
glucose homeostasis. 
 
Insulin secretion from the beta-cell occurs in a bi-phasic manner with a first acute phase 
happening within 10 minutes after a glucose load. The second more sustained phase of 
secretion, reaches a plateau very quickly as seen in mice or more gradually as seen in rats and 
humans (54). Although the mechanisms that control GSIS are not completely understood, the 
generally accepted model holds that glucose enters beta-cells via the low affinity, high 
capacity glucose transporter, GLUT 2. Glucose is then phosphorylated by GK (hexokinase 
4), which is the first and the rate-limiting step in glycolysis (55). The glycolytic end product 
pyruvate then enters the tricarboxylic acid cycle (TCA), where it is converted to oxaloacetate 
(OA) and acetyl CoA. OA and acetyl CoA combine to form citrate and subsequent 
intermediates of the TCA cycle. Oxidation of these TCA cycle intermediates leads to the 
generation of reducing equivalents, NADH and FADH2. During the oxidative 
phosphorylation that follows the oxidation of the TCA intermediates, both NADH and 
FADH2 act as electron donors and the electrons are passed from electron donors to electron 
accepters such as oxygen, in a series of redox reactions that happens in the inner 
mitochondrial membrane. These redox reactions generate a proton gradient across the inner 
mitochondrial membrane and the protons re-enter the mitochondrial matrix, down their 
electrochemical gradient, powering the ATP synthase and the energy is used to generate 
ATP, leading to an increase in ATP production. The subsequent rise in the cytosolic 
ATP/ADP levels promotes the closure of the ATP-sensitive potassium channels (KATP 
channels), causing beta-cell membrane depolarization and activation of voltage-dependent 
Ca2+ channels (VDCC). The opening of VDCCs facilitates influx of extracellular Ca2+, 
leading to a rise in the cytosolic Ca2+ levels, which then triggers the exocytosis of insulin-
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containing secretory granules. This pathway of insulin secretion is popularly known as the 
triggering pathway or the KATP channel-dependent pathway and is critical for the first acute 
phase of insulin release, where exocytosis of insulin granules occur from the “readily 
releasable pool” docked at the beta-cell plasma membrane (54,56-61). However, in the 
second and more sustained phase of insulin secretion, in addition to the requirement of KATP 
channel dependent triggering pathway as an initiating event, the KATP channel-independent 
events seem to be necessary for the amplification of GSIS. 
 
1.6  KATP Channel Independent Pathway of Insulin Secretion  
The KATP channel-independent pathway, also known as the amplifying pathway, is 
complementary to the triggering pathway and is critical for the sustained secretion of insulin. 
Important support for the KATP channel-independent pathway of GSIS comes from studies 
that showed the ability of glucose to cause a significant increase in insulin secretion in 
conditions where KATP channels are held open by application of diazoxide or high K+ or in 
animals lacking functional KATP channels (62-64). Islets from mice lacking the sulfonylurea 
receptor-1 (SUR1), a subunit of the KATP channel, retain the ability to secrete insulin and 
these mice are shown to have relatively normal glucose homeostasis. In addition to this, 
research has also shown that mitochondrial metabolism of glucose generates signals other 
than changes in the ATP/ADP ratio that are important for normal insulin secretion. Several 
molecules, including glutamate, malonyl-CoA/LC-CoA and NADPH, have been proposed as 
candidate coupling factors in GSIS (65-69) (Figure 2). 
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Figure 2: Glucose-stimulated insulin secretion (GSIS) from pancreatic beta-cells. Glucose equilibrates 
across the plasma membrane through glucose transporter, GLUT2, which initiates glycolysis. Pyruvate 
produced by glycolysis preferentially enters the mitochondria and is metabolized in the TCA cycle, producing 
reducing equivalents in the form of NADH and FADH2. The transfer of electrons from these reducing 
equivalents through the mitochondrial electron transport chain is coupled with the pumping of protons from the 
mitochondrial matrix to the inter membrane space, leading to the generation of ATP. ATP is transferred to the 
cytosol through adenine nucleotide carrier (ANC), raising the ATP/ADP ratio. This results in the closure of the 
ATP sensitive K+ channels (KATP), which in turn leads to membrane depolarization, opening of the voltage-
sensitive Ca2+ channels, promoting calcium entry and increase in cytoplasmic Ca2+ leading to exocytosis of 
insulin granules. Glucose also generates amplifying signals other than ATP, which play a significant role in the 
secretion of insulin from pancreatic beta-cells. 
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1.6.1 Role of Anaplerosis in GSIS 
Among the several potential pathways that play a critical role in supporting the KATP channel 
independent pathway of insulin release, the role of anaplerosis deserves special mention. The 
metabolic fate of pyruvate in the mitochondria has been well studied by several groups. 
When glucose is readily available, pyruvate enters the TCA cycle in roughly equal 
proportions via the oxidative and anaplerotic pathways (70-72). The oxidative entry of 
pyruvate is mediated by the enzyme pyruvate dehydrogenase (PDH), which decarboxylates 
pyruvate to acetyl CoA.  However, the anaplerotic entry of pyruvate is mediated by pyruvate 
carboxylase (PC), which carboxylates pyruvate to oxaloacetate (OAA). The PC-mediated 
anaplerosis or replenishment of OAA in the TCA cycle is extremely important for GSIS, as it 
not only increases TCA flux, but also facilitates the escape of other TCA intermediates from 
the mitochondria through a process called cataplerosis. These TCA intermediates then serve 
as a substrate for the generation of cytosolic coupling factors that augment insulin secretion. 
Several lines of evidence strengthen the role of PC and anaplerosis in beta-cell insulin 
secretion (70,73,74). 1) PC is highly expressed in beta-cells and 40-50% of the pyruvate 
entering the mitochondrion at stimulatory glucose concentrations is directed through the PC-
mediated anaplerotic pathway. Unlike hepatocytes, where PC is required to promote 
gluconeogenesis through phospho enol pyruvate carboxykinase (PEPCK), beta-cells lack the 
expression of PEPCK and express low amounts of fatty acid synthase (FAS) suggesting low 
gluconeogenesis and lipogenesis. This suggests that PC mediated anaplerosis is important in 
beta-cells and it mediates a different function as opposed to its primary role in the liver which 
is gluconeogenesis and lipogenesis. 2) Only 25% of the glucose-carbon entering the TCA 
cycle via PC is directed to protein synthesis 3) the capacity of various glucose responsive 
INS-1 derived beta-cell lines for GSIS is tightly correlated to PC-mediated anaplerotic influx 
of substrates to the TCA cycle and not to PDH-mediated decarboxylation. Thus, PC-
mediated anaplerosis and export of TCA intermediates such as citrate from the mitochondria 
to the cytoplasm is believed to be crucial for generation of anaplerotic signals such as 
glutamate, malonyl coA/LC-CoA and NADPH to maintain the beta-cell secretory response.   
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1.6.2 Role of Malonyl-CoA/LC-CoA in GSIS 
One of the critically analyzed hypotheses that supports the KATP channel independent 
pathway and anaplerosis is the malonyl Coenzyme A/Long Chain Acyl-Coenzyme A 
(Malonyl CoA/LC-CoA) hypothesis, where glucose induced rise in malonyl CoA/LC-CoA 
that takes place independently of the KATP channel function, positively correlates with GSIS 
(65,66,75). The malonyl CoA/LC-CoA model of GSIS holds that during glucose stimulation, 
PC-mediated anaplerosis or accumulation of TCA cycle intermediates raises mitochondrial 
citrate levels, thereby facilitating the escape of citrate from the mitochondria via the 
citrate/isocitrate carrier (CIC). In the cytosol, citrate serves as a substrate for ATP-dependent 
citrate lyase (CL) to generate OAA and acetyl CoA. Acetyl CoA then serves as a substrate 
for acetyl CoA carboxylase (ACC) to produce malonyl CoA, which mediates two important 
actions in the beta-cells. First, malonyl CoA is an important precursor for the de novo 
generation of free fatty acids (FFA). FFA can then be further processed to LC-CoA by LC-
CoA synthetase. Second, malonyl CoA is a potent inhibitor of carnitine palmitoyltransferase 
1 (CPT 1), a key regulator (suppressor) of fatty acid (LC-CoA) oxidation. Both of these 
actions will promote the accumulation of LC-CoA in the cytosol, which has shown to 
promote GSIS. However, studies have indicated that prevention of glucose-induced rise in 
malonyl CoA by overexpression of malonyl CoA decarboxylase (MCD) has no impact on 
GSIS. Furthermore, inhibition of citrate lyase (CL), which plays an important role in the 
generation of acetyl CoA, a precursor molecule to malonyl CoA, has also been shown to 
have no impact on GSIS (76), thereby putting into question the exact role of malonyl 
CoA/LC-CoA in the regulation of GSIS from pancreatic beta-cells. 
1.6.3 Role of Pyruvate Cycling in GSIS  
Another interesting model that supports the existence of the KATP channel independent 
pathway and generation of amplifying signals necessary for insulin secretion is the pyruvate 
cycling pathway. Pyruvate cycling is the process by which the glycolytic end product 
pyruvate is replenished in sufficient amounts in the TCA cycle through three different cycles 
namely the pyruvate-malate, pyruvate-citrate and the pyruvate-isocitrate cycle. Along with 
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the maintenance of the pyruvate pool in the cytosol, the three pathways generate reducing 
equivalents such as NADH and NADPH, which may act as potential stimulus-secretion 
coupling factors critical for GSIS (70,77-79). The relationship between pyruvate cycling and 
GSIS came to prominence when a study conducted by Lu et al (70) reported that insulin 
secretion is directly proportional to the activity of pyruvate cycling. Using 13C-NMR, the 
metabolic fate of pyruvate was analyzed in a set of INS-1 derived clonal cells with robust or 
poor GSIS. The results showed that the capacity of various lines of INS-1 clonal cells for 
GSIS was tightly correlated with PC-catalyzed anaplerotic influx into the TCA cycle and 
pyruvate cycling. Also, stimulation of pyruvate cycling by the addition of dimethyl malate, a 
membrane permeable methyl ester of malate, increases pyruvate cycling and GSIS, whereas, 
addition of phenylacetic acid (PAA), an inhibitor of PC decreases GSIS. In contrast, Jenssen 
et al reported that siRNA mediated inhibition of PC neither affects GSIS in 832/13 cells and 
rat islets nor does it affect glucose induced increments in pyruvate cycling. However, despite 
the suppression of PC protein levels by 60% in 832/13 cells, flux through PC at high glucose 
was decreased by only 20%, suggesting an increase in PC specific activity (80). In addition, 
Jenssen et al also reported that siRNA mediated suppression of PC increased the levels of 
acetyl CoA, which is an allosteric activator of PC. This may have aided in maintaining PC 
activity intact in an attempt to prevent impairment in anaplerosis, pyruvate cycling and GSIS. 
Thus, PC mediated anaplerosis and pyruvate cycling is believed to play a key role in GSIS.  
 
In an attempt to understand the identity of the pyruvate cycling pathway that is most critical 
for the generation of signalling molecules necessary for GSIS, recent studies have focused on 
uncovering the mechanisms that govern each of the pyruvate cycling pathway. In the 
pyruvate-malate cycle, oxaloacetate (OAA) is converted to malate via malate dehydrogenase 
(MDH), and subsequently, malate can be reconverted to pyruvate by NADP-dependent 
cytosolic malic enzyme (MEc) or NAD- dependent mitochondrial malic enzyme (MEm). 
Several lines of evidence suggest that this pathway is essential in the generation of NADH, 
which is a by-product of the MEm-catalyzed reaction. Studies carried out by Eto et al shows 
that NADH produced by cytosolic glyceraldehyde-3-phosphate dehydrogenase (GAPDH) 
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must be shuttled into the mitochondria for ATP production (81). When islets from GAPDH 
knock-out mice were treated with aminooxyacetate, an inhibitor that blocks the malate-
aspartate NADH shuttle, it led to the inhibition of glucose-induced increases in glucose 
oxidation, ATP production and insulin secretion. Others have also shown the importance of 
NADH generation through MEm, thus providing further proof that pyruvate-malate through 
MEm is important for GSIS (82). On the contrary, it has been reported that mouse islets with 
low MEc enzyme activity and MOD 1 mice, which lack the expression of MEc, have normal 
glucose homeostasis suggesting that pyruvate-malate cycling through MEc may not be 
universally correlated with GSIS (83,84). Further weakening the association of pyruvate-
malate cycling with GSIS, Ronnebaum et al has shown that although siRNA-mediated 
inhibition of MEc in 832/13 cells impaired GSIS, these effects were not due to changes in 
pyruvate cycling activity and inhibition of both MEc and MEm failed to impair GSIS in 
primary rat islets (85). Thus, although the pyruvate-malate cycle has been shown to play a 
role in pyruvate cycling, a definitive role for this cycle in GSIS is still being debated.  
 
In the pyruvate-citrate cycle, citrate formed from the TCA cycle is exported from the 
mitochondria to cytosol through the citrate/isocitrate carrier, where it is cleaved to 
oxaloacetate (OAA) and acetyl CoA by citrate lyase (CL). Cytosolic OAA is then converted 
back to pyruvate via a two-step process; 1) OAA is converted to malate by malate- 
dehydrogenase (MDH), 2) malate is converted to pyruvate by the cytosolic malic enzyme 
(MEc). Support for the pyruvate-citrate cycle in GSIS comes from several studies (86-88). It 
is generally believed that export of citrate from the mitochondria to the cytosol through CIC 
leads to an increase of citrate in the cytosol, which is needed for de novo lipogenesis and for 
the generation of long-chain acyl CoA, a factor that is thought to act a stimulus-secretion 
coupler and both of these correlate well with GSIS. Studies have also shown that both 
pharmacological and genetic inhibition of CIC, leads to impairment in GSIS coupled with 
decrease in cytosolic citrate and de novo lipogenesis. However, the importance of the 
pyruvate-citrate cycle in GSIS is also somewhat controversial, as inhibition of CL by 
hydroxyl citrate has yielded different effects on GSIS: one group showing inhibition of GSIS 
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(89) and the other showing no effects on GSIS (76). Thus, although the export of citrate to 
the cytosol plays a critical role in supporting GSIS, the exact role of CL in maintaining 
pyruvate-citrate cycling and GSIS is still not completely understood. 
 
In the pyruvate-isocitrate cycle, both citrate and isocitrate are exported from the 
mitochondria to the cytosol where cytosolic aconitase converts citrate to isocitrate and 
cytosolic isocitrate is converted to alphaketoglutarate (α-KG) through cytosolic isocitrate 
dehydrogenase (ICDc). α-KG may directly stimulate GSIS (90) or it re-enters the 
mitochondria where it is exchanged for malate, which is then transported to the cytosol and 
converted back to pyruvate through the MEc. α-KG that enters the mitochondria is converted 
ultimately to malate and malate to pyruvate through mitochondrial malic enzyme (MEm). 
The relevance of pyruvate-isocitrate cycling in GSIS was supported by a study where, siRNA 
mediated inhibition of ICDc lead to inhibition of GSIS in both 832/13 cells and primary rat 
islets coupled with decrease in pyruvate cycling activity and production of NADPH (91). 
Based on this evidence, it is believed that, among the three pyruvate cycling pathways, the 
pyruvate-isocitrate pathway is the most critical one for the maintenance of GSIS from beta-
cells (Figure 3). 
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Figure 3: Pyruvate cycling and production of NADPH: The anaplerotic substrate pyruvate is replenished in 
sufficient amounts through three different pathways. In the pyruvate-malate pathway, pyruvate is converted by 
the anaplerotic enzyme pyruvate carboxylase (PC) to oxaloacetate. Oxaloacetate is then converted to malate, 
which exits the mitochondria. Malate can then either be recycled to pyruvate via the mitochondrial, NAD-
dependent form of malic enzyme (MEm) or can be transported to the cytosol via the dicarboxylate carrier 
(DIC). In the cytosol, malate can be reconverted to pyruvate by the cytosolic NADP-dependent form of malic 
enzyme (MEc). In the pyruvate-citrate cycle, pyruvate enters the TCA cycle via PC. The oxaloacetate generated 
then condenses with acetyl-CoA to form citrate and isocitrate, which can exit the mitochondria via the 
citrate/isocitrate carrier (CIC). In the cytosol, citrate is cleaved to oxaloacetate and acetyl-CoA by ATP-citrate 
lyase (CL). Oxaloacetate is recycled to pyruvate via conversion to malate and engagement with the 
mitochondrial (MEm) or cytosolic (MEc) malic enzyme to reform pyruvate. In the pyruvate-isocitrate cycle, the 
cycle is again initiated by the conversion of pyruvate to oxaloacetate by PC. As in the pyruvate/citrate cycle, 
citrate and isocitrate leave the mitochondria via CIC. Citrate is then converted to isocitrate by cytosolic 
aconitase, and isocitrate can then be converted to α-Ketoglutarate (α-KG) by cytosolic, NADP-dependent 
isocitrate dehydrogenase (ICDc). α-KG can then serve either as a direct signal for insulin secretion or it is 
recycled back to pyruvate by one of several mitochondrial or cytosolic pathways that remain to be defined. An 
important by-product of all three pyruvate-cycling pathways is the cytosolic NADPH, which is potentially 
considered to be an insulin secretagogue.  
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1.6.4 NADPH as a Stimulus-Secretion Coupling Factor in GSIS 
An important stimulus-secretion coupling factor in GSIS that has received a lot of attention 
in the recent years is the pyridine nucleotide, NADPH. Examination of mitochondrial glucose 
metabolism in clonal beta-cell lines with various degrees of glucose responsiveness 
demonstrated a strong correlation between pyruvate cycling and glucose competence (70). 
This strong correlation may be attributed to the generation of cytosolic NADPH, which is 
produced by either NADP+-dependent malic enzyme (MEc) in the pyruvate/malate and 
pyruvate/citrate cycle or NADP+-dependent isocitrate dehydrogenase (ICDc) in the 
pyruvate/isocitrate cycle. A role for cytosolic NADPH in GSIS is supported by several 
studies. It has been shown that NADPH is an expected by-product of all the three proposed 
pyruvate cycling pathways (80,85,88,91). Studies have also shown that the NADPH/NADP+ 
ratio increases in direct proportion to GSIS in rodent islets and several beta-cell lines, 
whereas such a linear relationship does not seem to exist for the NADH/NAD+ ratio (67,91). 
The most exciting piece of evidence in support of NADPH was provided by Ivarsson et al, 
where they showed that addition of NADPH augmented insulin release from patch-clamped 
beta-cells and this stimulatory effect could be reversed by the addition of NADP+, suggesting 
that the NADPH/NADP+ ratio is a relevant signal in GSIS (67). Another convincing piece of 
evidence in favor of NAPDH and why it may be critical for GSIS is based on studies that 
showed that NADPH binds to voltage-gated potassium channels known as KV channels, 
causing the inactivation of these channels (92,93). KV channels are associated with 
repolarization of the plasma membrane and it is believed that binding of NADPH will assist 
in keeping the channels inactive and keeps the plasma membrane in a depolarized state 
sufficient to sustain insulin secretion. Accordingly, it has been reported that adenovirus 
mediated expression of truncated Kv2.1 subunit, specifically eliminating Kv2 family 
currents, enhanced GSIS from rat islets by 60% (94) and Kv2.1 null mice have elevated 
serum insulin levels (95). 
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1.7 ARNT/HIF-1β: Structure and Function  
Aryl hydrocarbon receptor nuclear translocator (ARNT)/hypoxia inducible factor -1β (HIF-
1β) is a member of the basic helix-loop-helix (bHLH)-periodicity/ARNT/Single minded 
(PAS) family of transcription factors, required for a wide variety of biological processes such 
as organogenesis, neural development and cellular responses to hypoxia and environmental 
pollutants (96). The gene that encodes ARNT/HIF-1β was mapped on human chromosome 
1q21 and mouse chromosome 3 and seems to be well conserved on an evolutionary scale 
(97). Human ARNT/HIF-1β gene is ~ 65 kilobases long with 22 exons and shares 89% 
sequence homology with the mouse ARNT/HIF-1β gene. Compared to other members of the 
bHLH-PAS family of transcription factors, the exon/intron arrangement in mouse 
ARNT/HIF-1β gene is different, where the gene was found to be TATA-less with multiple 
transcriptional start sites. The presence of multiple transcriptional start sites and GC-rich 
sequences in the promoter region are often considered as characteristic of “housekeeping” 
genes that have a TATA-less promoter (98).  
 
Earlier data regarding ARNT/HIF-1β structure was mostly derived from cultured wild type 
and mutant mouse hepatoma cell lines (99). It is generally believed that ARNT/HIF-1β is a 
nuclear protein, however, studies have also reported that ARNT/HIF-1β is localized to both 
the cytoplasm and the nucleus of palatal epithelial cells (100). The 94 kD human ARNT/HIF-
1β protein has a characteristic N-terminal bHLH motif required for DNA binding, the central 
PAS domains (PAS A and PAS B) that facilitates heterodimerization and a C-terminal 
domain that allows the recruitment of transcriptional co-regulators such as CBP/P300 and is 
789 amino acids long (101,102) (Figure 4). Recent evidence suggests that the PAS domain 
may also provide an additional binding site for co-activators, there by recruiting them in a 
step necessary for transactivation of target genes (103). One of the salient features of 
ARNT/HIF-1β is that it acts as an obligate binding partner for most bHLH-PAS family 
transcription factors and binds specific DNA sequences in the regulatory regions of target 
genes. The half-site for ARNT/HIF-1β is on the 3' side of the 5'-GTG-3' recognition 
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sequence. The sequence of the other half of the binding site depends upon the identity of the 
ARNT/HIF-1β dimerization partner (104). Although DNA binding of ARNT/HIF-1β is 
mostly mediated by its basic region, it is suggested that the PAS region may also be involved. 
Dimerization between ARNT/HIF-1β and other bHLH-PAS proteins is mediated by their 
bHLH and PAS regions (105,106). ARNT/HIF-1β was originally identified by Reyes et al in 
1992 as a factor required for the activity of the aryl hydrocarbon receptor (AhR) (107). The 
AhR- ARNT/HIF-1β complex induces the expression of xenobiotic enzymes in response to 
environmental pollutants such as dioxins (108). ARNT/HIF-1β was later also identified as 
the β-subunit of the HIF-1 transcription factor, required for the induction of genes necessary 
for cellular response to hypoxia (102). Some of the well-studied members of the bHLH-PAS 
family of transcription factors in mammals include AhR, HIF-1α, HIF-2α and HIF-3α. 
 
ARNT/HIF-1β has two homologues, namely ARNT 2 and ARNT 3 (also known as bMAL, 
MOP3, ARNTL1) (109-112). Despite the high sequence conservation within their DNA 
binding and dimerization domains and with very similar DNA recognition specificities, the 
homologues are functionally non-redundant and biologically essential. Gene expression 
analysis reveals that ARNT/HIF-1β has a ubiquitous expression pattern while ARNT 
homologues seem to be mainly restricted to the brain and the kidney (113). ARNT/HIF-1β is 
also known to have several splice variants, which were shown to arise from alternate splicing 
of the mRNA. Isoforms with deletions at exon 5, 3’ end of exon 6 or 5’ end of exon 11 or 
with an insertion at 5’ end of exon 20 were discovered in rat suggesting an intricate 
regulatory system (114).  
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Figure 4: Schematic representation of the human ARNT/HIF-1β protein domains: ARNT/HIF-1β is a 
member of the basic-helix-loop-helix (bHLH) family of transcription factors with a characteristic N-terminal 
bHLH domain facilitating DNA binding, two Per/ARNT/SIM (PAS) domains which helps in 
heterodimerization with partners such as HIF-1α, HIF-2α and AhR and a C-terminal transactivation domain 
(TAD), facilitating the recruitment of transcriptional co-activators. The boxes represent the length of each 
domain and the numbers represent the amino acids. 
 
The bHLH-PAS family of proteins usually function by binding the DNA in a dimeric form. 
Most bHLH-PAS transcription factors form heterodimers with other members of the family 
to activate gene transcription. Widely studied and well-accepted heterodimeric partnerships 
of ARNT/HIF-1β include its association with AhR following ligand activation of AhR, 
assisting in metabolism of xenobiotics, with HIF-1α subunits under low oxygen conditions, 
assisting with gene expression under hypoxia and with SIM proteins, assisting in neural 
development (115-117). In addition to forming heterodimers, ARNT/HIF-1β has been shown 
to form homodimers and regulate genes that typically contain the palindromic E-box 
(CACGTG) signature in their promoter (118,119). Although, physiological relevance of 
ARNT/HIF-1β homodimers was not known when they were initially reported in 1995, in 
2007, Arpiainen et al., reported that ARNT/HIF-1β homodimers are capable of inducing 
expression of the mouse Cyp2A5 gene, suggesting the involvement of ARNT/HIF-1β 
homodimers in xenobiotic metabolism (120).  
 
Despite the extensive research conducted to understand the biological role and physiological 
relevance of ARNT/HIF-1β in mammalian tissues, the post-translational regulation of 
ARNT/HIF-1β is largely unknown. Some studies report that ARNT/HIF-1β gene expression 
and protein levels are significantly increased under hypoxic conditions (96,102,121), 
suggesting that it plays an important role in the transcriptional response to low oxygen 
tension. Consistent with this idea, it has been shown that ARNT/HIF-1β is essential for HIF-
1α dependent hypoxic induction of vascular endothelial growth factor (VEGF) and the 
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glycolytic enzymes aldolase A (ALDO) and phosphoglycerate kinase (PGK) in a mouse 
hepatoma (Hepa 1c1c7) cell line (122,123). However, unlike HIF-1α, which has an oxygen 
dependent degradation domain (ODDD) and is expressed exclusively under hypoxic 
conditions, ARNT/HIF-1β protein does not have an ODDD and some studies have reported 
that it is constitutively expressed in most tissues with little or no response to hypoxia 
(121,124,125). Other studies have reported that ARNT/HIF-1β protein levels were decreased 
by hydrogen peroxide (H2O2) or reactive oxygen species (ROS) in human cell lines, 
however, the underlying molecular mechanism is currently unknown (126,127). A few 
groups have also investigated the phosphorylation status of ARNT/HIF-1β protein in an 
attempt to understand post-translational regulation of the protein. Generally, protein 
phosphorylation is thought to modify DNA binding ability, protein-protein interactions as 
well as translocation to the nucleus. Pongratz et al had shown the importance of AhR - 
ARNT/HIF-1β phosphorylation for the activation of the heterodimer, thus promoting DNA 
binding (128). In another study by Berghard et al, it was reported that DNA binding by 
human and mouse AhR - ARNT/HIF-1β heterodimers requires phosphorylation of both 
proteins, however, formation of AhR - ARNT/HIF-1β heterodimers requires phosphorylation 
of only ARNT/HIF-1β protein (129,130). Another group had shown that although human 
ARNT/HIF-1β is a phosphoprotein, the phosphorylation of serine residues in the PAS region 
does not modulate AhR - ARNT/HIF-1β or ARNT/HIF-1β - ARNT/HIF-1β-mediated signal 
transduction (131). Thus, although the exact consequence of ARNT/HIF-1β protein 
phosphorylation is unknown, it is generally believed that overall phosphorylation status 
rather than site-specific phosphorylation may be crucial in the regulation of ARNT/HIF-1β 
mediated signal transduction (131). 
1.8 ARNT/HIF-1β in Metabolism of Xenobiotics 
In response to ligand activation of AhR following exposure to xenobiotics such as polycyclic 
aromatic hydrocarbons and halogenated aromatic compounds, AhR, a cytoplasmic protein 
translocates to the nucleus, where it binds with its heterodimeric binding partner ARNT/HIF-
1β (132). Transcriptional induction of enzymes required for the metabolism of xenobiotics is 
initiated when AhR- ARNT/HIF-1β complex binds to the xenobiotic responsive element 
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(XRE: TNGCGTG) of target genes such as Cyp1A1, Cyp1B1, and NADP(H):oxidoreductase 
(NQO1)(133,134). Upon DNA binding, AhR- ARNT/HIF-1β complex like other nuclear 
receptors, recruits transcriptional co-activators such as CBP/p300, SRC-1, 
NCoA2/GRIP1/TIF2, and components of ATP-dependent chromatin remodeling complexes, 
such as Brahma-related gene 1 (BRG-1) and TRIP230. These proteins then interact and 
modulate the activity of the core transcriptional machinery, as well as modify local chromatin 
structure, thereby inducing gene expression. Subcellular localization studies and 
immunohistochemical analysis have revealed that AhR, prior to ligand activation, is localized 
in the cytoplasm bound to 2 molecules of 90-kDa-heat shock protein (HSP90) (135). Upon 
ligand activation, AhR transforms, releasing the HSP90, translocates to the nucleus and binds 
with ARNT/HIF-1β. In fact ARNT/HIF-1β was originally cloned as a factor required for the 
translocation of AhR from the cytoplasm to the nucleus. Briefly, a cell line expressing a 
“functional” AhR, but uninducible for Cyp1A1, a cytochrome p450 family member, was 
transfected with a collection of cDNA constructs. The expression of one of the cDNA 
construct restored the nuclear translocation of AhR and the expression of Cyp1A1. The 
product of this gene was therefore named ARNT (Ah receptor nuclear translocator), although 
we now know that ARNT is not directly involved in the AhR “translocation”. Following its 
cloning in 1992 by the Hankinson group (107), detailed structure and function analysis were 
carried out on ARNT/HIF-1β protein. These studies have clearly established that the 
transactivation potential of AhR-ARNT/HIF-1β complex is highly dependent on the 
availability of ARNT/HIF-1β (108,136). Although, ARNT/HIF-1β alone has no affinity for 
the XRE, the heterodimerization with AhR, promotes its interaction with the XRE of the 
target gene (137). Genetic analysis of a mouse hepatoma cell line deficient in ARNT/HIF-1β 
shows poor response to dioxins, which was restored by transfection of ARNT/HIF-1β cDNA 
(138). This and more studies indicate that ARNT/HIF-1β is an obligatory binding partner for 
AhR-mediated transcriptional response to the metabolism of environmental toxins or 
xenobiotics. 
The AhR - ARNT/HIF-1β heterodimer can also impact signal transduction by the estrogen 
receptor (ER). ARNT/HIF-1β was shown to be a potent co-activator of both ER-α and ER-β-
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dependent transcription and the C-terminal domain of ARNT/HIF-1β is believed to be 
essential for the transcriptional enhancement of ER activity (139,140). 
1.9 ARNT/HIF-1β in Hypoxia 
Oxygen is the primary substrate for generation of ATP and hence critical for maintaining 
cellular activities in all multicellular organisms. Hypoxia, a condition where oxygen levels 
become extremely low in our body, occurs in both physiological and pathophysiological 
conditions. To combat the adverse effects of hypoxia, our body has inherent and specialized 
signalling proteins called the hypoxia inducible factors (HIF), which are transcription factors 
regulating the signal transduction pathway called the hypoxia-signalling pathway. With 
cloning and characterization of HIF-1α by Semenza et al in 1992 (141), followed by 
purification and cloning of the components of the HIF-1 protein complex, consisting of HIF-
1α and ARNT/HIF-1β in 1995 by the same group (102), the hypoxia signalling pathway 
became a much celebrated pathway due its biological role in mammalian development and 
prominence in disease pathology.  
The signal transduction pathway induced by hypoxia is well studied and well accepted in 
mammals (142,143). When cells are exposed to low oxygen conditions, HIF-1α, a 
cytoplasmic protein that has an oxygen dependent degradation domain (ODDD), translocates 
to the nucleus where it binds to its heterodimeric binding partner, ARNT/HIF-1β. The HIF-
1α - ARNT/HIF-1β transcriptional complex then binds to the hypoxia responsive element 
(HRE: RCGTG, where the R is either an A or a G) in the promoter region of target genes. 
Upon binding to the HRE, HIF-1 complex also recruits transcriptional co-activators such as 
CBP/p300 which then assist in HIF-1 mediated gene transcription. 
Regulation of HIF-1α - ARNT/HIF-1β mediated gene transcription under hypoxic conditions 
is mainly dependent on the availability of HIF-1α, as the protein is normally degraded under 
normoxic conditions. HIF-1α, under normoxia, is post-translationally regulated by the prolyl 
hydroxylation of the ODDD (143). The hydroxylated HIF-1α protein is then a target of 
proteosomal degradation by promoting their interaction with von Hippel-Lindau (VHL) 
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protein, a component of E3 ubiquitin-ligase multi-protein complex (144). Although, 
ARNT/HIF-1β is believed to be constitutively expressed and available for binding with HIF-
1α under all conditions, studies have shown the absolute requirement of ARNT/HIF-1β for 
HIF-1α mediated hypoxic activation of gene transcription. Using a mouse hepatoma cell line 
that lacks functional ARNT/HIF-1β protein, both HIF-1 transcriptional complex formation as 
well as hypoxic induction of target genes were found to be defective (123,145,146). Taken 
together, ARNT/HIF-1β has been shown to be absolutely indispensible for HIF-1 DNA 
binding and transactivation (Figure 5).  
The HIF-1α - ARNT/HIF-1β complex is required for the hypoxic induction of target genes 
such as those that are required for the development of the hematopoietic and vascular system 
namely vascular endothelial growth factor (VEGF) and erythropoietin (EPO) and those that 
are required for cell proliferation and differentiation by regulation of enzymes in glucose 
uptake and metabolism and the mammalian target of rapamycin (mTOR), which regulates 
protein synthesis in response to the nutritional status of the body (4,147-154).In addition to 
hypoxia, several non-hypoxic stimuli can also induce HIF transcriptional activity. HIF-1α 
transcriptional activity has been shown to be promoted by effectors of immune response such 
as cytokines and those that modify the nuclear factor κB signalling pathway (155-158). 
Accumulation of HIF-1α protein was shown to be stimulated by the autocrine growth factors 
such as epithelial growth factor (EGF), fibroblast growth factor 2 (FGF2) and insulin-like 
growth factor (IGF). In addition, loss of function of tumor suppressors (such as ING4, p53, 
PTEN and VHL) as well as gain of function of oncogenes (such as AKT, myc, mTOR, PI3K 
etc) also regulates HIF-1α activity. 
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Figure 5: Transcriptional Regulation by ARNT-HIF-1α heterodimeric complex. In normoxia, a specific 
proline within HIF-1α (P 564) is hydroxylated by O2- and Fe2+-dependent HIF-1α prolyl hydroxylases (PHD). 
This modification prepares HIF-1α protein to associate with von Hippel Lindau protein (VHL) for 
ubiquitination by E3 ubiquitin ligase complex leading to the degradation of HIF-1α protein. In hypoxia, the 
required oxygen tension for PHD activity is absent. As a result, HIF-1α protein is stable and translocates to the 
nucleus where it heterodimerizes with ARNT/HIF-1β to form a stable transcriptional complex, which then 
associates with transcriptional activators such as CBP/p300. This complex subsequently binds to the hypoxia 
responsive element (HRE) of target genes and activates gene transcription of genes such as erythropoietin 
(Epo), vascular endothelial growth factor (VEGF), aldolase (Aldo) and lactate dehydrogenase (LDH).  Adapted 
from Fedele et al 2002 (159). 
 
 
   31 
1.10 Lessons from ARNT/HIF-1β Knock-Out Mice  
Observations from the ARNT/HIF-1β conditional knock-out mice and whole body knock-out 
mice have provided us with a wealth of information regarding the functional significance of 
this transcription factor in mammalian development. By the targeted disruption of the bHLH 
domain of the murine ARNT/HIF-1β gene, Maltepe et al showed that ARNT-/- embryonic 
stem cells (ES) failed to activate genes that normally respond to low oxygen tension such as 
ALDO, PGK and VEGF. ARNT-/- ES cells also failed to respond to a decrease in glucose 
concentration, indicating it is crucial in response to hypoxia and hypoglycemia.  ARNT/HIF-
1β seems to be essential for normal embryonic development as ARNT-/- embryos were not 
viable past day 10.5 and exhibited angiogenic abnormalities similar to those reported for 
mice lacking VEGF (160,161). More support for the requirement of ARNT/HIF-1β in normal 
embryonic development came from the Hankinson group who reported that whole body 
ARNT/HIF-1β knock-out mice were embryonic lethal between 9.5 and 10.5 days of 
gestation, with abnormalities that included neural tube closure defects, forebrain hypoplasia, 
delayed rotation of the embryo, placental hemorrhaging, and visceral arch abnormalities. 
However, the primary cause of lethality was reported to be failure of the embryonic 
component of the placenta to vascularize, which is related to ARNT/HIF-1β’s known role in 
hypoxic induction of angiogenesis (162). In order to study the role of ARNT/HIF-1β in an 
intact animal, a conditional knock-out mouse was generated by Tomita et al (163) using the 
Cre-loxP system, where treatment with polyinosinic-polycytidylic acid was used to induce 
expression of Cre resulting in complete disruption of the ARNT/HIF-1β gene expression and 
protein expression in the liver. This study was the first of its kind to show in an intact animal 
that complete disruption of ARNT/HIF-1β in the liver results in loss of AhR mediated gene 
activation in the liver. In addition, loss of ARNT/HIF-1β in liver was also shown to affect the 
expression of HIF-1 mediated expression of target genes such as hemoxygenase and GLUT1. 
Thus, these earlier in vivo studies established the undisputable role of ARNT/HIF-1β in 
mammalian development as well as in the hypoxia signal transduction pathway.  
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1.11 ARNT/HIF-1β and Type 2 Diabetes 
T2D is a complex metabolic disorder characterized by disturbances in whole body glucose 
and lipid homeostasis. Regulation of glucose and lipid homeostasis involves proper co-
ordination between multiple organs of the body, namely, the pancreatic beta-cells, the liver, 
the skeletal muscles, the adipose tissue and the brain. Since the discovery of ARNT/HIF-1β 
in 2005 as a protein required for the normal functioning of pancreatic beta-cells (164), 
several groups have investigated the role of this transcription factor in the pathogenesis of 
T2D. Recent research suggest that abnormal expression of ARNT/HIF-1β and its binding 
partner, HIF-1α can have a negative impact on the major metabolic regulators of the body 
such as the pancreatic beta-cells, the liver and the adipose tissue, potentially contributing to 
the pathophysiological abnormalities presented in T2D. 
1.11.1 ARNT/HIF-1β and Pancreatic Beta-Cells 
In 2005, a study published in Cell reported that ARNT/HIF-1β, a protein with previously 
unknown functions in pancreatic beta-cells, plays a significant role in mediating beta-cell 
dysfunction in T2D (164).  Genome-wide gene expression profiling of islets obtained from 
normal and type 2 diabetic patients revealed that expression of ARNT/HIF-1β was reduced 
by 90% under diabetic conditions. In addition to ARNT/HIF-1β, genes involved in glycolysis 
and insulin signalling were also found to be down-regulated in diabetic islets. Several 
enzymes in glycolysis, which were also ARNT/HIF-1β targets, including 
phosphoglucomutase (PGM), phosphoglucose isomerase (G6PI), phophofructokinase (PFK) 
and aldolase, were expressed at significantly lower levels in diabetic islets compared to 
normal islets. Expression of key regulators of the insulin signalling pathway, such as the 
insulin receptor (IR), insulin receptor substrate 2 (IRS2), and protein kinase B (Akt2) was 
also found to be down-regulated in diabetic islets. In addition, genes responsible for maturity 
onset diabetes of the young (MODY), a monogenic form of diabetes, namely, HNF-1α and 
HNF-4α, were found to be poorly expressed in islets obtained from type 2 diabetic patients. 
HNF-4α, mutated in MODY1, has been shown to interact with ARNT/HIF-1β possibly 
providing a connection between the two transcription factors (165). 
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In order to rule out the possibility that the profound ARNT/HIF-1β down-regulation in 
pancreatic beta-cells was not caused by the diabetic environment, Gunton and co-workers 
demonstrated that an identical gene profile was observed in a beta-cell-specific ARNT/HIF-
1β knock out mouse (β-ARNT KO) (164). β-ARNT KO mice had reduced expression of 
genes involved in glycolysis and insulin signalling, similar to those observed in diabetic 
islets.  The mice also exhibited impaired in vitro and in vivo GSIS and glucose intolerance, 
with no significant change in beta-cell insulin content and islet mass. Thus, through a series 
of in vivo and in vitro experiments in humans and rodents, Gunton et al provided strong and 
convincing evidence that reduction in ARNT/HIF-1β expression in pancreatic beta-cells has 
negative consequences in terms of beta-cell function and insulin secretion. However, the 
extent of ARNT/HIF-1β-mediated regulation of gene transcription seems much more 
complex than one might expect as it has the potential to bind with multiple partners affecting 
a multitude of signalling pathways.  
Following Gunton’s discovery of ARNT/HIF-1β as the most down-regulated gene in diabetic 
islets, a few groups have focused their attention to identify the upstream regulators of the 
transcription factor in pancreatic beta-cells. Dror et al identified presenilin, a protein that was 
shown to be involved in the regulation of beta-cell survival, in calcium homeostasis and 
response to hypoglycemia in neurons, as an upstream regulator of ARNT/HIF-1β (166-168).  
In another study, based on chromatin immunoprecipitation and high density oligonucleotide 
arrays, carbohydrate responsive element binding protein (ChREBP), a transcription factor 
involved in carbohydrate metabolism in the liver and pancreatic beta-cells, was identified as 
a negative regulator of ARNT/HIF-1β. Their results suggested that ChREBP-mediated 
repression of the HIF complex might contribute to beta-cell dysfunction induced by 
glucotoxicity (169). However, in 2010, Gunton’s group presented a substantial amount of 
evidence once again, where HIF-1α, the heterodimeric binding partner of ARNT/HIF-1β was 
identified as an upstream regulator of ARNT/HIF-1β (170). Similar to ARNT/HIF-1β, HIF-
1α levels were also found to be down-regulated in type 2 diabetic islets. Also, beta-cell 
specific HIF-1α knock-out mice had impaired GSIS and were glucose intolerant, leading to 
hyperglycemia. In an attempt to understand whether the observed phenotype could be 
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rescued by improving HIF-1α levels, treatment with iron chelators, which has been shown to 
increase HIF-1α protein levels, resulted in improved insulin secretion and it normalized 
ARNT/HIF-1β mRNA and downstream target gene expression in type 2 diabetic islets. This 
is the firs study that has shown that increasing HIF-1α protein levels positively influences 
ARNT/HIF-1β mRNA levels. However, the exact mechanism of this interaction is still not 
completely understood.   
1.11.2 ARNT/HIF-1β and Liver 
In both rodents and humans, the liver plays a critical role in maintaining glucose and lipid 
homeostasis. During fasting, hepatic glucose production is critical in providing glucose for 
the brain, the kidneys and the red blood cells. In liver, glucose is produced by glycogenolysis 
during the initial stages of fasting. However, after several hours of fasting, glucose is 
primarily produced from gluconeogenesis, a process by which the liver produces glucose 
from precursors such as lactate and pyruvate, thus preventing the body from going into 
hypoglycemic shock (171,172). Similar to the observation made by Gunton and co-workers 
in human type 2 diabetic islets and consistent with it, Wang et al in 2009 reported that 
ARNT/HIF-1β was severely reduced in the livers of type 2 diabetic patients (173). Gene 
expression profiling of liver specimens from normal, obese and obese diabetic patients 
revealed a 30% reduction in the expression of ARNT/HIF-1β gene in obese diabetic 
individuals. The study demonstrated that the reduced expression of ARNT/HIF-1β in the 
livers of humans with T2D was associated with high glucose levels, high insulin levels and 
insulin resistance. Wang et al also demonstrated that insulin, not glucose, regulates the 
expression of the ARNT/HIF-1β gene in the liver and that its expression is reduced in both 
insulin-deficient and insulin-resistant states. 
To understand the deleterious effects of disruption of the ARNT/HIF-1β gene in the liver, a 
liver specific ARNT/HIF-1β knockout mouse was generated (L-ARNT KO) (173). L-ARNT-
KO mice exhibited increased gluconeogenesis, lipogenesis and serum insulin levels, 
characteristic of human T2D. The association between the loss of ARNT/HIF-1β and 
increased hepatic gluconeogenesis and lipogenesis may be mediated by increased expression 
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of several important gluconeogenic and lipogenic genes including PEPCK, G6Pase, SCD1 
and FAS. Expression of C/EBPα and SREBP-1C, was also induced by 2-fold in L-ARNT 
KO mice. C/EBPα plays a major role in kick-starting hepatic glucose production at birth, and 
disruption of the C/EBPα gene in mice is known to cause hypoglycemia associated with the 
impaired expression of the gluconeogenic enzymes PEPCK and G6Pase (174,175). SREBP-
1C, on the other hand, is a major player in lipogenesis (176).  Thus, based on the above 
evidence, it seems that ARNT/HIF-1β acts as an upstream regulator of these transcription 
factors and plays a key role in maintaining whole body glucose and lipid homeostasis. 
However, as seen in pancreatic beta-cells, the exact pathways targeted by ARNT/HIF-1β in 
liver are not clearly understood and is complicated by the fact that ARNT/HIF-1β has 
multiple binding partners. 
1.11.3 ARNT/HIF-1β and Adipose Tissue 
Obesity leading to insulin resistance is one of the key pathophysiological abnormalities in 
T2D. Adipokines such as leptin and adiponectin secreted from the adipose tissue play a 
critical role in maintaining glucose metabolism, energy expenditure and inflammatory 
response (177,178). The occurrence of adipose tissue hypoxia is a characteristic feature of 
insulin-resistant obese state and exposure to hypoxia is known to have deleterious effects on 
adipose tissue. Wang et al reported that cultured adipocytes exposed to hypoxia showed 
increased expression of HIF-1α levels and this was associated with increased expression of 
inflammatory cytokines such as IL-6, raised leptin levels and decreased adiponectin levels 
(179). Similar observations were made in the adipose tissue of Ob/Ob mice and dietary obese 
mice, where hypoxia increased the expression of inflammatory genes and reduced the level 
of adiponectin, suggesting a potential role for hypoxia in the induction of chronic 
inflammation and inhibition of adiponectin in obese adipose tissue (180,181). Consistent 
with the deleterious effects of hypoxia and increased expression of HIF-1α protein, 
adipocyte-specific deletion of ARNT/HIF-1β in mice leads to protection of these mice from 
the consequences of high fat diet. Adipocyte-specific ARNT/HIF-1β knock-out mice were 
lean, had smaller adipocytes and were protected from age and diet-induced glucose 
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intolerance (182). These effects of ARNT/HIF-1β in adipose tissue were found to be 
mediated in part through HIF-1α. However, the effects HIF-1α deletion in adipocytes is 
inconclusive as studies conducted by two research groups yielded completely opposite results 
in mice. While Jiang et al’s (183) observations were similar to those seen in adipocyte-
specific ARNT/HIF-1β knock-out mice, where the adipocyte-specific HIF-1α mice were lean 
and protected from the effects of high fat diet, Zhang et al’s study showed entirely opposite 
effects. Zhang and co-workers showed that adipocyte-specific deletion of HIF-1α leads to 
obesity and glucose intolerance by impeding energy expenditure (184). What makes this 
more complicated is the observation that a global knock-out of asparginyl hydroxylase, a 
factor inhibiting HIF-1α (FIH) function, leads to reduced body weight, elevated metabolic 
rate, hyperventilation and improved glucose and lipid homeostasis (185). The mice are also 
resistant to high-fat-diet-induced weight gain and hepatic steatosis suggesting that a global 
increase in HIF-1α levels is beneficial to mice. An interesting observation noted in their 
research was that the neuron-specific knock-out of FIH phenocopies some of the major 
metabolic effects observed in global FIH-knock-out mice suggesting that HIF signalling may 
play a critical role in the central control of metabolism. Thus, based on these results, although 
it is difficult to interpret the precise role of the HIF-1α-ARNT/HIF-1β partnership in the 
adipose tissue, it is quite evident that the role played by this heterodimeric duo is much more 
complex than in other tissues such as the liver and the beta-cells. 
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1.12 Objectives and Hypothesis  
The main objective of this study was to understand the biochemical and physiological role of 
ARNT/HIF-1β in maintaining glucose-stimulated insulin secretion (GSIS) and glucose 
homeostasis in mice. In their study, Gunton and co-workers clearly demonstrated a role for 
ARNT/HIF-1β in maintaining normal beta-cell function, GSIS and glucose homeostasis in 
mice. However, a detailed analysis of the metabolic phenotype of beta-cells deficient in 
ARNT/HIF-1β and the mechanism by which the transcription factor regulated GSIS from 
pancreatic beta-cells was not fully investigated. Specifically, the extent of involvement of 
ARNT/HIF-1β in the regulation of key metabolic pathways such as the glucose metabolism 
pathway, which play a critical role in the control of GSIS, was largely unknown. The two 
specific objectives of the present study, therefore, are:  
1. To determine the involvement of ARNT/HIF-1β in beta-cell glucose metabolism 
and insulin secretion using an siRNA against ARNT/HIF-1β in the 832/13 clonal 
beta-cell line 
2. To determine the mechanism by which ARNT/HIF-1β maintains glucose 
homeostasis in vivo: 
(1) Generate pancreatic beta-cell specific ARNT/HIF-1β knock-out mice (β-
ARNT KO) 
(2) Characterize in vivo metabolic parameters of β-ARNT KO mice 
(3) Characterize in vitro beta-cell function of islets from β-ARNT KO mice 
Hypothesis: Based on the known role of ARNT/HIF-1β as a protein required for the 
transcriptional activation of glycolytic enzymes in response to hypoxia, we hypothesize that 
ARNT/HIF-1β regulates GSIS by altering the key biochemical events in the glucose 
metabolism pathway. As a consequence of altering the biochemical events, we expect to see 
concomitant changes in the amounts of metabolites in the glucose metabolism pathway and 
their tributaries such as the amino acid and the fatty acid pathways, thereby regulating the 
metabolic signal transduction pathways that control GSIS from pancreatic beta-cells. 
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Chapter 2 
Experimental Procedures 
2.1 Methodology and Models 
The functional significance of ARNT/HIF-1β in pancreatic beta-cells was investigated 
systematically through a loss of function strategy. RNA interference technology (RNAi), one 
of the most commonly used gene knock-down platforms, was used to transiently inhibit 
ARNT/HIF-1β mRNA and protein levels in the 832/13 clonal beta-cell line. In addition, the 
in vivo role of ARNT/HIF-1β was investigated through the disruption of the ARNT/HIF-1β 
gene specifically in the pancreatic beta-cells of mice using a widely used gene knock-out 
platform called the Cre-loxP recombination technology, the details of which are presented in 
section 2.14 of this chapter. The in vivo and in vitro characterization of beta-cells deficient in 
ARNT/HIF-1β was carried out using a number of biochemical assays and molecular biology 
techniques. The detailed experimental procedures used for performing these assays and 
techniques are described in the following sections.  
2.2 832/13 Clonal Beta-Cell Line 
832/13 cells were a kind gift from Dr. Christopher Newgard. These clonal cells were derived 
from rat insulinoma cell line, INS-1, by a transfection-selection strategy (186). Briefly, INS-1 
cells were stably transfected with a plasmid containing the human proinsulin gene. After 
antibiotic selection and clonal expansion, only 16% of the clones were found to be strongly 
responsive to glucose in terms of insulin secretion and these were designated as 832/13 cells. 
These cells showed an average of 10-fold increase in insulin secretion when the glucose 
concentrations were raised from low to high. Along with a strong response to glucose, 832/13 
cells were stable for 66 population doublings, which happened over 7.5 months, with a half-
maximal stimulation at 6 mM glucose. Further characterization revealed that 832/13 cells 
responded strongly to all major insulin secretagogues and in some cases responses were 
stronger than the parental INS-1. For cell culture, 832/13 cells were cultured in RPMI 1640 
medium containing 11.1 mM glucose (Fisher Hyclone - SH30027-FS) and supplemented 
with 10% FBS, 10 mM HEPES, 2 mM glutamine, 1 mM sodium pyruvate, and 50 µM β-
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mercaptoethanol at 37 ̊ C in a humidified atmosphere containing 5% CO2. Cells were 
maintained in a T75 flask at 1:3 ratio (cells: fresh culture medium) and passaged   2 - 3 times 
a week.  
2.3  Silencing RNA (siRNA) Mediated Gene Suppression  
Expression of ARNT/HIF-1β mRNA was silenced via introduction of 25-27 base pair siRNA 
duplexes (Integrated DNA Technologies (IDT), San Diego). Two siRNA duplexes were 
constructed against ARNT/HIF-1β mRNA (Accession number: NM_012780), siARNT 1 and 
siARNT 2. An siRNA sequence with no known gene homology was used as a control siRNA 
(siControl) for all experiments. Relative to the start codon, the 5’end of the siRNA target 
sequence corresponded to the following nucleotides in ARNT/HIF-1β as shown in table 1: 
Table 1:List of siRNA sequences 
Sequence Name Start nucleotide siRNA sequence (5’- 3’) 
siARNT 1 389 CCA UCU UAC GCA UGG CUG UUU CUC A 
siARNT 2 891 GGA AGG AGA GCC UCA CUU UGU GGT A 
siControl NA GAG ACC CUA UCC GUG AUU A 
 
Transfection: 832/13 cells were plated at 0.5 million cells/mL/well of RPMI in a 12 well 
plate or 1 million cells/2 mL/well on a 6 well plate. Approximately 60 pmoles of siRNA 
duplexes were introduced per well of a 12 well plate at 50% confluence using Lipofectamine 
RNAiMax according to the manufacturer’s instructions (Invitrogen).  Cells were incubated 
with the transfection complex containing siRNA duplex and the lipofectamine RNAiMax for 
24 h. Following 24 h transfection, transfection medium was changed and fresh RPMI growth 
medium was added and cells were cultured for an additional 48 h prior to metabolic assays, 
at which point cells were collected for RNA and protein.  
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2.4  RNA Isolation, cDNA synthesis and Real time PCR 
RNA isolations from 832/13 cells or islets were carried out using an Aurum Total RNA Mini 
kit (BioRad, Hercules, CA). Approximately 0.5 µg of cDNA was synthesized through 
reverse transcription using an Iscript cDNA synthesis kit (BioRad, Hercules CA). 
Approximately 50 – 100 ng of cDNA were used for real time PCR analysis, which was 
performed on Applied Biosystems, ABI 7500 series real time PCR machine using 
appropriate primer sets (table 2) and SsoFast EvaGreen real time PCR supermix (BioRad) 
OR using pre-designed fluorescent probes purchased from Applied Biosystems, Inc. (ABI, 
Foster City, CA) (table 3). PCR primer sets were designed using Primer-BLAST, a primer-
designing tool from NCBI and purchased from IDT (IDT, San Diego). Gene expression 
levels were corrected by cyclophilin E (Cyp) expression.  
Table 2: List of PCR primers used for gene expression profiling 
Gene NCBI ID Primer Sequence (Tm) Product Size 
ARNT NM_012780.1 
For: GCGGCGACGGAACAAGATGACA (62.2 ºC) 
Rev: ACACCACTCGGCCAGTCTCACA (62.7ºC) 
 
266 
 
CYP NM_001047868.1 
For: AGATGGCACAGGAGGAAAGAGCAT (60.3 ºC) 
Rev: AGGGTTTCTCCACTTCGATCTTGC (59.0 ºC) 
 
302 
CIC NM_017307 For: TTGGGATGTTCGAGTTCCTCAGCA (60.3 ºC) 
Rev: TTGTCTCCTTGGTACCAGTTGCGT (60.5 ºC) 
 
334 
DIC NM_133418 For: CCAGCAGATTTGGTCAATGTCAGG (58.3 ºC) 
Rev: GGTCCAAGCTTTGCTGTCTCCA (59.8 ºC) 
 
392 
OGC NM_022398 
For: TCTGTGCCACTTCTGCGCCA (62.1 ºC) 
Rev: AGCCACTGAGGAAGAGACGCT (60.4 ºC) 
 
287 
GK NM_012565.1 
For: ATGCTGGATGACAGAGCCAGGAT (60.4 ºC) 
Rev: TCGGGGATGGAGTACATCTGGTG (60.2 ºC) 
 
335 
GLUT 2 NM_012879.2 
For: CCTGGCCGGGATGATTGGCA (62.9 ºC) 
Rev: AGGCCCGAGGAAGTCCGCAA (63.9 ºC) 
 
283 
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Gene NCBI ID Primer Sequence (Tm) Product Size 
PC NM_012744 For: TGACGTGGCCATGCGCTTCT (62.4 ºC) 
Rev: ACTGCCAGCTGCTTCCATGC (61.1 ºC) 
 
250 
PDH NM_001004072  
For: AGTCTGCTGCGCTCCATGAGG (62.8 ºC) 
Rev: CACACAGCAGGCTTCCTGACC (61.8 ºC) 
 
321 
FAS NM_017332 
For: TTTCCGCCATCTCCAAGACCTTCT (60.2 ºC) 
Rev: CAAGGTTCAGGGTGCCATTGTACT (59.3ºC) 
 
390 
CPT-1α L07736 
For: TGGCAGAGGCTCACCAAGCTGT (60.37 ºC)  
Rev: GGCTTGACATTCGGCCAGTGGT (59.67 ºC) 
 
297 
HNF-1α NM_012669 
For: TGGCTCAGCAATTCACCCACGC (60.24 ºC) 
Rev: T TGGCCAGCTTATGCCGAAAGGC (60.05 ºC) 
 
330 
HNF-4α 
AF329936 
 
For: CTCCAGTGGCGAGTCCTTATGA (59.8 ºC) 
Rev: AGCACTTCTTGAGCCTGCAGTA (58.6 ºC) 
 
381 
HIF-1α NM_024359  
For: AGCTCACCTGAGCCTAACAGTCC (60.5 ºC) 
Rev: TTGCGGTGGCAGTGACAGTGA (61.7 ºC) 
 
322 
PGC-1α NM_031347.1 
For: TGCCATTGTTAAGACCGA (61.2ºC) 
Rev: CCAGTAAACCACTGAGACC (61ºC) 
 
300 
EPAC 2 XM_215985.5 
For: ATACTGCCAGAACGGTGCGCT (61.1 ºC) 
Rev: AAGCTACGGCATGTCCGCGTT (62 ºC) 
 
377 
ARNT Floxed N/A  For: TGCCAACATGTGCCACCATG   Rev: GTGAGGCAGATTTCTTCCATGCTC 
WT (290) 
+/Fl (290, 340) 
Fl/Fl (340) 
Cre 
 N/A 
For: AAAATTTGCCTGCATTACCG (62ºC) 
Rev: ATTCTCCCACCGTCAGTACG (62ºC) 553 
ARNT  NM_001037737.2 For: AGCGGTTTGCCAGGTCGGATG (59ºC) Rev: GATGTGTTGCCAGTTCCCCTCAA (58.2ºC) 232 
PC NM_001162946.1 For: GCTGTGCCATTCAGTGTCGGGT (59ºC) Rev: TGGGGTGGTCTTTGCCGTGT (60ºC) 201 
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Table 3: List of fluorescent probes used for gene expression profiling 
Fluorescent Probes NCBI ID Reference ID Product Size 
MEc NM_012600.2 Rn01445345_m1 112 
ICDc NM_031510.1 Rn01438266_m1 121 
ACS NM_023104.1 Rn01646009_g1 80 
PLC-g1 NM_013187.1 Rn01640806_m1 114 
CL NM_001111095.1 Rn00566411_m1 89 
 
2.5 Protein Isolation and Western Blot 
Cellular proteins were extracted with cell lysis buffer (Cell Signalling, Danvers, MA) 
containing phenylmethylsulfonyl fluoride (0.5 mM), leupeptin (10 µg/ml), aprotinin (10 
µg/ml), and pepstatin (5 µg/ml). Protein quantification was performed using the 
bicinchoninic acid (BCA) protein assay. In the BCA assay, total protein extracted with cell 
lysis buffer was compared to protein standards through a colorimetric assay. The assay 
exhibits a strong linear absorbance at 562 nm with increasing protein concentrations.  Protein 
extracts (40 µg) were resolved on 10% Bis-Tris SDS-polyacrylamide gels and electro 
transferred to nitrocellulose membranes (Invitrogen). ARNT/HIF-1β was detected with a 
monoclonal antibody against ARNT (1:1000) (BD Bioscience) followed by horse-radish 
peroxidase-conjugated anti-mouse antibody (1:10,000) (Amersham Biosciences). γ-Tubulin 
was detected by immunoblotting with a mouse antibody against γ-tubulin (1:4000) (Sigma) 
followed by horseradish peroxidase-conjugated antimouse antibody (1:15,000) (Amersham 
Biosciences). Protein bands were detected with the ECL Advance immunoblot detection kit 
(Amersham Biosciences). All protein bands were visualized and quantified using a Kodak 
Imaging ChemStation (187). 
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2.6 Glucose-Stimulated Insulin Secretion Assay – 832/13 Cell line 
832/13 cells were plated on either a 6 well plate with an initial seeding density of 1 million 
cells/2mL/well or a 12 well plate with an initial seeding density of 0.5 million cells/mL/well 
and cultured for 5 days in RPMI 1640 medium with all nutritional supplements as noted in 
section 2.1. Insulin secretion was measured by pre-incubating cells in Kreb’s ringer buffer 
(KRB) containing 129 mM NaCl, 4.7 mM KCl, 1.5 mM KH2PO4, 1.16 mM MgSO4, 10 mM 
HEPES, 5 mM NaHCO3, 3.11 mM CaCl2, 0.2% bovine serum albumin, pH 7.4 with 2 mM 
glucose for 2 x 1h at 37o C with 5% CO2. Following 2 x 1h pre-incubation, cells were 
incubated in KRB containing either 2 mM, 7 mM or 16.7 mM glucose as indicated for 2 h at 
37o C with 5% CO2.  At the end of the 2 h incubation, the plates were gently swirled and 
samples (500 µL) of KRB from each well were removed and stored in appropriately labeled 
eppendorf tubes until insulin was measured through a radioimmunoassay (Coat a Count, 
Siemens) according to the manufacturer’s directions. All insulin values were normalized to 
protein content (186). 
For treatment with various insulin secretagogues, secretagogues were directly added to 2 
mM, 7 mM or 12 mM glucose as indicated on the day of the assay. 3 M KCl stock was 
prepared in water and diluted to 30 mM in freshly prepared KRB. Diazoxide was prepared in 
0.05 M NaOH stock solution stored in -20 o C and was diluted in freshly made KRB to reach 
the final concentration (100 µM in 832/13 cells and 200 µM in mice islets). For the 
preparation of amino acids, both leucine and glutamine were added to freshly prepared KRB 
(weight/volume) without glucose to reach a final concentration of 10 mM each in solution. 
For low amino acid concentration, 10 mM solution was diluted 1:10 in KRB without glucose. 
For dimethyl malate (DMM – Sigma 374318) and dimethyl alpha ketoglutarate (DMAKG – 
Sigma S84045), 5 mM each of the stock solution (density/volume) was added to freshly 
prepared KRB solution on the day of the assay. 
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2.7 Preparation of Palmitate complex for GSIS 
1 mM Palmitate /0.17 mM BSA – Caution: 1) Use glass vials for preparation of palmitate-
BSA as the complex will readily adhere to plastic. 2) Maintaining suggested temperatures for 
preparation of the complex is critical to achieve quality conjugation.  
A stock of 2 mM palmitate solution was prepared by dissolving sodium palmitate (Sigma 
P9767) in 50 mL of 150 mM NaCl at 70 o C. To minimize vapour loss, the beaker was 
covered with parafilm and NaCl/Palmitate solution was heated to 70°C on a hot plate, with 
continued stirring and monitoring of the temperature using a thermometer. 2 % Fatty Acid-
Free (FFA) BSA solution was prepared in 100 mL KRB (without the phosphates – Islet 
KRB) at 37 o C and filtered using 0.45-micron filter. Half of the BSA solution was diluted 
with phosphate-free KRB to get a 1% BSA solution and stored at -20 o C. This was used as a 
vehicle control.  The remaining half of the BSA solution was used for the preparation of 
palmitate-BSA complex.  
Once the palmitate and BSA solutions were ready, 40 mL of the palmitate solution at 70 o C 
was slowly transferred to the BSA solution at 37 o C while stirring. Since palmitate solution 
will precipitate if it is allowed to sit in the pipette, 5 mL of the palmitate was transferred at a 
time to the BSA solution, aspirating and dispensing quickly. Once the transfer was done, the 
beaker was covered with parafilm while continuing to stir at 37 o C for 1 h, monitoring the 
temperature of the water bath to stay between 37 o C and 40 o C. Once the palmitate was 
completely dissolved in BSA solution, pH was adjusted to 7.4 and a final volume to 100 mL 
with phosphate-free KRB solution. The palmitate-BSA complex was filtered using 0.45-
micron filter and stored in glass vials at -20 o C. For use in INS-1 derived 832/13 cells, since 
the palmitate-BSA complex is prepared in phosphate-free KRB, phosphates were added in 
appropriate amounts at a later stage when the complex preparation was completed and before 
storing the solution at -20 o C. The amount of free-fatty acids in the solution was measured 
using a NEFA kit (HR Series NEFA-HR (2), Wako Diagnostics) and the concentration of 
palmitate needed for GSIS was achieved by diluting with KRB (188). 
   45 
2.8 Glucose Utilization  
832/13 cells were plated on a 12 well plate at an initial seeding density of 0.5 million 
cells/mL/well. Cells were transfected with siRNA duplexes and cultured for a total of 72 h 
post transfection. On the day of the assay, cells were pre-incubated in KRB containing 2 mM 
glucose for 2 h, followed by 2 h treatment in KRB containing either 2 mM or 16.7 mM [5-
3H] glucose (Perkin Elmer) as a tracer at a specific activity of 0.08 Ci/mol. At the end of 2 h 
treatment with tracer, KRB was collected and protein was precipitated using 10% TCA. 
Following centrifugation at 12,000 x g for 5 min, the remaining buffer was transferred to a 
capless eppendorf tube placed inside a scintillation vial, and allowed to equilibrate overnight 
at 50°C in a CO2 -free incubator. Following overnight incubation, vials were allowed to cool 
to room temperature for 1 h, capless tubes were removed and the vials were counted using 
liquid scintillation fluid (Economical Biodegradable Counting Cocktail; Econosafe, Research 
Products International (RPI), Mount Prospect, Illinois). Efficiency of the equilibration was 
determined by measuring equilibration of 3H2O (Amersham). All glucose utilization values 
were normalized to protein content (189).  
2.9 Glucose Oxidation  
832/13 cells were plated on a 12 well plate at an initial seeding density of 0.5 million 
cells/mL/well. Cells were transfected with siRNA duplexes and cultured for a total of 72 h 
post transfection. On the day of the assay, cells were pre-incubated in KRB containing 2 mM 
glucose for 2 h, followed by 2 h treatment in KRB containing either 2 mM or 16.7 mM [U-
14C] glucose (Perkin Elmer) as a tracer at a specific activity of 0.5 Ci/mol. Before 2 h 
incubation of cells with tracer, each well containing cells was loaded with a trap system 
containing 1 N NaOH. The trap system was tightly sealed and incubated at 37 o C for 2 h. At 
the end of 2 h incubation, 70% perchloric acid was carefully injected into each well for 
protein precipitation. The trap was then incubated on a shaker at 125 rpm for 90 min. NaOH 
was transferred to scintillation vials containing UniScint BD scintillation fluid (BD 
Biosciences), mixed, and then counted to determine glucose oxidation rates and normalized 
to protein content (74,189). 
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2.10 ATP – ADP Measurements 
832/13 cells were plated on a 6 well plate at an initial seeding density of 1 million 
cells/mL/well. Cells were transfected with siRNA duplexes and cultured for a total of 72 h 
post transfection. On the day of the assay, cells were pre-incubated in KRB containing 2 mM 
glucose for 2 h, followed by 2 h treatment in KRB containing either 2 mM or 16.7 mM 
glucose. At the end of the 2 h treatment, KRB buffer was collected for insulin assay. Cells 
were scraped off and snap frozen in a dry-ice ethanol bath and stored at -80 o C until the day 
of the ATP-ADP assay.  ATP and ADP were extracted from the samples with 20 units of 
10% (w/v) perchloric acid. After centrifugation, the supernatants were neutralized with 2 N 
KOH and 0.5 M triethanolamine. Aliquots of each deproteinized sample were assayed for 
ATP directly with luciferase. Other aliquots were treated with ATP sulfurylase in the 
presence of molybdate to hydrolyze the endogenous ATP to AMP and PPi. After boiling the 
samples to inactivate the sulfurylase, ADP was then converted to ATP with pyruvate kinase. 
ATP content in these samples was measured with luciferase (Sigma L9506) in the presence 
of luciferin (Sigma L9504) mixed with ATP assay mix dilution buffer (Sigma- FLAAB-1VL) 
Luminescence was measured using a spectrophotometer and normalized to protein content 
(190). 
2.11 NADPH-NADP Measurement 
832/13 cells were plated on a 6 well plate at an initial seeding density of 1 million 
cells/2mL/well. Cells were treated with siARNT or siControl for 72 h.  On the day of the 
assay, cells were pre-incubated in KRB containing 2 mM glucose for 2 h, followed by 2 h 
treatment in KRB containing either 2 mM or 16.7 mM glucose. At the end of the 2 h 
treatment, KRB buffer was collected for insulin assay. Cells were scraped off and snap 
frozen in dry-ice ethanol bath and stored at -80 o C until the day of the NADPH-NADP assay. 
The assay was performed using a NADPH/NADP quantification kit from Sigma (MAK038) 
following the manufacturer’s instructions. The assay is specific for NADP and NADPH and 
does not detect NAD or NADH. NADP (total) (NADP and NADPH) and NADPH are 
quantified in a colorimetric assay (450 nm) (67).  
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2.12 Gas Chromatography- Mass Spectrometry Analysis of Metabolites (GC-
MS 
 832/13 cells were plated on a 6 well plate at an initial seeding density of 1 million 
cells/2mL/well. Cells were treated with siARNT or siControl for 72 h. On the day of the 
experiment, cells were first incubated for 2 h at low glucose (2.8 mM) followed by 
incubating the cells with either low (2.8 mM) or high glucose (16.7 mM) for 2 h. After the 
insulin secretion assay, cells were washed once with ice-cold PBS, scraped off the plates 
followed by centrifugation at 3,500 rpm for 1 min at 4°C. The supernatant was discarded and 
the cell pellet was resuspended in 100 µl of water followed by sonicating for 60 sec (~40 
KHz, ~140 W). One ml of methanol was added followed by centrifugation for 5 min at 
13,300 rpm. Supernatant was mixed with 5 µl of 0.25 mg/ml myristic acid-d27 as an internal 
standard (used for retention time locking) followed by drying with nitrogen. Derivatization 
was then performed in two steps: first, carbonyls were protected by methoximation using 
methoxyamine hydrochloride in pyridine at 50°C for 30 min. Second, acidic groups were 
silylated with 90 µl N-methyl-N-(trimethylsilyl) trifluoroacetamide (MSTFA) with 1% 
TMCS at 50°C for 30 min. 
GC-MS analysis: One microliter of the derivatized sample was injected in split mode with 
1:2 split ratio onto a GC (7890A Agilent, USA; DB-5MS column (30 min × 250 µm × 0.25 
µm)). Detection was performed with a quadrupole mass spectrometer (5895C Agilent USA). 
Each sample was run four times. 
Deconvolution and Identification: The Automated Mass Spectral Deconvolution and 
Identification System software (AMDIS, Version 2.65) was used for peak detection and mass 
spectrum deconvolution. Target compounds were identified using retention time and by 
matching mass spectra in either Fiehn GC/MS Metabolomics Retention Time Locking (RTL) 
Library (Version 2.0f) or NIST library (2008). A known amount internal standard (myristic 
acid-d27) was used to calculate relative metabolite levels (191)   
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2.13 Animal housing 
All mice were housed in the temperature controlled central animal facility of the University 
of Waterloo and were handled according to the Canadian Council of Animal Care guidelines. 
All animal studies were approved by the Office of Research Ethics, University of Waterloo- 
(Animal Utilization Project Proposal – AUPP 11-19). Mice were subjected to a 12 h light and 
dark cycle and were fed on breeder chow. All mice used in this study were from a C57BL/6 
genetic background.  
2.14  Generation of ARNT/HIF-1β Knock-Out Mice 
The generation of pancreatic beta-cell specific ARNT/HIF-1β knock-out mice (β-ARNT KO) 
requires two types of transgenic mice: the ARNT Floxed mice (ARNTFl/Fl) and mice 
expressing Cre-recombinase under the influence of rat insulin promoter (RIP-Cre). Briefly, 
tissue specific expression of Cre-recombinase in pancreatic beta-cells is achieved by keeping 
the Cre under the control of rat insulin promoter (RIP).  When pancreatic beta-cells that have 
loxP sites in their genome express Cre-recombinase, the Cre protein will recognize and cut 
the loxP sites, leading to deletion of the floxed target DNA sequence. Floxed mice were 
generated by integrating the loxP sites on either side of exon 6 of the ARNT gene (163). The 
RIP-Cre transgene was constructed by the ligation of 668 nucleotides of the rat insulin 
promoter sequence to the coding sequence of Cre with a nuclear localization signal and a 
poly adenylation signal (192). Since ARNT floxed allele has the loxP sites flanking exon 6 of 
the ARNT gene, Cre-mediated recombination event will lead to the deletion of exon 6, 
resulting in the loss of ARNT protein function (Figure 6). 
Homozygous ARNT Floxed mice were a kind gift from Frank Gonzalez (NIH) and RIP-Cre 
mice were a kind gift from Dr. Mike Wheeler (University of Toronto). ARNT floxed mice 
and RIP-Cre mice were bred together to generate the knock-out mice at the Central Animal 
Facility, University of Waterloo. 
β-ARNT KO mice were generated in a two-step breeding process: In the first step, mice 
expressing the RIP-Cre transgene were bred to homozygous ARNT Floxed mice (ARNTFl/Fl), 
resulting in the generation of mice heterozygous for Floxed ARNT (ARNTWT/Fl) and 
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containing a copy of the RIP-Cre transgene (F1). In the second set of breeding, the F1 
heterozygotes were bred together to generate F2 mice, one fourth of which were homozygous 
for the ARNT Floxed gene with a copy of the Cre transgene (ARNTFl/Fl,Cre). The presence 
of RIP will ensure that Cre-recombinase is expressed only in the beta-cells resulting in the 
tissue specific deletion of ARNT protein (193).  Mice were born in the expected Mendelian 
ratio and the knock-out mice were phenotypically similar to their control littermates. 
 
 
Figure 6: Schematics of Cre mediated DNA recombination.  The Cre protein, which is a site-specific DNA 
recombinase, catalyzes the recombination of DNA between the loxP sites flanking exon 6 of ARNT gene 
resulting in the deletion of exon 6 that encodes the bHLH region of the ARNT protein. Briefly, the double 
stranded DNA is cut at both loxP sites and the strands are then rejoined by DNA ligase. The deletion process 
also results in the formation of a covalently closed circular DNA. 
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2.15 Genotyping – DNA Extraction and PCR 
Mice were ear-notched and DNA was extracted from the ear-clips using PureLinkTM 
Genomic DNA Mini Kit (Invitrogen) according to the manufacturer’s instructions. Briefly, 
ear notches were digested using genomic digestion buffer and proteinase K for 3 - 4 hr at 55 o 
C in a heating block. Residual RNA was removed by RNase digestion prior to sample 
binding to the silica membrane. The lysate was mixed with ethanol and PureLinkTM genomic 
binding buffer that allows high DNA binding to the silica-based membrane in the column. 
Impurities were removed by thorough washing with Wash Buffers 1 and 2. The genomic 
DNA was then eluted in low salt elution buffer. 
PCR was carried out to determine the presence of WT (290 bp), ARNT WT/Fl (290 and 340 
bp), ARNTFl/Fl (340 bp) and RIP-Cre (553 bp) transgenes using a Platinum Blue PCR 
supermix (Invitrogen) according to the manufacturer’s instructions. The following thermal- 
cycling profile was used for the detection of the floxed ARNT gene: 1 cycle of 5 min at 
95°C, 30 cycles at 95°C for 45sec, 60°C for 45 sec, 72°C for 45 sec and a final extension of 1 
cycle of 72°C for 6 min. PCR to detect the RIP-Cre transgene was achieved with 35 cycles of 
94°C for 30 sec, 62°C for 30 sec, and 72°C for 30 sec. PCR products were separated on 1% 
agarose gels using 0.5 X TAE (20 mM Tris-acetate and 2 mM Na2EDTA.2H2O, pH 8.5) as 
the running buffer and were visualized under UV light after staining with 0.1% ethidium 
bromide. A 100 bp low-scale DNA ladder was used for size comparison (Fischer – B2581-
200). A list of PCR primers used for genotyping is given in table 2. 
2.16 Intraperitoneal Glucose Tolerance Test (ipGTT) 
Age matched (15-20 weeks) male and female mice were fasted for 16 h, weighed and the 
tails were nicked with a fresh razor blade and gently massaged to collect 5 -10 µL of blood 
sample on to a glucose test strip. Basal glucose measurements were taken (0 min) followed 
by an intraperitoneal injection of glucose (1.5g/kg). Glucose solution was freshly prepared 
for each experiment in sterile phosphate buffered saline (PBS). Blood glucose measurements 
were taken at 10, 20, 30, 60 and 120 minutes using a Bayer Contour blood glucose 
monitoring system (Bayer Healthcare, Canada) 
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2.17 Insulin Tolerance Test (ITT) 
Age matched (15-20 weeks) male and female mice were fasted for 4 h, weighed and the tails 
were nicked with a fresh razor blade and gently massaged to collect 5 -10 µL of blood 
sample on to the glucose test strips. Basal glucose measurements were taken (0min) followed 
by an intraperitoneal injection of exogenous insulin (Humulin R- Lilly, Canada. 1.2 U/Kg 
body weight for females and 1.5 U/Kg body weight for males). Stock insulin (100 U/mL) 
was diluted in sterile PBS. Blood glucose measurements were taken at 10, 20, 30, 60 and 120 
minutes using a Bayer Contour blood glucose monitoring system (Bayer Healthcare, 
Canada). 
2.18 Comprehensive Lab Animal Monitoring System (CLAMS)– Assessing 
metabolic phenotype through indirect calorimetry 
Using indirect calorimetry, we examined the following parameters: VO2, VCO2, respiratory 
quotient (RER-VCO2/VO2), heat production, food intake and dual beam activity. All 
parameters were normalized to body weight. Male mice between15-20 weeks of age were 
used for this study. CLAMS with O2 and CO2 sensors and an infrared system to monitor 
X,Y,Z activity was used (Oxymax, Columbus Instruments, Columbus, OH). Both control and 
knock-out animals were studied simultaneously in individual chambers connected to the 
same O2 and CO2 sensors in an effort to minimize the effect of environmental variations and 
calibration on data. After a 24 h acclimatization period, mice were monitored in the 
metabolic chambers for an additional 24 h with ad-libitum access to food and water. Gas 
samples were collected and analyzed every 30 minutes per animal and the data collection was 
performed by an integrated program and exported to an EXCEL file. Output parameters 
include VO2 (mL/kg/min), VCO2 (mL/kg/min), heat production (calories/h) RQ 
(VCO2/VO2), food intake (grams/24 h) and dual beam activity. All measurements were 
averaged over each 30 minutes of the 24-h period from each group (n = 8 per genotype). An 
average of two separate trials were used for data analysis (194).  
2.19 Islet Isolation  
Mice were anesthetized by intraperitoneal injection of approximately 1µL/g of body weight 
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of sodium pentabarbitol (NaP). (NOTE: NaP is a controlled substance and must be stored in a 
locked cabinet). Once the mice are anesthetized, they were surgically opened and the 
pancreas was perfused through the common bile duct with about 3 - 4 mL of liberase 
(0.1WU/mL, Liberase TL Research Grade, Roche) made in 1 x Hank’s buffer (136 mM 
NaCl, 0.3 mM NaH2PO4, 4.16 mM NaHCO3, 5.36 mM KCl, 0.4 mM KH2PO4, 0.8 mM 
MgSO4 . 7H2O, 1.25 mM CaCl2 . 2H2O, 10 mM HEPES). The perfused pancreas was then 
extracted from surrounding tissues and digested at 37 °C for approximately 10 min. 
Digestion time is dependent on the enzyme activity and perfusion status of the pancreas. 
Once the digestion is completed, ice-cold Hanks’media was added immediately to arrest the 
digestion process. Islets were then sieved and washed in 2 x basic medium (RPMI 1640 with 
1% HEPES) by spinning them at 1000 rpm for 30 sec and removing the supernatant with 
each wash carefully without losing the pellet. The pellet containing the islets was then 
resuspended in islet culture medium (RPMI 1640 with 1.25% FBS, 1% HEPES, 0.1 % 
glutamine, 0.02 % of penicillin/streptomycin). Islets were then hand picked using a 
dissection microscope and cultured overnight in islet culture medium in a 6 well plate with 
approximately 200 islets/ 5 mL /well and at 37o C with 5% CO2 (88). 
2.20 Glucose-Stimulated Insulin Secretion - Islets 
For the islet secretion assay, islets were washed and incubated for 2 x 30 min in 5 mL of 
KRB containing 120 mM NaCl, 4.8 mM KCl, 1.2 mM KH2PO4, 1.2 mM MgCl2, 5 mM 
HEPES, 2.5 mM CaCl2, 24 mM NaHCO3, 0.1% bovine serum albumin, pH 7.4, with 2 mM 
glucose in a 6 well plate with approximately 100 islets/well at 37o C with 5% CO2. Islets 
were then divided into groups of 10 in a 1.5 mL eppendorf tube with 500 µl KRB buffer 
containing either 2 mM or 16.7 mM glucose for 1 h at 37o C with 5% CO2. After 1 h 
incubation, eppendorf tubes were taken out of the incubator and KRB buffer was gently 
mixed and left at room temperature for 5 min, allowing the islets to settle at the bottom. 400 
µl of KRB was aspirated from each tube and stored at -20 o C until the day of the radio 
immuno assay (RIA) for insulin.  RIA for measuring insulin in samples was carried out using 
Coat A Count Kit (Siemens) according to manufacturer’s directions (88). 
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2.21 Mitochondrial Membrane Potential 
Mitochondrial membrane potential was quantified in whole islets using a mitochondrial-
specific dye, rhodamine 123. Islets were loaded with rhodamine 123 (25 ug/ml, 10 min) in 
Krebs-Ringer buffer (KRB) containing 1 mM glucose, 0.1% BSA, 120mM NaCl, 2 mM 
CaCl2, 1 mM MgCl2, 24 mM NaHCO3, and 10 mM Hepes (pH 7.3) and fluorescence was 
measured for 100 secs at 37o C. After 100 sec at basal glucose concentration and achieving a 
stable baseline, 20 mM glucose was added for the next 400 sec. At the end of the experiment, 
1 mM sodium azide (NaN3) was added to inhibit the respiratory reaction and fully dissipate 
the potential. Membrane potential was measured using an Olympus IX70 inverted 
epifluorescence microscope connected to an Ultrapix camera and a computer with Merlin 
imaging software (LSR) (195). 
2.22 Cellular Oxygen Consumption Measurement  
Cellular oxygen consumption rates (OCR) were measured using a Seahorse flux analyzer 
(Seahorse Bioscience, Billerica, MA, USA). 40-50 islets were placed in XF24 islet plates 
following the protocol from Seahorse Biosciences and cultured overnight in islet culture 
medium (Section 2.19) at 37°C with 5% CO2. This allows the islets to adhere to the bottom 
of the plate overnight. Following overnight culture, islets were gently washed in KRB (islet 
KRB – section 2.20) containing 2 mM glucose to remove any traces of the culture medium. 
After the washes, islets were incubated 2 x 30 minutes in KRB containing 2 mM glucose (0.5 
mL) at 37°C with 5% CO2. Following the incubation, KRB containing 2 mM glucose was 
gently aspirated and fresh 0.5 mL KRB with 2 mM glucose was added. At this point, the 
XF24 plate was ready to be loaded into XF24 Seahorse Flux Analyzer (Seahorse Bioscience) 
for OCR measurements. For 832/13 cells, cells were seeded at 50,000 cells per well in XF24 
plates (Seahorse Bioscience) and treated with either siControl or siARNT using 
lipofectamine RNAimax as described before in section 2.3. On day 5, cells were pre-
incubated in KRB buffer containing 2 mM glucose (0.5 mL) for 2 h, changing the solution 
after 1 h, adding fresh KRB and placed at 37°C with 5% CO2. At this point plates are ready to 
be loaded into XF24 Seahorse Flux Analyzer (Seahorse Bioscience) for OCR measurements. 
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The cartridge (Seahorse Bioscience) was loaded with respective mitochondrial drugs 
prepared ahead of time and the loaded cartridge was kept at 37°C until the sample plate 
(XF24 islet or cell plate) was ready to be loaded to the Flux Analyzer. OCR was measured in 
response to 2 mM (basal) and 16.7 mM glucose, 5 µM oligomycin, 50 µM 2,4-dinitrophenol 
(DNP) and 10 µM rotenone + myxothiazol in the following configuration: mixing 2 min, 
waiting 2 min, measuring 3 min, loop x4. Raw OCR data was normalized to basal OCR. 
These values were then expressed as a percentage of the basal OCR. Normalized OCR values 
were then used to calculate different mitochondrial parameters such as ATP turn over, proton 
leak and spare respiratory capacity (196).  
Mitochondrial drugs: The XF24 Seahorse Flux Analyzer is used to measure the 
bioenergetic profile of the mitochondria and therefore commonly used to study the oxygen 
consumption by the cells (197). The functional state of mitochondria is studied through the 
use of various chemicals or drugs that have been proven to interfere with the normal oxygen 
consumption processes in the mitochondria. Each drug generates a typical OCR profile 
specific for the cell-type used. Following OCR measurements under basal (2 mM) and high 
glucose (16.7 mM) conditions, the mitochondrial drug oligomycin is added. Oligomycin 
inhibits ATP synthase (198) and is used to isolate the portion of oxygen consumed that is 
used by proton leak. Next, an uncoupling drug, 2,4-dinitrophenol (DNP), was administered 
along with a fuel to ramp up the OCR to the maximum level possible. Uncouplers destroy the 
proton gradient and allow the protons to easily flow back across the mitochondrial 
membrane. This causes an increased flux of electrons through the electron transport chain as 
the mitochondria try to maintain the proton gradient. Thus, under the influence of an 
uncoupler, the maximum possible OCR is found. Finally, a combination of rotenone and 
myxothiazol were administered which completely inhibits mitochondrial respiration by the 
inhibiting the enzyme complexes of the electron transport chain and OCR readings observed 
were an indication of oxygen consumption from non-mitochondrial components of the cell.  
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2.23 Intracellular Calcium Measurement 
Changes in intracellular calcium concentrations were assessed using dispersed islets plated 
on glass coverslips and cultured in islet culture medium with 5% CO2 at 37°C.  24 – 36 h post 
dispersion, cells were first gently washed in islet KRB with 2 mM glucose and loaded with 2 
µmol/l Fura-2 AM dye (Molecular Probes, Invitrogen) and incubated in a CO2 incubator at 
37°C for 50 min. At the end of the incubation, coverslips containing dispersed islets were 
loaded on the microscope and cells were perfused with KRB containing 2 mM glucose for 
100 Sec, 20 mM glucose for 400 sec and with 20 mM glucose and 30 mM KCl for 200 sec at 
a flow rate of 1 mL/min at 37°C. Experiments were performed using an Olympus BX51W1 
microscope (Tokyo, Japan) with an x20/0.95 water immersion objective and cooled charge-
coupled device camera. Measurements were taken using ImageMaster version 3.0 software 
(Photon Technology International, London, ON, Canada). Analysis was performed using Igor 
Pro version 4.0 software (Wavemetrics, Lake Oswego, OR, USA) and normalized to 
baseline. Only cells showing a response to 30 mmol/l KCl solution were included for data 
analysis (199). 
2.24 Statistical Test 
Statistical significance was assessed by Student’s t-test or analysis of variance post hoc 
Tukey’s test using GraphPad Prism 4. A p-value of less than 0.05 was considered significant. 
All data is expressed as mean ± SEM. 
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Chapter 3 
ARNT/HIF-1β Plays a Critical Role in Maintaining Glucose-
stimulated Anaplerosis and Insulin Release from Pancreatic Beta-
Cells 
3.1 Synopsis 
Despite its relevance in type 2 diabetes, the fundamental biochemical mechanisms and the 
metabolic pathways that regulate glucose-stimulated insulin secretion (GSIS) from pancreatic 
beta-cells are not completely understood.  One potential regulator of the metabolic phenotype 
of beta-cells is the transcription factor ARNT/HIF-1β, which was found to be profoundly 
reduced in islets from type 2 diabetic patients. The main objective of this study was to 
investigate the biochemical mechanisms by which ARNT/HIF-1β regulates GSIS and 
identify the key metabolic pathways that are targeted by the transcription factor in the 
regulation of GSIS from pancreatic beta-cells. Here we confirm that siRNA-mediated 
knockdown of ARNT/HIF-1β inhibits GSIS in the INS-1 derived 832/13 cell line. We 
demonstrate that beta-cells with reduced ARNT/HIF-1β expression levels exhibit a 31% 
reduction in glycolytic flux without generating significant changes in glucose oxidation or 
the ATP/ADP ratio, suggesting that ARNT/HIF-1β mediates GSIS independent of rise in 
ATP/ADP ratio which is one of the most critical signals required for triggering GSIS.  
Metabolic profiling of 832/13 cells treated with siRNA against ARNT/HIF-1β reveals a 
significant reduction in glucose-induced rise in the amounts of metabolites generated in 
glycolysis, TCA cycle and fatty acid pathway. These changes in metabolite levels were 
associated with a corresponding change in the gene expression pattern of key enzymes 
regulating these biochemical pathways. Together, our data suggest that ARNT/HIF-1β is 
required to maintain glucose-stimulated anaplerosis and thereby regulates insulin secretion 
from the pancreatic beta-cells in a manner that is independent of rise in ATP/ADP ratio. 
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3.2 Introduction 
Pancreatic beta-cells secrete the hormone insulin in response to a rise in the blood glucose 
levels. Abnormal insulin secretion is one of the earliest detectable defects at the onset of type 
2 diabetes (28) and despite its relevance, the mechanisms underlying glucose-stimulated 
insulin secretion (GSIS) are not completely understood. It is therefore critical that we 
understand the exact mechanism of insulin release from pancreatic beta-cells to develop 
successful strategies in the treatment of type 2 diabetes. 
The ability of the pancreatic beta-cells to maintain glucose homeostasis mainly depends on 
its capacity to secrete insulin in response to a change in arterial blood glucose concentration. 
It is generally accepted that the metabolism of glucose generates signals that are necessary 
for the acute stimulation of insulin secretion. The consensus model of GSIS holds that 
metabolism of glucose leads to an elevation of the ATP/ADP ratio to a point where it 
promotes the closure of the KATP channels, resulting in the depolarization of the beta-cell 
plasma membrane and opening of voltage-gated calcium channels. This allows calcium to 
enter the cytosol and promote insulin granule exocytosis (54,57,200). This so-called KATP 
channel-dependent pathway appears to be particularly important for the first, acute phase of 
insulin release. However, in the second and more sustained phase of insulin secretion, in 
addition to the initiation by the KATP channel dependent pathway, the KATP channel-
independent mechanism seems to be necessary for the amplification of GSIS. 
Important support for the KATP channel-independent pathways of GSIS comes from studies 
showing that glucose still causes a significant increase in insulin secretion in conditions 
where KATP channels are held open by application of diazoxide and high K+, or in animals 
lacking functional KATP channels (58,79,201,202). Other studies have suggested that 
mitochondrial metabolism of glucose generates signals other than changes in the ATP/ADP 
ratio that are important for normal insulin secretion. Several molecules, including glutamate, 
malonyl-CoA/LC-CoA and NADPH, have been proposed as candidate coupling factors in 
GSIS (65,66,68,69,71,203,204). 
Transcription factors regulate a variety of pancreatic beta-cell processes such as cell 
differentiation, proliferation, cell signalling and apoptosis (205-209). 
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functional and mature beta-cell phenotype requires the optimal expression of key 
transcription factors. In the context of T2D, it is a well-known fact that abnormal gene 
expression contributes to a myriad of beta-cell abnormalities. Support for this comes from 
studies on maturity-onset diabetes of the young (MODY), a monogenic form of T2D 
characterized by an early onset of the disease and defects in insulin secretion leading to 
hyperglycemia. With the exception of MODY-2, which is caused by a mutation in glycolytic 
enzyme glucokinase (GK), MODY-1, 3, 4, 5 and 6 result from mutations in genes encoding 
transcription factors, hepatocyte nuclear factor (HNF) HNF-4α, HNF-1α, HNF-1β, Pdx-1, 
and NeuroD/BETA-2 respectively (210-217). 
Among the large number of transcription factors identified as essential for the proper 
maintenance of beta-cell function, one of the recently emerged key players is the 
transcription factor ARNT/ HIF-1β. In an attempt to look at the expression profile of genes in 
human islets under normal and diabetic conditions, Gunton et. al discovered that ARNT/HIF-
1β was the most down-regulated gene in type 2 diabetic islets and the expression was 90% 
less in diabetic human islets (164). The importance of ARNT/HIF-1β in GSIS was further 
confirmed by the diminished GSIS in islets obtained from beta-cell specific ARNT/HIF-1β 
knock-out mice (β-ARNT KO) as well as in Min6 cells where the transcription factor was 
effectively silenced by siRNA technology. Furthermore, β-ARNT KO mice were glucose 
intolerant and islets from β-ARNT KO mice showed a significant decrease in the expression 
of genes that are critical for beta-cell secretory competence such as HNF-4α, the insulin 
receptor, IRS-2 and Akt2 which were all shown to be critical for maintaining glucose 
homeostasis. Several enzymes in the proximal part of the glycolysis pathway, including 
phosphoglucomutase (PGM), glucose-6-phosphate isomerase (G6PI), phospho fructokinase 
(PFK) and aldolase A (ALDO) were also found to be expressed at significantly lower levels 
in islets from β-ARNT KO mice compared to those observed in normal mice islets. Based on 
these evidence, it was concluded that ARNT/HIF-1β is indeed one of the key players 
regulating the transcriptional network of pancreatic beta-cells and that it may play an 
important role in the pathogenesis of T2D. 
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Although ARNT/HIF-1β was identified as important for maintaining beta-cell functional 
competence and normal glucose homeostasis in mice, we did not know the identity of the key 
metabolic pathways that are regulated by the transcription factor which are critical for 
glucose-stimulated insulin secretion. Our goal was to investigate the metabolic consequence 
of loss of ARNT/HIF-1β in pancreatic beta-cells using the INS-1 derived 832/13 beta-cell 
line where ARNT/HIF-1β expression was knocked down by an siRNA. In agreement with 
Gunton et al, we found that reduction of ARNT/HIF-1β expression decreases GSIS in the  
832/13-cell line. We also found that loss of ARNT/HIF-1β affects glucose utilization without 
affecting glucose oxidation or ATP/ADP ratio. Our results indicate the novel finding that 
ARNT/HIF-1β regulates glucose-stimulated anaplerosis and it is necessary for the glucose-
induced rise in fatty acids and that the mechanism of ARNT/HIF-1β-mediated insulin release 
is independent of beta-cell ATP production.  
3.3 Contributions 
Gas chromatography-mass spectrometry (GC-MS) based analysis of the metabolites was 
done in collaboration with Mei Huang, PhD candidate in Dr. Jamie Joseph’s lab. 832/13 cells 
were seeded, transfected and prepared for GC-MS by Renjitha Pillai. Samples were run on 
GC-MS and data analyzed by Mei Huang. 
3.4 Results 
3.4.1 siRNA Mediated Knock-Down of ARNT/HIF-1β in 832/13 Cell Line 
832/13 cells were transfected with one of the two siRNA duplexes targeting two different 
regions of the ARNT/HIF-1β gene transcript namely, siARNT1 and siARNT2 (see section 
2.2 under “Experimental Procedures” for sequence details) or a control, nonspecific siRNA 
sequence (siControl). 72 h post transfection, cells were harvested to measure ARNT/HIF-1β 
RNA and protein expression levels by real time PCR and Western blot, respectively. 
Treatment of 832/13 cells with siARNT1 resulted in a 78 ± 4% reduction of ARNT/HIF-1β 
mRNA as compared with the 56 ± 5% knockdown achieved by siARNT2. The effect on 
ARNT/HIF-1β mRNA knockdown mediated through siARNT1 was found to be statistically 
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more significant than mediated through siANRT2 (p<0.01, siARNT1 vs siARNT2, student’s 
t-test)  (Figure 7A).  ARNT/HIF-1β protein levels in 832/13 cells treated with siARNT1 were 
reduced by 67 ± 15% (Figure 7 B, C). 
 
 
 
 
Figure 7: Effects of siARNT1 and siARNT 2 duplexes on gene expression and protein levels in 832/13 
cells. A) Both siARNT 1 and siARNT2 decrease ARNT/HIF-1β mRNA levels. B, C) Immuno blot analysis of 
extracts from 832/13 cells-treated with siControl (S) and siARNT 1 (A). Results represent mean ± SEM from 3 
- 6 experiments. **p<0.01, ***p<0.001 siControl Vs siARNT, ANOVA post hoc Tukey’s test.  ## p <0.01 
siControl Vs siARNT, Student’s t-test. 
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3.4.2 ARNT/HIF-1β Suppression Impairs GSIS in 832/13 Cells 
832/13 cells were either left untreated or transfected with siControl, siARNT1, or siARNT2 
duplexes. After 72 h, GSIS was performed by pre-incubating cells for 2 h at low glucose 
concentrations (2 mM) followed by stimulating the cells with either low glucose (2 mM) or 
high glucose (16.7 mM) for the next 2 h. Insulin release at high glucose was significantly 
inhibited by 60 ± 10% for siARNT1 and by 52 ±17% for siARNT2 as compared with the 
siControl (Figure 8). These results were consistent with the results obtained by Gunton et al 
where GSIS was inhibited in MIN6 cells treated with siRNA against ARNT/HIF-1β (164). 
Insulin secretion was normalized to total protein content. 
NOTE: Although the impact of siARNT1 and siARNT2 on GSIS was not statistically 
different, based on the gene expression analysis, siARNT1 inhibited ARNT/HIF-1β gene 
expression significantly more compared to siARNT2. Hence siARNT1 was used for all 
subsequent gene knock down experiments and from here on it will be denoted as siARNT. 
 
Figure 8: Effect of siARNT 1 and siARNT 2 on glucose-stimulated insulin secretion in 832/13 cells. LG, 
low glucose (2 mM); HG, high glucose (16.7 mM); Compared to siControl, both siARNT 1 and siARNT 
inhibited GSIS in 832/13 cells. Results represent mean ± SEM from 3 - 6 experiments. *p<0.05, **p<0.01 HG 
siControl Vs HG siARNT. Anova, post hoc Tukey’s test. 
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3.4.3 ARNT/HIF-1β Suppression Impairs Glucose Utilization without 
Affecting Glucose Oxidation in 832/13 Cells 
Glucose utilization and oxidation were assessed to evaluate changes in glucose metabolism 
following ARNT/HIF-1β knockdown. ARNT/HIF-1β is a heterodimeric transcription factor 
necessary to mediate cellular responses under low oxygen conditions (96). In this capacity, 
ARNT/HIF-1β was shown to activate the expression of key glycolytic enzymes and based on 
this we hypothesized that loss of ARNT/HIF-1β may lead to impairment in glucose 
utilization, which may result in concomitant changes in glucose oxidation. 
As expected, when glucose was raised from 2 mM to 16.7 mM, siControl cells exhibited 
significant increase in glycolytic flux as measured by [5-3H] glucose usage assay. 
Differences in glucose utilization were not statistically different at 2 mM glucose between 
siControl and siARNT cells (Figure 9A). However, in the presence of 16.7 mM glucose the 
glycolytic flux was significantly reduced by 31 ± 6% in siARNT-treated cells compared to 
siControl-treated cells.  
As for glucose oxidation, when glucose was raised from 2 mM to 16.7 mM, siControl cells 
exhibited a significant increase in glucose oxidation as measured by the CO2 production by 
[U-14C] glucose. Although glycolytic flux was negatively affected by ARNT/HIF-1β 
knockdown at 16.7 mM glucose, we could not detect significant changes in glucose oxidation 
at both 2 mM and 16.7 mM glucose in siARNT-treated cells (Figure 9B). 
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Figure 9: Effects of siARNT on glucose utilization and glucose oxidation in 832/13 cells. A) glucose 
utilization. B) glucose oxidation. LG, low glucose (2 mM); HG, high glucose (16.7 mM).  Data represent mean 
± SEM. of 6 - 8 independent experiments. *p < 0.05 HG untreated Vs HG siControl Vs HG siARNT, Anova, 
post hoc Tukey’s test. 
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3.4.4 ARNT/HIF-1β Suppression Does Not Significantly Alter the Glucose-
Induced Changes in the ATP/ADP Ratio in 832/13 Cells 
Glucose-stimulated ATP production is one of the most critical signals coupling metabolism 
of glucose to insulin granule exocytosis. Although there was a reduction in glycolytic flux by 
31% in siARNT-treated cells, glucose oxidation was not affected suggesting that glucose-
stimulated ATP levels may not be altered in siARNT-treated cells.  We observed a slight 
reduction in both ATP levels and the ATP/ADP ratio following ARNT/HIF-1β knockdown, 
however, this was not statistically different from that observed in siControl-treated 832/13 
cells (Figure 10A, B). Our ATP data is consistent with the observation that glucose oxidation 
remained unaltered in the absence of ARNT/HIF-1β in 832/13 cells.  
 
    
       
Figure 10: Effects of siARNT on A) ADP and ATP amount B) ATP:ADP ratio in 832/13 cells. LG, low 
glucose (2 mM); HG, high glucose (16.7 mM). Data represents mean ± SEM. of 6 independent experiments. 
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3.4.5 GC-MS-based Metabolic Profiling of Glycolysis and TCA 
Intermediates in 832/13 Cells with Reduced ARNT/HIF-1β Levels 
To further understand the key metabolic pathways affected by ARNT/HIF-1β knockdown, a 
GC-MS based metabolomics approach was employed. Assessment of the metabolic profile of 
the glycolytic, pentose phosphate, TCA cycle, free fatty acid and amino acid pathways in 
both siControl and siARNT-treated cells was performed using an Agilent GC-MS system. 
This comparative analysis revealed that levels of most of the glycolytic (Figure 11) and TCA 
cycle intermediates (Figure 12) were markedly reduced by ARNT/HIF-1β knockdown. 
Glycolytic intermediates such as dihydroxyacetone phosphate, 3-phosphoglycerate and 
pyruvate were significantly reduced in siARNT-treated cells exposed to 16.7 mM glucose. 
However, the amount of lactate was significantly down at both 2 mM and 16.7 mM in 
siARNT-treated cells. Glucose-stimulated rise in glucose 6-phosphate levels was not affected 
by ARNT/HIF-1β knockdown, suggesting that glucokinase activity is preserved in siARNT-
treated cells. These findings are in agreement with the observation that glycolytic flux is 
markedly reduced by ARNT/HIF-1β knockdown at 16.7 mM glucose.  
Glucose-stimulated rise in the levels of TCA intermediates were significantly lower in 
siARNT-treated cells compared to siControl-treated cells (Figure 12). Levels of 
citrate/isocitrate, α-ketoglutarate, succinate, fumarate and malate were significantly lower in 
siARNT-treated cells in the presence of 16.7 mM glucose. Among the TCA intermediates, 
the reduction in metabolite levels following ARNT/HIF-1β knockdown was most notable for 
α-ketoglutarate (90 ± 5%), followed by succinate (68 ± 2%), fumarate (67 ± 1%), malate (65 
± 2%) and citrate/isocitrate (49 ± 8%). In addition, this marked difference in the amount of 
TCA metabolites was also significantly reduced at low glucose concentrations (2 mM). The 
fact that glucose oxidation was not significantly affected under high glucose conditions, 
suggests that the amounts of TCA metabolites seen in siARNT-treated cells are likely 
sufficient for maintaining glucose oxidation and preservation of cell viability. The reduced 
amounts of malate, citrate, and isocitrate are of direct interest in the regulation of GSIS 
because these metabolites act as intermediates in the pyruvate cycling pathways and 
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generation of NADPH, which have been suggested to play a key role in GSIS 
(67,70,76,79,91,218). They also serve as a source of glucose carbon for lipogenesis, which 
has also shown to be important for GSIS (75,219-221). 
 
Figure 11: Effects of siARNT on glycolytic metabolite levels in 832/13 cells. Data presented as a ratio of 
target metabolite corrected for an internal control (myristic acid-d27) and represents mean ± SEM of 3 
independent experiments. LG, low glucose (2 mM); HG, high glucose (16.7 mM). *, p < 0.05, HG siControl Vs 
HG siARNT; p < 0.01, LG siControl Vs LG siARNT. Student’s t-test. 
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Figure 12: Effects of siARNT on TCA metabolite levels in 832/13 cells. Data presented as a ratio of target 
metabolite corrected for an internal control (myristic acid-d27) and represents mean± SEM of 3 independent 
experiments. LG, low glucose (2 mM); HG, high glucose (16.7 mM). *p<0.05, **p < 0.01, ***p < 0.001 HG 
siControl Vs HG siARNT; p < 0.05, p < 0.05, LG siControl Vs LG siARNT. Student’s t-test. 
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3.4.6 GC-MS-based Metabolic Profiling of Pentose Phosphate Pathway 
(PPP) Intermediates in 832/13 Cells with Reduced ARNT/HIF-1β Levels 
Although the role of PPP in GSIS is still highly debated, some studies have shown that PPP 
plays a critical role in the generation of NADPH and that activation of PPP is necessary for 
scavenging reactive oxygen species (ROS) produced as a result of chronic exposure to high 
glucose (222,223). Upon stimulation with 16.7 mM glucose, levels of 6-phosphogluconate 
were similar in siARNT-treated cells compared to siControl-treated cells indicating that the 
amount of glycolytic substrate entering the PPP under these conditions is preserved although 
glycolysis itself was impaired in the absence of ARNT/HIF-1β (Figure 13). ARNT/HIF-1β 
knockdown led to a reduction in ribose 5-phosphate levels when exposed to 16.7 mM 
glucose. The final step in the oxidative phase of PPP does not seem to be affected by 
ARNT/HIF-1β silencing as glucose-induced rise in ribulose 5-phosphate levels were similar 
in siARNT-treated cells compared to siControl-treated cells. In conclusion, we observed that 
the non-oxidative branch of PPP was more affected by ARNT/HIF-1β knockdown than the 
oxidative branch. 
 
Figure 13: Effects of siARNT on pentose phosphate pathway in 832/13 cells. Data presented as a ratio of 
target metabolite corrected for an internal control (myristic acid-d27) and represents mean ± SEM of 3 
independent experiments. LG, low glucose (2 mM); HG, high glucose (16.7 mM). *p < 0.05 HG siControl Vs 
HG siARNT. Student’s t-test. 
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3.4.7 GC-MS-based Metabolic Profiling of Free Fatty Acids and Amino 
Acids in 832/13 Cells with Reduced ARNT/HIF-1β Levels 
Glucose-induced rise in fatty acid production associated with the rise in glucose 
concentration from basal (2 mM) to stimulatory concentration (16.7 mM), was completely 
absent in siARNT-treated cells compared to siControl-treated cells. The levels of fatty acid 
species including palmitic acid, palmitoleic acid, oleic acid and stearic acid were 
significantly reduced in siARNT-treated cells under high glucose concentrations (16.7mM), 
indicating that mitochondrial export of citrate to the cytosol, critical for lipogenesis could be 
diminished in siARNT-treated cells under high glucose conditions.  
 
Figure 14: Effects of siARNT on glucose induced fatty acid production in 832/13 cells. Data presented as a 
ratio of target metabolite corrected for an internal control (myristic acid-d27) and represents mean  ± SEM of 3 
independent experiments. LG, low glucose (2 mM); HG, high glucose (16.7 mM). *p < 0.05, ***p < 0.001 HG 
siControl Vs HG siARNT. Student’s t-test. 
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Finally, the impact of ARNT/HIF-1β knockdown also seems to extend into amino acid 
metabolism but to a lesser extent. Only a few amino acids were affected in siARNT-treated 
cells as the levels of L-glutamate, L-threonine and L-alanine were significantly lowered at 
high glucose concentrations (16.7 mM) (Figure 15). The discovery that L-glutamate 
production is diminished in siARNT-treated cells is interesting as it represents another 
potential candidate coupling factor that is believed to play important signalling roles in GSIS 
(68,203).  
 
Figure 15: Effects of siARNT on amino acid levels in 832/13 cells. Data presented as a ratio of target 
metabolite corrected for an internal control (myristic acid-d27) and represents mean  ± SEM of 3 independent 
experiments. LG, low glucose (2 mM); HG, high glucose (16.7 mM). *p < 0.05, **p < 0.01, ***p < 0.001 HG 
siControl Vs HG siARNT. Student’s t-test. 
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3.4.8 Gene Expression Profiling of 832/13 Cells with Reduced ARNT/HIF-
1β Levels 
In an attempt to understand the molecular mechanism involved in the regulation of GSIS by 
ARNT/HIF-1β, we assessed the expression of those transcription factors that are critical for 
maintaining beta-cell function in 832/13 cells treated with siARNT (Figure 16 A). Hypoxia-
inducible factor-1α (HIF-1α), the heterodimeric binding partner for ARNT/HIF-1β, was used 
as a positive control in 832/13 cells as previous studies have shown that the expression of 
HIF-1α was independent of ARNT/HIF-1β (163). Expression of genes that are known to be 
important for maintaining normal beta-cell function such as the hepatocyte nuclear factor-1α 
(HNF-1α), HNF-4α, peroxisome proliferator-activated receptor-gamma coactivator 1α 
(PGC-1α) and guanine exchange protein activated by cAMP, Epac 2, was significantly 
reduced in response to siRNA-mediated reduction of ARNT/HIF-1β. This data suggests that 
ARNT/HIF-1β acts upstream of these transcription factors in beta-cells.  
Next, we assessed the expression of genes that are critical for maintaining normal glucose 
metabolism in siARNT-treated 832/13 cells (Figure 16 B). Particularly, the expression of 
genes that are involved in glucose entry and phosphorylation namely, glucose transporter 2 
(GLUT2) and glucokinase (GK), were significantly reduced in 832/13 cells with reduced 
ARNT/HIF-1β levels. Expression of genes that play a critical role in the maintenance of 
mitochondrial glucose metabolism, specifically the oxidative and the anaplerotic enzymes, 
namely, pyruvate dehydrogenase α1 (PDHα1) and pyruvate carboxylase (PC), were both 
found to be significantly reduced in siARNT-treated 832/13 cells. PDH expression was found 
to be less impacted than PC in siARNT-treated cells. PDHα1 is important for the generation 
of NADH and ATP and PC is important for the anaplerotic entry of pyruvate into the 
mitochondria. Export of mitochondrial metabolites to the cytosol occurs via metabolite 
carriers namely dicarboxylate carrier (DIC; malate transporter), 2 oxoglutarate carrier (OGC; 
α-ketoglutarate transporter), and citrate carrier (CIC; citrate transporter). The optimal 
expression of these carriers is critical for maintaining glucose-stimulated anaplerosis and 
GSIS in beta-cells (88,224,225). Interestingly, both DIC and OGC were significantly reduced 
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in the absence of ARNT/HIF-1β. Reductions in PC, DIC, and OGC in the absence of 
ARNT/HIF-1β are in agreement with our metabolomics data showing a reduction in 
anaplerosis in siARNT-treated cells. Expression of two key enzymes involved in the 
proposed pyruvate cycling pathways, namely, cytosolic NADP+-dependent malic enzyme 
(MEc) and cytosolic NADP+-dependent isocitrate dehydrogenase (ICDc) was also studied. 
(87,91,226). Only MEc and not ICDc expression was significantly down regulated in 
siARNT-treated cells.  
Based on our metabolomics data, the levels of certain free fatty acids were lower in siARNT-
treated cells and therefore, we also assessed the expression of key fatty acid metabolism 
enzymes (Figure 17). Expression of acetyl CoA synthase (ACS), an enzyme that is required 
for the formation of the precursor molecule, acetyl CoA, for fatty acid synthesis was found to 
be unaffected by siARNT treatment. We also looked at the expression of enzymes such as 
citrate lyase (CL), fatty-acid synthase (FAS) and carnitine palmitoyltransferase 1α (CPT1α) 
in the absence of ARNT/HIF-1β. Both FAS and CPT1α were significantly lower in siARNT-
treated cells compared to siControl cells. Expression of CL, which is critical for de novo 
lipogenesis, was found to be significantly reduced in the absence of ARNT/HIF-1β in 832/13 
cells. 
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Figure 16: Effects of siRNA-mediated suppression of ARNT/HIF-1β on key genes involved in maintaining 
beta-cell function 832/13 cells. Gene expression is expressed as a percentage of the target gene from siControl-
treated cells and corrected by an internal control gene cyclophilin E (Cyp). There was no significant difference 
seen between treatment groups for cyclophilin E. A) HIF1α, hypoxia-inducible factor 1α; HNF4a, hepatocyte 
nuclear factor-4α; HNF1a, hepatocyte nuclear factor-1α; Epac 2, Guanine exchange protein, PGC 1α, 
peroxisome proliferator-activated receptor-gamma coactivator 1α; B) GK, glucokinase; GLUT2, glucose 
transporter-2; PC, pyruvate carboxylase; PDH, pyruvate dehydrogenase; MEc, cytosolic malic enzyme; ICDc, 
cytosolic isocitrate dehydrogenase; CIC, citrate carrier; DIC, dicarboxylate carrier; OGC, α-ketoglutarate 
carrier; Data represents mean  ± SEM. of 7 independent experiments. *p<0.05, **p<0.01, ***p<0.001 
siControl Vs siARNT. Student’s t-test. 
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Figure 17: Effects of siRNA-mediated suppression of ARNT/HIF-1β on key genes involved in fatty-acid 
synthesis in 832/13 cells. Gene expression is expressed as a percentage of the target gene from siControl-
treated cells and corrected by an internal control gene cyclophilin E (Cyp). Cl, citrate lyase; ACS, acetyl CoA 
synthase, PLCg1, phopholipase C-gamma 1, FAS, fatty-acid synthase; CPT1α, carnitine palmitoyltransferase 
1α. Data represents mean  ± SEM of 7 independent experiments. *p<0.05, ***p<0.001  siControl Vs siARNT. 
Student’s t-test. 
3.4.9 Effects of Amino Acids, Fatty Acids and IBMX on Insulin Secretion in 
the Absence of ARNT/HIF-1β in 832/13 cells 
A variety of signals generated either through the metabolism of glucose or other non-
carbohydrate nutrients like amino acids and fatty acids are involved in the acute stimulation 
of insulin secretion from the pancreatic beta-cells. In an effort to determine whether these 
additional pathways are functional in beta-cells deficient in ARNT/HIF-1β, siARNT-treated 
832/13 cells were subjected to further investigation using various insulin secretagogues.  
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Both leucine and glutamine are known to increase insulin secretion in 832/13 cells as well as 
in islets in the absence of glucose. Stimulation of insulin secretion by leucine is through the 
allosteric activation of glutamate dehydrogenase whereas glutamine provides carbons to the 
TCA cycle (227-229). In order to assess the impact of ARNT/HIF-1β knockdown on amino 
acid stimulated insulin secretion, we tested the effects of a mixture of both leucine and 
glutamine  (both at 2 mM and 10 mM each) on insulin secretion on 832/13 cells deficient in 
ARNT/HIF1β. As shown in Figure 18 A, the combination of two amino acids increased 
insulin secretion in the absence of glucose under all conditions and no significant difference 
was observed between the siControl and siARNT-treated cells at both 2 mM and 10 mM 
amino acid concentrations. 
 
The role of GLP-1 in beta-cell survival and function mediated through the cAMP signalling 
pathway is a well-studied phenomenon in beta-cells (230,231). Increase in intracellular 
cAMP leads to the activation of protein kinase A (PKA), which then phosphorylates and 
activates a number of beta-cell proteins like cAMP response element binding protein 
(CREB), which in turn regulates the expression of key genes that are important for beta-cell 
survival and insulin secretion. In addition, increase in intracellular cAMP concentration has 
been found to increase the accumulation of HIF-1α, the heterodimeric binding partner for 
ARNT/HIF-1β in pancreatic beta-cells (232). In an attempt to understand whether 
ARNT/HIF-1β mediates its effect on GSIS through the incretin pathway, we decided to study 
insulin secretion in response to 3-isobutyl-1-methylxanthine (IBMX), a non-specific 
phosphodiesterase (PDE) inhibitor, which raises the intracellular cAMP level and activates 
PKA (233). Insulin secretion was measured in response to 50 µM IBMX in the presence of 
both 2 mM and 7 mM glucose (Figure 18 B). In the presence of 2 mM glucose, we observed 
a mild increase in insulin secretion in both siControl and siARNT-treated cells, however, this 
was not significantly different between the two groups. In the presence of 7 mM glucose, 
IBMX clearly increased insulin secretion by 2 fold in siControl cells and the potentiating 
effect of IBMX was clearly visible in siARNT-treated cells as well. However, glucose 
induced increments in insulin secretion were significantly lower and reduced by about 56% 
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in siARNT-treated cells compared to siControl-treated cells, suggesting that defects in insulin 
secretion observed in the absence of ARNT/HIF-1β are specific to glucose.  
 
 
 
Figure 18: Effects of amino acids and IBMX on insulin secretion in siARNT-treated 832/13 cells. A) 
Amino acids, Leucine (Leu)  + Glutamine (Glut), L-low, 1 mM each of Leu+ Glut; H- high, 10 mM each of Leu 
+Glut B) IBMX, 3-isobutyl-1-methylxanthine (50 µM)  LG, low glucose (2 mM); HG, high glucose (7 mM).  
Data represents mean  ± SEM of 4 independent experiments. **p<0.01 for HG siControl Vs HG+IBMX 
siControl, ***p<0.001 siControl HG Vs siARNT HG, p < 0.001 siControl HG+IBMX Vs siARNT 
HG+IBMX. Student’s t-test.  
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The ability of fatty acids to potentiate insulin secretion acutely in the presence of glucose is 
well studied (221,234,235). Several mechanisms were proposed to explain the effectiveness 
of fatty acids on insulin secretion including the binding of free fatty acids to cell surface 
receptor GPR40, leading to phospholipase C activation, IP3 production and rise in 
intracellular Ca2+ (236-238). To see whether acute stimulation by fatty acids is effective in 
832/13 cells treated with siARNT, we exposed the cells to 250 µM palmitate, a well studied 
saturated fatty acid (C16:0), abundantly found in the plasma. Insulin secretion in response to 
palmitate was measured in the presence of both 2 mM and 7 mM glucose in 832/13 cells 
treated with siARNT (Figure 19 A). As expected, the potentiating effects of palmitate were 
absent in the presence of 2 mM glucose. We observed that palmitate acutely stimulated 
insulin secretion in the presence of 7 mM glucose in both siControl and siARNT-treated 
cells, however, the extent of stimulation was around 25% less in siARNT-treated cells 
compared to siControl cells in the presence of glucose. Since the ability of palmitate to 
potentiate GSIS is partly dependent on its capacity to bind to GPR40, thereby increasing 
intracellular Ca 2+ (239), we looked at the expression of GPR40 in 832/13 cells treated with 
siARNT. We found that the expression of GPR40 was reduced by 40 % in the absence of 
ARNT/HIF-1β (Figure 19 B). Thus, ARNT/HIF-1β seems to be necessary for the acute 
stimulation of GSIS by palmitate in 832/13 cells. 
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Figure 19: Fatty-acid potentiation of insulin secretion in siARNT-treated 832/13 cells. A) Insulin secretion 
in response to low glucose (LG, 2mM) and high glucose (HG, 7 mM) in the presence of palmitate (Pal, 250 
µM). 2) mRNA expression of GPR40 in siARNT-treated cell. Data represents mean  ± SEM. of 4 independent 
experiments. *p < 0.05 siControl HG + Pal Vs siARNT HG + Pal, **p<0.01 siControl HG Vs siControl 
HG+Pal,  ***p<0.001 siControl HG Vs siARNT HG,  p<0.001 siControl Vs siARNT.  Student’s t-test.  
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3.5 Discussion 
Genome-wide gene expression profiling of islets obtained from normal and type 2 diabetic 
humans revealed that the expression level of transcription factor ARNT/HIF-1β was reduced 
by 90% under diabetic conditions (164). Down regulation of ARNT/HIF-1β in mouse islets 
was also associated with reduction in the expression of several of its target genes such as 
those involved in glycolysis, insulin signalling and those that are necessary to maintain 
normal beta-cell function. In this chapter, we assessed the metabolic profile of the 832/13-
pancreatic beta-cell line with low ARNT/HIF-1β expression levels to provide more insight 
into the mechanism of ARNT/HIF-1β mediated GSIS. Specifically, our aim was to 
understand the identity of key metabolic pathways regulated by ARNT/HIF-1β and 
understand the mechanism by which it helps sustain normal GSIS from pancreatic beta-cells.  
Using an siRNA against ARNT/HIF-1β mRNA (siARNT), we first demonstrated that 
knocking down ARNT/HIF-1β mRNA and protein inhibits GSIS in 832/13 cells. Since 
insulin secretion from pancreatic beta-cells requires the complete metabolism of glucose 
through glycolysis and the TCA cycle, we decided to study the impact of ARNT/HIF-1β 
knock down on glucose utilization (glycolysis) and glucose oxidation (mitochondrial glucose 
metabolism) in 832/13 cells treated with siARNT. Although glucose utilization was 
decreased by 31% in siARNT cells, this reduction in glycolytic flux did not translate into 
changes in the rate of glucose oxidation or glucose - stimulated ATP production. To gain 
further insight into the metabolic phenotype of beta-cells deficient in ARNT/HIF-1β, GC-MS 
based metabolite profiling was carried out in 832/13 cells treated with siARNT. Consistent 
with ARNT/HIF-1β’s known role as a master regulator of several key glycolytic enzymes 
such as phosphofructokinase (PFK), aldolase and glucose 6 phosphoisomerase (G6PI) 
(161,164), we found that glycolytic intermediates were significantly reduced in siARNT-
treated cells; however, the most dramatic reductions were seen for metabolites involved in 
the TCA cycle suggesting that anaplerosis is an important target of ARNT/HIF-1β. These 
studies demonstrate that the role of ARNT/HIF-1β in regulating insulin release in response to 
glucose is independent of changes in glucose oxidation and ATP production and likely 
involves altered anaplerosis. 
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The critical involvement of glucose-stimulated anaplerosis in insulin secretion was confirmed 
by several studies (72,240-244). When glucose is abundantly present in the plasma, it enters 
the beta-cells where the metabolism of glucose into pyruvate prepares the hexose molecule to 
enter the mitochondria for further oxidation. The entry of pyruvate into the mitochondrial 
TCA cycle occurs via 2 distinct pathways, namely PDH mediated oxidative pathway and PC 
mediated anaplerotic pathway. In beta-cells, since PC is extremely active and highly 
expressed, PC catalyzed anaplerosis happens in almost equal proportions to the PDH 
catalyzed oxidation, giving rise to the existence of two separate pyruvate pools, with one 
feeding acetyl-CoA into the TCA cycle for oxidation and generation of ATP (PDH pathway) 
and the other leading to a net accumulation of TCA intermediates (PC pathway) (79). The 
novel finding that loss of ARNT/HIF-1β leads to a profound reduction in the expression of 
PC, DIC and OGC and a reduction in TCA metabolites, even though glucose oxidation and 
ATP production were unaltered, is an unexpected outcome of this study. It seems that the 
beta-cells in the absence of ARNT/HIF-1β preserve the ability to maintain their oxidative 
capacity in a bid to meet basic cellular energy demands and they do so at the expense of the 
anaplerotic input into the TCA cycle, leading to the defective secretion of insulin in response 
to glucose. 
Loss of anaplerosis in beta-cells can have a significant impact on the 3 main pyruvate cycling 
pathways that are prevalent in the beta-cells, namely the pyruvate-malate, pyruvate-citrate 
and pyruvate-isocitrate pathways (79,88,91,225,226) Studies have shown that the flux 
through the 3 pyruvate cycling pathways strongly correlate with GSIS (70,78,240). The fact 
that there is a 50-70% reduction in the amounts of pyruvate, malate, citrate/isocitrate and α-
ketoglutarate in siARNT-treated 832/13 cells suggests the possibility that the flux through all 
the 3 pyruvate cycling pathways may be compromised in the absence of ARNT/HIF-1β. It is 
also interesting to note that pyruvate cycling generates two potentially important signalling 
molecules for insulin release, namely, α-ketoglutarate and NADPH. NADPH can be 
produced via the three pyruvate cycling pathways (88,91,225). A key NADPH-producing 
enzyme for both the pyruvate malate and pyruvate citrate pathways is the cytosolic malic 
enzyme (MEc) (245). We found that MEc, which catalyzes the conversion of malate back to 
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pyruvate in the cytosol of the beta-cells, was significantly reduced in the absence of 
ARNT/HIF-1β. The key enzyme for the pyruvate isocitrate pathway is the cytosolic isocitrate 
dehydrogenase (ICDc) (91).  However, we did not find any change in the expression of ICDc 
in the absence of ARNT/HIF-1β. Although strong evidence for a role of the pyruvate-
isocitrate pathways exists (79,91), studies have also shown a role for the other two pyruvate 
cycling pathways (87,226,246) and therefore, the identity of the pyruvate cycling pathway(s) 
that is most critical for insulin release is still debated.  
The observation that there is a complete lack of glucose induced rise in the production of 
fatty acids also supports the idea that anaplerosis is down regulated in siARNT-treated cells. 
In the normal scenario, when glucose is raised from basal to stimulatory concentrations, 
metabolism of glucose through glycolysis and TCA cycle leads to increased production of 
citrate. Citrate is then exported to the cytosol through the citrate/isocitrate carrier (CIC), 
where citrate then serves as a substrate for generation of lipid molecules such as malonyl 
CoA and LC-CoA, which have been suggested to serve as metabolic coupling factors in 
GSIS (65,66). Reduced levels of citrate in siARNT-treated cells and insufficient transport of 
citrate to cytosol may affect the ability of beta-cells to produce metabolic coupling factors 
necessary to maintain GSIS.  
In an attempt to determine whether the secretory defects found in ARNT/HIF-1β deficient 
832/13 cells are specific to glucose or affect other non-carbohydrate pathways as well, we 
examined insulin secretion in response to amino acids (leucine + glutamine), fatty acids 
(palmitate) and cAMP in 832/13 cells treated with siARNT. Leucine allosterically activates 
glutamate dehydrogenase and stimulates the conversion of glutamate to α-ketoglutarate, 
which can be oxidized in the TCA cycle to form ATP (247). It is also believed that leucine 
can be converted to ketoacid, α-ketoisocaproic acid (KIC), which can be then metabolized to 
hydroxymethyl glutarate –CoA (HMG-CoA) and acetyl CoA (227,248). Thus, two things can 
be inferred from an intact secretory response to leucine and glutamine in ARNT/HIF-1β 
deficient pancreatic beta-cells. 1) Oxidative capacity of beta-cells with reduced ARNT/HIF-
1β is normal and the defects in insulin secretion seen are specific to glucose. 2) Since 
metabolism of leucine and glutamine generates ATP, potentially leading to the closure of the 
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KATP channels and insulin granule exocytosis, the KATP dependent pathway of insulin release 
is intact in the absence of ARNT/HIF1β. The potentiating effects of both palmitate and 
cAMP also seems to be intact in siARNT-treated 832/13 cells which again confirms the idea 
that defects in insulin secretion evident in ARNT/HIF-1β deficient 832/13 cells are specific 
to glucose.  
In conclusion, based on our metabolomics and gene expression data, we strongly identify 
glucose-stimulated anaplerosis and pyruvate cycling as the two critical targets of ARNT/HIF-
1β in pancreatic beta-cells. We show that ARNT/HIF-1β plays an important role in beta-cell 
glucose metabolism as siRNA-mediated knockdown of the transcription factor causes a 
significant reduction in gene expression, glycolytic flux and glucose-stimulated anaplerosis. 
Considering glucose oxidation and ATP production is intact in the absence of ARNT/HIF-1β, 
we believe that the observed metabolic phenotype can be attributed to a significant reduction 
in glucose-stimulated anaplerosis. The idea that low levels of ARNT/HIF-1β negatively 
affects the anaplerotic input into the TCA cycle is furthermore supported by the observation 
that glucose-induced fatty acid and glutamate production are completely absent in siARNT-
treated 832/13 cells. Taken together, our data suggests that ARNT/HIF-1β is absolutely 
necessary to keep the pancreatic beta-cells in a glucose-responsive state and it does so by 
ensuring sufficient substrate flow through anaplerotic pathways that regulate GSIS. 
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Chapter 4 
ARNT/HIF-1β is Indispensible for Maintaining Beta-Cell Secretory 
Function, but not for Glucose Homeostasis in Mice 
4.1 Synopsis 
ARNT/HIF-1β is a transcription factor that was previously shown to be critical for 
maintaining glucose homeostasis and glucose-stimulated insulin secretion (GSIS) in mice. 
Our goal was to understand the key metabolic signals regulated by ARNT/HIF-1β and 
evaluate its role in vivo in maintaining glucose homeostasis. Pancreatic beta-cell specific 
ARNT/HIF-1β knock-out mice (β-ARNT KO) and an ARNT/HIF-1β siRNA-treated 832/13 
beta-cell line (siARNT) were used in this study. Both β-ARNT KO islets and siARNT cells 
showed impaired GSIS as expected. Mitochondrial oxygen consumption and mitochondrial 
membrane potential was unaltered upon glucose stimulation in β-ARNT KO islets. Further 
analysis of β-ARNT KO islets revealed impaired intracellular calcium response after 
stimulation with glucose and KCl. Subsequent analysis revealed reduced secretory response 
to glucose in the presence of KCl and diazoxide indicating a defect in the amplifying 
pathway of GSIS in β-ARNT KO islets. PC expression and the rise in glucose-stimulated 
NADPH/NADP ratio were completely absent in the absence of ARNT/HIF-1β. Consistent 
with this, the defect in GSIS in β-ARNT KO islets could be almost completely rescued by 
treatment with membrane permeable TCA intermediates. Surprisingly, β-ARNT KO mice 
have normal glucose homeostasis in both males and females. Further investigation revealed 
β-ARNT KO mice exhibited a small but significant increase in RER suggesting a preference 
in utilizing carbohydrates as a fuel source, possibly leading to improved glucose uptake from 
the blood stream. Response to exogenous insulin was completely normal in β-ARNT KO 
mice suggesting intact functioning of the skeletal muscles. Our data suggests an important 
role for ARNT/HIF-1β in maintaining normal beta-cell secretory function, however β-ARNT 
KO mice are protected from the adverse effects of hyperglycemia by activation of a 
compensatory mechanism in the peripheral tissues, the nature of which is currently unknown. 
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4.2 Introduction 
Transcription factor ARNT/HIF-1β is important for a wide range of cellular functions such as 
response to hypoxia, angiogenesis, placental development and metabolism of xenobiotics 
(150). Although its role in the pathogenesis of type 2 diabetes (T2D) was previously 
unknown, Gunton et al’s discovery in 2005, recognized ARNT/HIF-1β as one of the most 
critical transcription factors required to maintain normal beta-cell function. The discovery 
that ARNT/HIF-1β was 90% down-regulated in human type 2 diabetic islets and that it was 
necessary to maintain normal glucose homeostasis and insulin secretion in mice, provided a 
novel and unexpected role for this transcription factor in the beta-cells (164). The importance 
of ARNT/HIF-1β in GSIS, beta-cell function and in the progression of T2D was further 
supported by several recent in vivo studies performed by different research groups. Cheng et 
al showed that increasing the expression of ARNT/HIF-1β and its binding partner HIF-1α in 
human T2D islets markedly improved GSIS (170). The involvement of ARNT/HIF-1β in the 
pathogenesis of T2D was also evident in a few studies where ARNT/HIF-1β was found to be 
down-regulated in other metabolic tissues of the body such as the liver and the adipose tissue 
in humans and mice respectively (173,182,210). Ablation of ARNT/HIF-1β in liver was 
associated with glucose intolerance in mice. In adipose tissue however, the functional 
significance of ARNT/HIF-1β seems to be more complex than in beta-cells. Studies done by 
Jiang et al suggests that impaired HIF-1 signalling in the adipose tissue protects these mice 
from the deleterious effects of a high fat diet, leading to normal glucose homeostasis, 
improved insulin sensitivity and energy regulation. Improved insulin sensitivity in these mice 
was attributed to the decreased expression of Soc3 in the white adipose tissue and induction 
of adiponectin (183). However, in another study where the expression levels of HIF-1α, 
ARNT/HIF-1β binding partner, was inhibited by the expression of a dominant negative form 
of the protein, mice were found to be glucose intolerant and insulin resistant compared to 
wild-type littermates (184). Thus, several in vivo as well as in vitro data have been presented 
to the scientific community since 2005 providing compelling evidence pointing to the 
involvement of ARNT/HIF-1β in the progression and pathogenesis of T2D. 
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In the previous chapter, we did a detailed analysis of the metabolic phenotype of INS-1 
derived 832/13 clonal beta-cells with low levels of ARNT/HIF-1β which revealed a reduction 
in glucose utilization, without affecting glucose oxidation and ATP/ADP ratio (249). 
Metabolic profiling of 832/13 cells deficient in ARNT/HIF-1β demonstrated reduced levels 
of glycolytic end product pyruvate and TCA intermediates citrate/isocitrate, α-ketoglutarate, 
fumarate and malate suggesting impaired anaplerosis. Taken together, we along with others 
have shown that ARNT/HIF-1β is undoubtedly one of the key transcription factors in 
pancreatic beta-cells, critical for maintaining GSIS, glucose-stimulated anaplerosis and 
glucose homeostasis in mice.  
 
In this study, beta-cell specific ARNT/HIF-1β knock-out mice (β-ARNT KO) were generated 
using the Cre-loxP recombination system, where the Cre transgene was under the control of 
rat insulin promoter (RIP-Cre). The main goal of this study was to determine the role of 
ARNT/HIF-1β in maintaining glucose homeostasis in vivo. Gunton et al (164) had presented 
some valuable data on the in vivo role of ARNT/HIF-1β in mice where they found that the β-
ARNT KO mice were glucose intolerant, with impaired insulin secretion and altered islet 
gene expression. However, they did not perform a detailed analysis of the metabolic 
phenotype of islets from β-ARNT KO mice. Specifically, our aim was three fold:  
1) Functionally characterize islets from β-ARNT KO mice 2) identify the metabolic signals 
that are critically regulated by ARNT/HIF-1β for maintaining normal GSIS in mice 3) 
identify the mechanism by which ARNT/HIF-1β maintains glucose homeostasis in vivo. 
 
As previously mentioned in the experimental procedures (section 2.14), generation of a beta-
cell specific knock-out mice requires two types of transgenic mice: mice that express Cre 
recombinase in a tissue-specific manner (RIP-Cre) and mice that have the gene of interest 
flanked by loxP sequence (ARNT Fl/Fl). Recently it has been shown that presence of the RIP-
Cre transgene alone leads to glucose intolerance in mice (250). To overcome any variation in 
phenotype due to the presence of RIP-Cre and to establish that the phenotype observed in β-
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ARNT KO mice is due to the deletion of ARNT/HIF-1β protein, all controls used for in vivo 
studies were RIP-Cre positive (WT, Cre or WT/Fl, Cre).  
Using β-ARNT KO mice and 832/13 cells treated with siRNA against ARNT mRNA 
(siARNT), we show that ARNT/HIF-1β plays a critical role in maintaining the glucose-
stimulated rise in NADPH/NADP ratio and rise in intracellular Ca2+ levels, two major 
stimulus-secretion coupling factors required to maintain normal GSIS from the pancreatic 
beta-cells. However, contrary to previous reports, we found that both male and female β-
ARNT KO mice have normal glucose homeostasis and these mice exhibited increased 
utilization of carbohydrates as a fuel source, possibly protecting them from the adverse 
effects of hyperglycemia.  
4.3 Contributions 
Evaluation of whole body bioenergetics in mice using CLAMS was carried out in 
collaboration with Dr. Russell Tupling and Dr. Eric Bombardier, Department of Kinesiology, 
University of Waterloo. Calcium and mitochondrial membrane potential measurements were 
carried out in collaboration with Dr. Mike Wheeler and Kacey Prentice, Department of 
Physiology, University of Toronto, Toronto, ON, Canada. 
4.4 Results 
4.4.1 Genotyping 
To study the role of ARNT/HIF-1β in pancreatic beta-cells, we employed Cre-loxP 
technology as previously described in the experimental procedures to specifically delete the 
gene in pancreatic beta-cells. RIP-Cre mediated recombination resulted in the deletion of 
exon 6 that encodes the bHLH region of the ARNT/HIF-1β protein. As expected, a PCR 
based genotyping for the detection of loxP targeted ARNT-floxed allele and the RIP-Cre 
gene resulted in a 290 bp fragment for the wild-type allele, a 340 bp fragment for the 
homozygous ARNT-floxed allele and a 553 bp for the RIP-Cre transgene (Figure 20 A, B, C) 
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Figure 20: Schematics of PCR based genotyping for the detection of A) wild-type allele (WT) B) 
ARNT floxed allele. C) Representative PCR genotyping for ARNT-floxed allele and Cre recombinase 
transgene obtained using mouse tail genomic DNA. PCR products were separated on a 1 % agarose 
gel and visualized by ethidium bromide staining. A100-bp DNA ladder was used as a size marker for 
both ARNT-floxed and RIP-Cre genes. Black arrows in A, B represent the position of the forward 
(ARNT-F) and reverse (ARNT-R) primers used for genotyping.  
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4.4.2 Effective Deletion of ARNT/HIF-1β mRNA in β-ARNT KO islets and 
INS-1 832/13 cell-line 
A quantitative PCR analysis of the expression of ARNT/HIF-1β mRNA revealed 76.8% and 
60.6% reduction in gene expression in β-ARNT KO islets compared to WT,Cre and 
WT/Fl,Cre control mice islets respectively. ARNT mRNA expression was not found to be 
significantly different between WT,Cre and WT/Fl, Cre mice islets used in this study (Figure 
21 A). ARNT/HIF-1β was also knocked down using an siRNA in the 832/13 beta-cell line 
(validated in the first chapter), which resulted in an efficient 76% knockdown of ARNT/HIF-
1β mRNA (Figure 21 B).  
  
 
Figure 21: Deletion of ARNT/HIF-1β in β-ARNT KO mice and 832/13 cells A) qPCR analysis of 
ARNT/HIF-1β mRNA in islets from wild-type and positive for Cre (WT,Cre), heterozygous ARNT floxed and 
positive for Cre (WT/Fl, Cre) and β-ARNT KO mice. B) qPCR analysis of ARNT/HIF-1β mRNA in 832/13 
cells treated with siARNT compared to siControl-treated cells. Results represent mean ± SEM 3 – 5 mice for 
each genotype and 3 – 5 independent experiments run in duplicates for siARNT 832/13 cells. *p<0.05 WT/Fl, 
Cre Vs  β-ARNT KO islets,** p<0.01 for WT, Cre Vs β-ARNT KO islets, *** p<0.001 for siControl Vs siARNT.  
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4.4.3 Fasting Blood Glucose Measurements 
Blood glucose measurements were taken in both male and female β-ARNT KO mice after 12 
h of fasting. Blood samples were collected from the tail clipping and glucose concentration 
was measured using a glucose meter. We did not observe any difference in the glucose values 
between β-ARNT KO and control mice (WT,Cre and WT/Fl,Cre) in both males and females 
(Figure 22). 
 
 
Figure 22: Fasting blood glucose measurements in male and female β-ARNT KO mice. Following 12 hours 
of fasting, blood samples were collected from the tail vein and glucose was measured using a glucose meter. 
n=6 -10 per genotype for both males and females. Results represent mean ± SEM.  
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their controls (Figure 23 B, D). Both male and female mice with beta-cell specific deletion of 
ARNT/HIF-1β were previously shown to be glucose intolerant (164). 
 
 
 
 
Figure 23:  Intraperitoneal glucose tolerance test (ipGTT) in β-ARNT KO mice. A) ipGTT in male β-
ARNT KO mice (green trace) in comparison with male ARNT WT/Fl, Cre controls (black trace) and WT, Cre 
controls (red trace) B) AUC for male β-ARNT KO mice C) ipGTT in female β-ARNT KO mice (green trace) in 
comparison with ARNT WT/Fl, Cre controls (black trace) and WT,Cre controls (red trace). D) AUC for female 
β-ARNT KO mice. n=6 -10 per genotype for both males and females. Results represent mean ± SEM.  
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4.4.5 Glucose-Stimulated Insulin Secretion in β-ARNT KO Islets 
Our observation that both male and female β-ARNT KO mice had normal glucose 
homeostasis was quite unexpected and not in agreement with a previously published report 
by Gunton et al (164). To determine whether islets from β-ARNT KO mice responded 
normally to glucose and secreted insulin in the normal amounts, a glucose-stimulated insulin 
secretion (GSIS) assay was performed on islets from both male and female β-ARNT KO 
mice. At 2 mM glucose, we found hyper secretion of insulin in islets from male β-ARNT KO 
mice, where they secreted 52 % more compared to islets from control mice. Although islets 
from female β-ARNT KO mice exhibited a similar trend, results were not statistically 
significant. At 16.7 mM glucose, islets from male β-ARNT KO secreted ~ 46 % less insulin 
and islets from female β-ARNT KO mice secreted ~ 42 % less insulin compared to control 
islets (Figure 24). Thus, glucose-stimulated insulin secretion was found to be defective in 
islets from β-ARNT KO mice. 
 
Figure 24: Glucose-stimulated insulin secretion in male and female β-ARNT KO islets. LG, low glucose (2 
mM); HG, high glucose (16.7 mM). Results represent mean±SEM of 3-6 independent experiments.p<0.05 LG 
male control islets Vs LG β-ARNT KO islets. *p<0.05 HG male control islets Vs HG β-ARNT KO islets; 
**P<0.01 HG female control islets Vs HG β-ARNT KO islets. Student’s t-test. 
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4.4.6 Evaluating Whole Body Bioenergetics in β-ARNT KO mice  
In an attempt to understand the mechanism by which β-ARNT KO mice maintain normal 
glucose homeostasis despite a significant reduction in GSIS observed in β-ARNT KO islets, 
we decided to evaluate the whole body metabolic changes that are associated with beta-cell 
specific deletion of ARNT/HIF1β. Metabolic cages were used to assess food intake, 
locomotive activity (dual beam activity), volume of oxygen consumption (VO2) and volume 
of carbon dioxide exhaled (VCO2) in 15-20 week old male β-ARNT KO mice. Measurements 
were all normalized to body weight and the mice had ad libitum access to food and water. 
We did not find any significant differences in food intake, body weight and dual beam 
activity in β-ARNT KO mice compared to their control littermates (Figure 25 A, B, C). 
However, respiratory exchange ratio (RER), which is the ratio of VCO2 /VO2 was slightly but 
significantly higher in β-ARNT KO mice (0.99) compared to their control littermates (0.93) 
(Figure 25 D). RER closer to 1 signifies preferential utilization of carbohydrates and closer to 
0.7 suggests utilization of fat for meeting the whole body energy demands (251). Increased 
RER in β-ARNT KO mice suggests that these mice may utilize more glucose compared to 
their controls, possibly leading to normal glucose homeostasis. Some studies have shown that 
RIP-Cre can also be expressed in the hypothalamus, often leading to the deletion of the 
floxed gene in the hypothalamus, negatively impacting food intake and body weight (250). 
The fact that neither food intake nor the body weight was affected implies that RIP-Cre 
mediated recombination events may not have had the expected impact in the hypothalamus 
of β-ARNT KO mice and that ARNT/HIF-1β function may not be compromised in the brain. 
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Figure 25: Indirect calorimetry measurement of whole body bioenergetics in male β-ARNT KO mice A) 
Food intake B) Dual beam activity C) Body weight D) RER. n=8 per genotype. Data represents mean ± SEM. 
**p<0.01 WT,Cre Vs β-ARNT KO. Student’s t-test. 
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4.4.7 Insulin Tolerance Test (ITT) in β-ARNT KO mice 
The fact that β-ARNT KO mice had a higher RER in comparison to control mice suggested 
the possibility of improved sensitivity of skeletal muscles to glucose thereby leading to better 
glucose disposal. In order to test this hypothesis, an intraperitoneal insulin tolerance test was 
conducted in both male and female β-ARNT KO mice. 1.5 IU/kg and 1.2 IU/kg of insulin 
were injected intraperitoneally in male and female mice respectively after 4 h fasting. In male 
β-ARNT KO mice, although overall insulin sensitivity was better, this was not statistically 
significant. However, we observed improved glucose disposal rate at several time points, 
which was found to be statistically significant at 60 min compared to the control mice. 
(Figure 26 A, B). In female β-ARNT KO mice, no significant differences were observed in 
insulin sensitivity between β-ARNT KO and control mice (Figure 26 C, D). 
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Figure 26: Insulin tolerance test (ITT) in male and female β-ARNT KO mice. A) ITT in male β-ARNT KO 
mice (green trace) compared to WT,Cre controls (black trace) B) Incremental area under the curve (AUC) to 
assess overall glucose clearance in male β-ARNT KO mice C) ITT in female β-ARNT KO mice (green trace) 
compared to WT,Cre controls (black trace). D) Incremental area under the curve (AUC) to assess overall 
glucose clearance in female β-ARNT KO mice. n= 6 – 7 per genotype for ITT and data represent mean ± SEM. 
*p<0.05 glucose clearance in WT,Cre Vs β-ARNT KO mice at 60 minutes. Student’s t-test.  
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4.4.8 Mitochondrial Oxygen Consumption Rate (OCR) in β-ARNT KO 
Islets  
To further investigate mechanisms underlying altered insulin response in β-ARNT KO islets, 
we decided to examine the mitochondrial function by measuring the OCR using a Seahorse 
flux analyzer. Under stimulatory glucose concentration, the OCR ramps up in response to 
increased oxidative phosphorylation. In addition to glucose, we also looked at the OCR in 
response to various mitochondrial drugs to understand the mitochondrial bioenergetics in the 
absence of ARNT/HIF1β. As suggested by our glucose oxidation measurements from 832/13 
cells with low levels of ARNT/HIF1β, we found that at both 2 mM and 16.7 mM glucose, 
OCR was not significantly different in β-ARNT KO islets compared to control islets (Figure 
27 A). This suggests that the oxidative capacity was not reduced in these cells. OCR in 
response to mitochondrial drugs oligomycin (ATP synthase inhibitor), 2, 4 dinitrophenol 
(DNP - uncoupler) and rotenone and myxothiazol (electron transport chain inhibitor) were 
also not significantly different in β-ARNT KO islets compared to control islets.  
Mitochondrial function was also studied in 832/13 cells treated with siARNT. We found a 
very similar trend where the OCR in response to glucose, oligomycin, DNP and rotenone + 
myxothiazol in siARNT-treated cells was comparable to siControl cells (Figure 26 B).  
In addition to measuring the OCR, the use of mitochondrial drugs also allows us to study 
various mitochondrial parameters such as the ATP turn over, proton leak and spare 
respiratory rate in our cells. The rate of mitochondrial ATP turn over was estimated by 
comparing the difference in OCR upon inhibiting ATP synthase to OCR in the presence of 
either 2 mM or 16.7 mM glucose. Proton leak is inversely related to mitochondrial efficiency 
and is estimated by comparing the difference in OCR upon inhibiting ATP synthase to OCR 
in the presence of respiratory chain inhibitors, rotenone and myxothiazol. Finally, spare 
respiratory capacity, which denotes the ability of cells to respond to an increase in energy 
demand, was calculated by measuring the difference in OCR after the injection of DNP 
compared to OCR at either 2 mM or 16.7 mM glucose. It also indicates how close the cells 
are operating to their bioenergetics limits (252). All parameters were found to be similar in 
siARNT-cells compared to siControl-cells (Figure 28 A, B, C). These results indicate that 
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loss of ARNT/HIF-1β does not lead to mitochondrial dysfunction and that this is not a 
mechanism through which the transcription factor regulates GSIS. 
 
 
Figure 27: Mitochondrial oxygen consumption rate in A) Mice islet - WT/Fl, Cre (black trace) compared to 
β-ARNT KO islets (red trace) B) siARNT treated 832/13 cells. siControl cells (black trace) compared to 
siARNT-treated 832/13 cells (red trace) under basal 2 mM glucose (Glc), 16.7 mM glucose (glc), 5 μM 
oligomycin (Oligo), 50 μM di-nitrophenol (DNP) and 10 μM each of rotenone and myxothiazol. Results 
represents mean ± SEM 3 – 4 independent experiments (3 mice per genotype and ~ 50-60 islets per mice). For 
siRNA treatment, n=4 independent experiments with a minimum of 4 replicates per experiment.  
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Figure 28: Evaluating mitochondrial bioenergetics in 832/13 cells treated with siARNT. A) ATP turn over 
at 2 mM (LG) and 16.7 mM (HG) glucose B) Proton leak C) Spare respiratory capacity at 2 mM (LG) and 16.7 
mM (HG) glucose. Results represent mean ± SEM 3 – 4 independent experiments. 
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4.4.9 Mitochondrial Membrane Potential (MMP) in β-ARNT KO Islets 
Upon glucose stimulation, an increase in proton motive force inside the mitochondria leads to 
hyperpolarization of the inner mitochondrial membrane and significant increase in ATP 
synthesis. To investigate the mechanisms underlying defective insulin secretion observed in 
β-ARNT KO islets, MMP was measured upon glucose stimulation using the mitochondrial 
specific dye rhodamine 123 (Rh123).  A representative trace shows that addition of 20 mM 
glucose results in the hyperpolarization of the mitochondrial membrane and addition of 1 
mM sodium azide (NaN3) a respiratory chain inhibitor, results in the depolarization of 
mitochondrial membrane potential in control islets. As expected, β-ARNT KO islets did not 
show any difference in MMP upon stimulation with 20 mM glucose when normalized to 
baseline (Figure 29). As changes in MMP often indicate perturbations in ATP production, 
our data suggest that the process of oxidative phosphorylation and ATP production is 
undisturbed in β-ARNT KO islets. 
 
Figure 29: Mitochondrial membrane potential in β-ARNT KO islets. Representative traces of Rhodamine 
123 (Rh123) fluorescent signal in β-ARNT KO islets (red trace) compared to control islets (black trace). No 
significant differences were observed between β-ARNT KO and control islets. (n=4 mice per group, with a 
minimum of 50 islets per mice). 
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4.4.10 Defects in Anaplerosis and Amplifying Pathway of GSIS in β-ARNT 
KO Islets 
Lack of impairment in mitochondrial membrane potential and cellular oxygen consumption 
rates in β-ARNT KO islets suggest that ARNT/HIF-1β regulates GSIS independent of the 
triggering or the KATP dependent pathway of insulin release and that defective insulin 
secretion could be attributed to perturbations in the amplifying pathway of GSIS. Since our 
previous results from 832/13 cells with low ARNT/HIF-1β expression also suggested the 
same, we decided to investigate whether the amplifying pathway is operational in β-ARNT 
KO islets. Insulin secretion was assessed in β-ARNT KO islets in the presence of KCl (30 
mM) and diazoxide (200 µM) at both 2 mM and 12 mM glucose (Figure 30 A). Diazoxide 
keeps the KATP channels open and KCl depolarizes the beta-cell membrane directly and 
clamps the cytoplasmic Ca2 at high levels, thus bypassing the KATP channel function and the 
triggering pathway of GSIS.  At 2 mM glucose, β-ARNT KO islets secreted 76 % less insulin 
compared to control islets. Since depolarizing the membrane with 30 mM KCl in the 
presence of diazoxide and 2 mM glucose, increases intracellular Ca2+, loss of insulin 
secretion in β-ARNT KO islets under these conditions, indicate possible defects in the Ca2+ 
influx. At 12 mM glucose, β-ARNT KO islets secreted 19 % less insulin compared to control 
islets indicating a key role for ARNT/HIF-1β in the metabolic amplifying pathway of GSIS.  
 
Anaplerosis and signals generated from glucose-stimulated anaplerosis play critical role in 
the amplifying pathway of GSIS. Since pyruvate carboxylase (PC) is the master regulator of 
anaplerosis that modulates the flow of substrates through the anaplerotic pathway of the TCA 
cycle, we measured the expression of PC in β-ARNT KO islets. Loss of ARNT/HIF-1β leads 
to a 57% reduction in the expression of PC in pancreatic islets (Figure 30 B). Down-
regulation of PC will likely lead to a decrease in the substrate flux through the TCA cycle as 
shown previously in siARNT-treated 832/13 cells (249), thus having an impact on the 
generation of anaplerotic signals necessary for GSIS.  
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Figure 30: Involvement of amplifying pathway and anaplerosis in ARNT/HIF-1β mediated GSIS A) GSIS 
in β-ARNT KO islets in the presence of 30 mM KCl and 200 µM Diazoxide (Diaz) with either 2 mM (LG) or 
12 mM (HG) glucose B) qPCR analysis of pyruvate carboxylase (PC) expression in β-ARNT KO. Results 
represent mean ± SEM of 3- 4 independent experiments. * p<0.05 HG Control KCl+Diaz Vs HG β-ARNT KO 
KCl+Diaz. ** p<0.01 HG Control vs. HG β-ARNT KO islets,  p<0.01 LG Control KCl+Diaz vs. LG β-ARNT 
KO KCl+Diaz, #p<0.05 Control HG Vs Control HG+KCl, ## p<0.01 PC expression in Control vs. β-ARNT 
KO islets. Student’s t-test. 
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of DMAKG and DMM, membrane permeable esters of alpha ketoglutarate and malate and 
assessed insulin secretion in the presence of 12 mM glucose. Both DMAKG and DMM were 
shown to increase insulin secretion in the presence of glucose through stimulation of the 
anaplerotic pathway (70,77,245). As shown in Figure 31A, in the presence of 12 mM 
glucose, insulin secretion was decreased by around 30% in β-ARNT KO islets. However, the 
addition of 5 mM each of DMAKG and DMM nearly doubled GSIS in both control and β-
ARNT KO islets.  
 
A similar rescue experiment was also carried out in 832/13 cells treated with siARNT. In 
these clonal cells, a glucose concentration of 7 mM was found to be optimal for the 
potentiating action of DMAKG and DMM. Both siControl and siARNT cells were treated 
with 5 mM each of DMAKG and DMM in the presence of 7 mM glucose. A shown in Figure 
31 B, siARNT-treatment resulted in almost 50 % reduction in GSIS compared to siControl 
cells. However, GSIS was rescued to almost near-normal levels by the addition of DMAKG 
and DMM along with 7 mM glucose. These results show that GSIS can be rescued in β-
ARNT KO islets if the flow of substrates through the TCA cycle is maintained, suggesting 
that abnormal insulin secretion could be attributed to impaired anaplerosis.   
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Figure 31: Effects of dimethyl malate (DMM)+dimethyl alpha-ketoglutarate (DMAKG) treatment on 
GSIS. A) GSIS in β-ARNT KO islets with either 2 mM (LG) or 7 mM Glucose (HG) and in the presence of 5 
mM DMM+DMAKG with HG. B) GSIS in 832/13 cells treated with either siControl or siARNT with either 2 
mM (LG) or 7 mM (HG) glucose and 5 mM DMM +DMAKG with HG. Results represent mean ± SEM of 3-6 
independent experiments. *p<0.05 Control HG Vs Control HG +DMM+DMAKG, ** p <0.01 Control HG Vs 
β-ARNT KO HG; p<0.05 siControl HG Vs siControl HG+DMM+DMAKG, p<0.001 siControl HG Vs 
siARNT HG. Student’s t-test. 
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4.4.12 Measurement of NADPH: NADP ratio  
To understand the nature of the amplifying signals that may be blunted in the absence of 
ARNT/HIF1β, we decided to investigate glucose induced rise in NADPH: NADP ratio in 
832/13 cells treated with siARNT.  It is generally believed that stimulation of insulin 
secretion by glucose leads to a rise in metabolic coupling factors like NADPH 
(67,72,91,253,254). As shown in Figure 32 A, B a two-fold rise in NADPH: NADP ratio was 
observed in siControl-treated 832/13 cells when glucose concentration was raised from 2mM 
to 16.7 mM. However, the glucose induced rise in NADPH: NADP ratio was negligible in 
siARNT-treated 832/13 cells. 
  
Figure 32: Effect of siARNT-treatment of NADPH: NADP ratio in 832/13 cells. A) 832/13 cells were 
treated with siControl or siARNT. NADPH and NADP levels were measured as described in “Experimental 
Procedures” in 832/13 cells exposed to either 2 mM (LG) or 16.7 mM glucose (HG). B) Data in (A) represented 
as HG/LG fold change in NADPH/NADP ratio in siControl and siARNT 832/13 cells. Results represent the 
mean ± SEM for 4 independent experiments. *p<0.05 siControl Vs siARNT. Student’s t-test.  
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4.4.13 Intracellular Calcium Measurements in β-ARNT KO Islets 
Calcium (Ca2+) is yet another essential signal in the stimulus-secretion coupling that is 
critical to trigger insulin granule exocytosis. Ca2+ also plays a key role in the activation of 
many mitochondrial dehydrogenases that can stimulate cellular respiration (255). To 
investigate whether impairment in GSIS observed in β-ARNT KO islets is due to changes in 
intracellular Ca2+ levels, we measured intracellular Ca2+ concentrations in response to change 
in glucose concentration using Fura-2AM, a ratiometric Ca2+ indicator (Figure 33 A, B). We 
did not find any difference in Ca2+ under low glucose conditions (2 mM) between control and 
β-ARNT KO islets.  However, upon stimulation with 20 mM glucose, intracellular Ca2+ 
levels were 26.4% less in β-ARNT KO islets compared to control islets. To see whether the 
reduction in intracellular Ca2+ could be due to changes in the activity of the voltage-gated 
calcium channels, direct depolarization of the beta-cell plasma membrane was induced by 30 
mM KCl. We observed a small but significant reduction in intracellular Ca2+ levels (19.7%) 
in β-ARNT KO islets compared to control islets upon KCl stimulation in the presence of 20 
mM glucose. Our data indicates that loss of ARNT/HIF-1β leads to a reduction in glucose 
induced calcium influx and it may be caused by abnormalities in the activity of the calcium 
channels. 
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Figure 33: Changes in intracellular Ca2+ in β-ARNT KO islets A) Representative kinetic trace of the 
Fura2AM fluorescent signal from pooled β-ARNT KO islets (red trace) and control (black trace) islets; glucose 
(glc) B) Average calcium influx under low glucose (LG; 2 mM glucose), high glucose (HG; 20 mM glucose) 
and high glucose plus KCl (20 mM HG + 30 mM KCl) in control (black bar) and β-ARNT KO islets (red bar). 
Results represent mean ± SEM of 3 independent experiments (n=3 - 4 mice per genotype). *** p<0.001 for HG 
Control vs HG β-ARNT KO islets,  p<0.001 HG+KCl Control Vs HG+KCl β-ARNT KO islets. Student’s t-
test. 
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4.5 DISCUSSION 
In the previous chapter, we characterized the metabolic phenotype of INS-1 derived 832/13 
cells where siRNA mediated knock down of ARNT/HIF-1β led to impairments in glucose-
stimulated anaplerosis and insulin secretion (249). In the present study, we generated a 
pancreatic beta-cell specific ARNT/HIF-1β knock-out mouse using the Cre-loxP system, 
where the Cre expression was driven by a rat insulin promoter. Using isolated islets from β-
ARNT KO mice, we further characterized the defective insulin secretion that is inherent in 
these islets and identified the metabolic amplifying signals that are necessary for 
ARNT/HIF1β-mediated GSIS. Our study indicates that ARNT/HIF-1β is critical for 
maintaining the normal secretory function of pancreatic beta-cells in mice. However, 
contrary to previous results (164) both male and female β-ARNT KO mice generated for this 
study have normal glucose homeostasis. Further analysis into the whole body metabolic 
phenotype of β-ARNT KO mice shows slightly but significantly higher preference for 
carbohydrate utilization leading to an increase in RER. This suggests a possible activation of 
a compensatory pathway in the peripheral tissues leading to normal glucose clearance and 
maintenance of normal glucose homeostasis in β-ARNT KO mice.  
 
The lack of glucose intolerance in β-ARNT KO mice was an unexpected outcome of this 
study. Gunton et al., (164) had reported impaired glucose tolerance in both male and female 
β-ARNT KO mice. The difference in results could be due to the following reasons: 1) Use of 
specific controls – Studies have shown that presence of RIP-Cre transgene alone can lead to 
glucose intolerance in mice (250). Therefore, all control animals used in our study were 
positive for the Cre transgene. In contrast, the glucose tolerance test conducted for β-ARNT 
KO mice in Gunton et al’s study was compared only to the floxed littermates. 2) Differences 
in the background strain of mice used for generating knock-out models can often lead to 
differences in phenotypes as observed in beta-cell specific HNF-4α knock-out mice 
(212,213). Further investigation is indeed needed to assess the differences observed between 
the β-ARNT KO mice in these two studies. Maintenance of whole body glucose homeostasis 
mainly depends on the uptake and storage of glucose by peripheral tissues such as skeletal 
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muscles, adipose tissue and liver (256). The observation that β-ARNT KO mice have higher 
RER compared to control mice suggests a few possibilities. Considering the fact that indirect 
calorimetry provides an index of overall substrate disappearance rates and not substrate 
oxidation rates (257), a higher RER in β-ARNT KO mice could be an indication that 
peripheral tissues would utilize more glucose, leading to improved glucose clearance from 
the blood stream. If this is the case, then it may result in changes in the glycogen reserves in 
the muscles of β-ARNT KO mice compared to the control mice, depending on whether 
glucose is utilized in the oxidative pathway or non-oxidatively stored as glycogen. In 
addition, our β-ARNT KO mice showed comparable or slightly improved (non-significant) 
insulin sensitivity in skeletal muscles leading to similar glucose tolerance as control mice. 
Lima et al had proposed a role for muscle HIF-1 (HIF-1α and ARNT/HIF1β) in glucose 
homeostasis where HIF-1 up-regulated the expression of GLUT-4 mRNA following muscle 
contraction (258). However, we did not study the expression of GLUT-4 in the muscles of β-
ARNT KO mice. The involvement of the central nervous system (CNS) in the regulation of 
whole body glucose sensing in β-ARNT KO mice was also ruled out as we did not find any 
changes in metabolic parameters that are typically regulated by the CNS such as food intake 
or body weight. This suggests that hypothalamic glucose sensing may not be impaired in β-
ARNT KO mice. Consistent with this, ablation of ARNT/HIF-1β in hypothalamic POMC 
neurons leads to overeating and obesity indicating that HIF-mediated signalling in the 
hypothalamus is required for maintaining glucose sensing and energy balance in mice and 
this was found to be mostly mediated through HIF-2α - ARNT/HIF-1β partnership (259). 
Further investigation is indeed necessary to assess how local inhibition of ARNT/HIF-1β can 
evoke compensatory responses in the peripheral tissues. 
 
Our results with isolated islets from β-ARNT KO mice clearly indicate that ARNT/HIF-1β is 
necessary for normal insulin secretion. The fact that the two signals critical for insulin 
secretion, namely, the rise in NADPH/NADP ratio and rise in intracellular Ca2+, are both 
regulated by ARNT/HIF-1β is a new discovery. As shown earlier in this thesis, loss of 
ARNT/HIF-1β in 832/13 cells leads to a decrease in glucose-induced rise in TCA cycle 
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intermediates (249). Others have shown that reduction in mitochondrial substrate availability 
also leads to reduction in the generation of cytosolic NADPH (260). Therefore, loss of 
NADPH/NADP ratio was an expected outcome of ARNT/HIF-1β protein deletion. An 
increasing amount of evidence suggests that anaplerosis is very important for GSIS 
(72,79,240). Whether TCA cycle intermediates play a direct role or indirectly assist insulin 
secretion is largely unknown. However, it is important to note that some of these TCA cycle 
intermediates should be exported from the mitochondria to the cytosol and may have extra-
mitochondrial signalling activity, where they aid in potentiating or triggering insulin 
secretion (65,66,68,204). NADPH has long been proposed as one such signalling molecule 
important for insulin secretion, as the ratio of this pyridine nucleotide increases in direct 
proportion with glucose and GSIS. Also, addition of NADPH has been shown to cause 
exocytosis of insulin granules in beta-cells (67,72,91). The fact that loss of GSIS in β-ARNT 
KO islets and 832/13 cells with low levels of ARNT/HIF-1β could be restored to near-
normal levels by treatment with TCA cycle intermediates namely DMAKG and DMM 
provides further proof that ARNT/HIF-1β plays a critical role in maintaining glucose-
stimulated anaplerosis and signals generated thereof in the regulation of insulin secretion 
from pancreatic beta-cells. 
 
In conclusion, the data presented here clearly shows the critical role played by ARNT/HIF-1β 
in maintaining the secretory function of pancreatic beta-cells mainly through the regulation 
of anaplerosis, glucose-stimulated rise in NADPH/NADP ratio and rise in intracellular Ca2+ 
levels. In vivo, contrary to previous reports, loss of ARNT/HIF-1β does not subject the mice 
to glucose intolerance, possibly due to the activation of a compensatory mechanism in the 
peripheral tissues as suggested by the higher RER in the knock-out mice. However, the exact 
nature of this compensation is currently unknown.  
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Chapter 5 
Summary and Conclusions 
5.1 Summary of Findings 
5.1.1 In vitro Findings from siARNT-treated 832/13 Beta-Cell Line 
• The following parameters were found to be significantly reduced in siARNT-treated 
832/13 cells compared to siControl-treated cells: 
1) Insulin secretion in response to glucose, IBMX and palmitate 
2) Glucose utilization or glycolytic flux 
3) Glucose-stimulated anaplerosis 
4) Glucose-stimulated rise in NADPH/NADP ratio 
5) Gene expression of PC, PDH, DIC, OGC, MEc, CPT1, FAS and GPR40 
• No significant differences were observed between siARNT and siControl-treated 
832/13 cells in the following parameters: 
1) Insulin secretion in response to amino acids  
2) Glucose oxidation 
3) ATP/ADP ratio 
5.1.2 In vivo Findings from β-ARNT KO Mice 
• RER was found to be slightly, but significantly higher in β-ARNT KO mice 
• No significant differences were observed between β-ARNT KO mice and control 
mice in the following parameters: 
1) Body weight 
2) Fasting blood glucose 
3) Glucose tolerance 
4) Insulin sensitivity 
5) Feeding and activity 
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5.1.3 In vitro Findings from β-ARNT KO Islets 
• The following parameters were found to be significantly reduced in islets from β-
ARNT KO mice compared to islets from control mice: 
1) Insulin secretion in response to glucose, KCl and diazoxide 
2) Glucose-stimulated rise in intracellular calcium 
3) Gene expression of anaplerotic enzyme, PC 
• No significant differences were observed between islets from β-ARNT KO and 
control mice in the following parameters: 
1) Insulin secretion in response to DMM, DMAKG in the presence of glucose 
2) Glucose oxidation 
3) Mitochondrial membrane potential 
 
5.2 Conclusions  
The alarming rise in the incidence of T2D across the globe calls for better understanding of 
the disease and development of better therapeutic options to manage or delay the onset of the 
disease. Pancreatic beta-cell dysfunction leading to decreased insulin secretion is one of the 
hallmark features of T2D. In addition, people with T2D also have lowered sensitivity to 
insulin in the peripheral tissues such as the skeletal muscles, the liver and the adipose tissue, 
leading to whole body insulin resistance. Indeed, improving insulin sensitivity and increasing 
insulin secretion by the pancreatic beta-cells require proper understanding of the mechanisms 
that govern these processes in our body. Therefore, before we begin to develop new 
therapeutics for the treatment of T2D, it is imperative that we understand the biology of the 
pancreatic beta-cells and the basic mechanisms that regulate glucose-stimulated insulin 
secretion (GSIS).  
The mechanism of GSIS from pancreatic beta-cells has been well studied for the past several 
decades. Unlike hormones and neurotransmitters, which binds their beta-cell receptors and 
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stimulates insulin secretion through the classical PKA or PKC signal transduction pathway, 
the mechanism that governs GSIS from pancreatic beta-cells is mainly dependent on its 
ability to act as a fuel sensor, metabolize these fuels and adapt to the variation in plasma 
concentration of glucose and other nutrients (56,200,261). Accordingly, the best-
characterized pathway of GSIS, also known as the KATP dependent pathway, produces the 
triggering signals, namely, the rise in ATP/ADP ratio and increase in intracellular Ca2+, for 
the exocytosis of insulin granules. A second pathway that has gained wide popularity is the 
KATP independent pathway, which is largely based on the ability of glucose to amplify insulin 
secretion even in the absence of a functional KATP channel (64,262). Here, it is generally 
believed that glucose does not cause any further increase in intracellular Ca2+, but increases 
its efficacy on the exocytotic machinery. It is also believed that mitochondrial metabolism of 
glucose generates signals other than ATP, which play a critical role in further amplification 
of insulin granule exocytosis. Although the existence of this pathway is widely accepted, the 
underlying mechanisms that govern this pathway are still unclear.  
Dissection of the transcriptional network and genetic regulators of pancreatic beta-cells has 
led to the identification of a number of genes that are critical for proper maintenance of beta-
cell function and insulin secretion. One potentially important player in the pathogenesis of 
beta-cell dysfunction leading to T2D is ARNT/HIF1β. Since its discovery in 2005 as the 
most down-regulated gene in human type 2 diabetic islets and as a positive regulator of 
insulin secretion, a number of research groups have evaluated its role, not just in the beta-
cells, but also in other metabolically active tissues in our body. The main objective of our 
study was to investigate the metabolic phenotype of beta-cells deficient in ARNT/HIF-1β and 
understand how the transcription factor regulates GSIS from the beta-cells and assists in the 
maintenance of glucose homeostasis in mice. 
5.2.1 Conclusions from siARNT-treated 832/13 cells and β-ARNT KO Islets  
Consistent with its role as a positive regulator of glucose metabolism, we found that loss of 
ARNT/HIF-1β in 832/13 cells led to a significant reduction in GSIS and glucose-stimulated 
rise in glycolysis. However, we found that this reduction in the rate of glycolysis neither 
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affected the rate of glucose oxidation nor the amount of ATP synthesized by the beta-cell 
mitochondria. These data clearly demonstrated that the mechanism of regulation of GSIS by 
ARNT/HIF-1β was independent of rise in ATP/ADP ratio, which is one of the most 
important triggering signals required for GSIS from beta-cells. This also suggested that 
regulation of GSIS by ARNT/HIF-1β was mediated through mechanisms or pathways that 
are independent of the KATP channel function. As mentioned previously, studies conducted by 
multiple groups had suggested the importance of mitochondrial pathways of glucose 
metabolism and the signals generated by these pathways in the regulation of GSIS. To gain a 
better understanding of the metabolic pathways that are regulated by ARNT/HIF1β, a 
metabolite profiling of 832/13 cells with low ARNT/HIF-1β levels was performed using GC-
MS. The results yielded from this study were very dramatic as we discovered a significant 
decrease in most glycolysis and TCA cycle intermediates in the absence of ARNT/HIF1β. 
Not only did the loss of ARNT/HIF-1β affects glucose metabolism pathway, but it also 
negatively impacted the fatty acids and the amino acids pathway.  On further investigation, it 
was revealed that ARNT/HIF-1β regulates a number of genes that are critical for the 
maintenance of the anaplerotic pathway and pyruvate cycling such as PC, PDH, DIC, OGC 
and MEc, which were all shown to be crucial for the maintenance of GSIS from the beta-
cells. Especially, the down-regulation of PC, the critical regulator of anaplerosis, was 
significant in both siARNT-treated 832/13 cells and β-ARNT KO islets. Loss of PC 
expression has a severe impact on GSIS as demonstrated by siRNA and pharmacological 
inhibition of PC in 832/13 cells as well as in rat islets (70,72,246,263,264). PC mediated 
anaplerosis not only helps to export the TCA intermediates from the mitochondria to the 
cytoplasm where they serve as amplifying signals for insulin secretion, but studies have 
shown that loss of PC decreased both first and second phase insulin secretion and ATP/ADP 
ratio in rat islets suggesting that it helps in the generation of sufficient ATP to regulate both 
phases of GSIS. Consistent with the observation that ARNT/HIF-1β regulates the PC-
mediated anaplerotic pathway, it was not surprising to see that loss of ARNT/HIF-1β tends to 
have a negative impact on NADPH/NADP ratio. NADPH is an expected by-product of all 
three pyruvate cycling pathways and is considered to be one of the most important signalling 
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molecules generated by the mitochondrial metabolism of glucose for the maintenance of the 
amplifying pathway of GSIS. Taken together, our results from 8321/13 cells clearly suggest a 
critical role for ARNT/HIF-1β in maintaining GSIS from pancreatic beta-cells.  
The biochemical characterization of β-ARNT KO islets also yielded similar results as 
observed in 8321/3 cells and clearly suggested the involvement of ARNT/HIF-1β in the 
regulation of GSIS through amplifying or the KATP independent pathway of insulin release. 
Islets obtained from both male and female β-ARNT KO mice showed severe and significant 
impairments in GSIS. Monitoring β-ARNT KO islets for changes in mitochondrial 
membrane potential in response to glucose, which also serves as a surrogate marker for ATP 
production, yielded results that implied the lack of involvement of ARNT/HIF-1β in the 
regulation of the ATP-dependent triggering pathway of GSIS. This was further confirmed by 
the results obtained from the oxygen consumption studies using Seahorse flux analyzer in β-
ARNT KO islets, where the rate of oxygen consumption in β-ARNT KO islets in response to 
glucose, yet another indicator of cellular ATP production, was found to be similar in control 
and knock-out islets. Insulin secretion studies using KCl and diazoxide were used to 
investigate the functionality of the amplifying pathway or the KATP independent pathway in 
β-ARNT KO islets and the results indicated a defect in this pathway. Consistent with this, 
addition of anaplerotic and pyruvate cycling intermediates DMAKG and DMM restored 
insulin secretion in β-ARNT KO islets, suggesting the involvement of anaplerosis in the 
regulation of GSIS mediated by ARNT/HIF1β. Both alpha ketoglutarate and malate are part 
of the pyruvate cycling pathways, which aid in the influx of pyruvate to the mitochondria to 
enter the TCA cycle and promote the efflux of TCA intermediates such as citrate and malate 
for the generation of amplifying signals (70,245,265). Besides the fact that DMAKG and 
DMM are the most widely used methyl esters of alpha-ketoglutarate and malate, one of the 
compelling reasons to use them in our study was the fact that both these TCA intermediates 
were found to be critically low in 832/13 cells in the absence of ARNT/HIF1β. Use of DMM 
has previously been shown to increase GSIS through increasing pyruvate cycling and 
anaplerosis (70). Alpha-ketoglutarate serves several functions in pancreatic beta-cells. It 
helps in the proper maintenance of the malate-aspartate shuttle and in the transportation of 
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NAD+ from the mitochondria to the cytosol for its re-use in glycolysis (71,266). Research 
also suggests that there is no fuel insulin-secretagogue that is incapable of producing alpha-
ketoglutarate and in addition to its role in the maintenance of TCA cycle and as a precursor 
for anaplerosis, it may also have a signalling role in the beta-cells. Specifically, alpha-
ketoglutarate is a substrate for several alpha-ketoglutarate hydroxylases or dioxygenases, 
which are involved in the post-translational hydroxylation of proteins (225,267). Taken 
together, the recovery of insulin secretion by DMAKG and DMM suggest that loss of GSIS 
in β-ARNT KO islets is partially mediated through alterations in the metabolic fate of 
pyruvate and the associated signalling molecules generated from potential pyruvate cycling 
pathways.  
One of the main findings from the studies using β-ARNT KO islets is the significant decrease 
in the influx of intracellular Ca2+ in response to high glucose as well as high glucose and 
KCl. The triggering Ca2+ signalling is an essential part of GSIS, which ensures the exocytosis 
of insulin granules (242). The importance of Ca2+ in GSIS was further strengthened by the 
observation that any experimental condition that interferes with the rise in intracellular Ca2+ 
impairs GSIS, whereas physiological or pharmacological agents, that increase beta-cell 
intracellular Ca2+, regardless of the mechanism, induce insulin secretion (268). In fact, many 
of the T2D drugs used to enhance insulin secretion thrive on this mechanism (269). Drugs 
such as the sulfonylureas, stimulate insulin secretion by binding to the beta-cell KATP 
channels, depolarizing the plasma membrane, inducing a rise in intracellular Ca2+, which 
then triggers the exocytosis of insulin granules. Although the supremacy of the KATP channel 
dependent pathway in the stimulation of intracellular Ca2+ influx is very evident, it should be 
noted that promotion of Ca2+ influx is not always a KATP channel dependent event (58). 
Insulin secretagogues such as KCl or amino acids such as arginine or alanine can cause beta-
cell membrane depolarization and promote Ca2+ influx without affecting the KATP channels. 
Also, studies from mice lacking KATP channels SUR1 or Kir6.2 in beta-cells indicate that 
glucose can still elicit insulin secretion in a KATP independent manner by promoting 
membrane depolarization and influx of Ca2+ (63). The Ca2+ data obtained from β-ARNT KO 
islets in the presence of high glucose and high KCl indicates possible defects in the voltage 
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dependent Ca2+ channels and points to the possibility that defects may be independent of the 
KATP channels. The essential role played by L-type Ca2+ channels in the influx of extracellular 
Ca2+ is undisputable (270). However, a concerted activation of a variety of channels 
contributes to Ca2+ influx during the triggering and the amplifying phase of insulin release. 
Particularly, it has been shown that genetic or pharmacological inhibition of the R-type 
channels (CaV2.3) lead to a significant reduction in the second phase or the amplifying phase 
of GSIS both in vitro and in vivo in mice (271). Reduced Ca2+ response to KCl in β-ARNT 
KO islets could also be therefore attributed to a defect in the channel activity of the R-type 
channels, however, this was not further investigated in our study.  
Overall, our study clearly shows that ARNT/HIF-1β regulates GSIS predominantly through 
the KATP independent pathway of insulin release and that it is required to maintain glucose-
stimulated anaplerosis and generation of anaplerotic signal, NADPH. In addition, 
ARNT/HIF-1β is required to maintain the influx of intracellular Ca2+ in response to glucose, 
most likely independent of the activity of the KATP channels.  
5.2.2 Conclusions from β-ARNT KO Mice 
The unexpected outcome of this study was the lack of a diabetic phenotype in both male and 
female β-ARNT KO mice. β-ARNT KO mice were born at expected Mendelian ratios and 
did not differ in size or weight from their control littermates. Metabolic parameters that are 
indicative of abnormal glucose homeostasis such as fasting blood glucose measurements and 
the intraperitoneal glucose tolerance test were normal and comparable to control mice, 
indicating that secretory abnormalities observed in islets from β-ARNT KO mice did not 
translate to glucose intolerance in our model of mice. This was quite an interesting outcome 
since Gunton et al had previously shown that both male and female β-ARNT KO mice were 
glucose intolerant (164). Based on the fact that ARNT/HIF-1β is a metabolic regulator and to 
determine whether beta-cell specific deletion of ARNT/HIF-1β has any impact on the whole 
body metabolic phenotype, indirect calorimetry was used in β-ARNT KO mice to measure 
complex metabolic parameters such as food intake, activity, energy expenditure, volume of 
O2 (VO2) consumed and CO2 (VCO2) expelled and respiratory exchange ratio (RER) under 
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ad libitum conditions. Except for RER which we found to be slightly but significantly 
increased in β-ARNT KO mice, we did not find any significant changes in other metabolic 
parameters in β-ARNT KO mice. An increase in RER (VCO2/VO2) and a value that is closer 
to 1 in β-ARNT KO mice is indicative of increased carbohydrate utilization compared to 
control mice. Typically RER values are also indicative of metabolic flexibility, which is the 
body’s capacity to match fuel oxidation to fuel availability (272). A higher RER in the post-
prandial or fed state, conditions under which β-ARNT KO mice were analyzed, is often 
associated with increased sensitivity to insulin and lower RER is associated with obesity, 
insulin resistance and T2D. T2D patients are often found to metabolically inflexible, 
meaning, they are unable to efficiently switch to carbohydrate oxidation in the post-prandial 
state and often have to depend on oxidation of lipids for energy expenditure, reducing the 
RER values (273,274). Based on this, an increased RER in β-ARNT KO mice also suggests 
two things 1) increased sensitivity of muscle tissues to insulin, leading to better glucose 
disposal 2) skeletal muscles in β-ARNT KO mice are metabolically more flexible than 
control mice, protecting them from hyperglycemia.  Although our insulin tolerance test did 
not show a statistically significant increase in overall insulin sensitivity in both male and 
female β-ARNT KO mice, these mice generally responded better to exogenous insulin 
compared to their control littermates and statistically significant results were obtained at 60 
minutes in male β-ARNT KO mice, indicating better insulin stimulated glucose uptake. 
Results from both RER and insulin tolerance tests were indicative of improved functioning of 
the skeletal muscles, as systemic substrate use is largely dependent on the muscles compared 
to any other metabolically active peripheral organs in our body. Thus, based on the data 
generated from this study, disruption of ARNT/HIF-1β in pancreatic beta-cells does not lead 
to glucose intolerance in mice. Although islets from β-ARNT KO mice secrete less insulin 
compared to their controls, these mice seemed to be protected from hyperglycemia through 
increased utilization of carbohydrates through the skeletal muscles possibly leading to 
improvements in overall glucose clearance from the body.  
   118 
5.3 Does Loss of ARNT/HIF-1β in Pancreatic Beta-cells Play a Role in the 
Progression of T2D? 
T2D generally results from the inability of pancreatic beta-cells to secrete enough insulin 
over time to compensate for the insulin resistance that is evident in our body. Maintenance of 
normal beta-cell function requires the expression of key transcription factors, which assist in 
the optimal expression of genes that are critical for mature beta-cell function such as 
maintenance of beta-cell mass and insulin secretion. This is supported by several studies 
where the functional significance of these transcription factors has been critically evaluated 
through loss of function or gain of function analysis, both in vitro and in vivo (207,275,276). 
Our in vitro data from 832/13 cells and β-ARNT KO islets clearly indicates a critical role for 
ARNT/HIF-1β in maintaining normal beta-cell function and insulin secretion. As observed in 
Gunton’s study (164), where ARNT/HIF-1β was found to regulate key genes involved in 
glucose metabolism, our study also recognizes the importance of ARNT/HIF-1β in 
maintaining the expression of several key genes involved in both arms of glucose 
metabolism, namely, glycolysis and the TCA cycle, thereby regulating glucose-stimulated 
anaplerosis and GSIS from pancreatic beta-cells. However, the in vivo data obtained from β-
ARNT KO mice in our study was quite a contrast to the data obtained from Gunton’s study 
where both male and female β-ARNT KO mice were found to be glucose intolerant. It was 
indeed intriguing to see that the in vitro impairment in GSIS in the absence of ARNT/HIF-1β 
did not translate to an in vivo diabetic phenotype resulting in glucose intolerance and 
hyperglycemia as reported by Gunton’s study. Not only did our model of β-ARNT KO mice 
have normal glucose homeostasis, but we discovered that maintenance of normal glucose 
homeostasis was achieved through a small but significant up-regulation of carbohydrate fuel 
oxidation in the skeletal muscles.  Therefore, based on our results, loss of ARNT/HIF-1β 
specifically in pancreatic beta-cells does not lead to abnormal glucose homeostasis, resulting 
in type 2 diabetes in mice. However, our study has presented compelling evidence showing 
the requirement of ARNT/HIF-1β in maintaining normal glucose-stimulated insulin secretion 
and normal beta-cell function in mice. Over time, lack of ARNT/HIF-1β may severely 
impact beta-cell function creating a perfect storm for the genesis of type 2 diabetes.  
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Collectively, the results obtained from site-specific deletions of ARNT/HIF-1β in 
metabolically active tissues such as the pancreas, the liver and the adipose tissue, indicates an 
important role for this transcription factor in maintaining metabolic homeostasis 
(164,170,173,183). Given the known alteration of ARNT/HIF-1β and its binding partner 
HIF-1α in diabetic pancreatic beta-cells and diabetic liver of humans, it is quite reasonable to 
speculate that the HIF-signalling pathway plays a central role in the pathogenesis of type 2 
diabetes in humans as seen in mice. However, more studies are definitely needed for an in-
depth understanding of the complexities involved in HIF-1 signalling and to explain the 
phenotypic and metabolic disparities that exist in mice models generated by different 
research groups where HIF-1 signalling is impaired as observed in adipocytes and pancreatic 
beta-cells specific HIF-1α and ARNT/HIF-1β knock-out mice. 
5.4 Future Directions 
5.4.1 Further Studies on β-ARNT KO Mice 
1. In vivo Insulin Measurements: Plasma insulin measurement is an important 
indicator of whole body glucose homeostasis and progression of type 2 diabetes. 
Although islets from β-ARNT KO mice secreted significantly less insulin compared 
to their control littermates, these mice maintained normal glucose homeostasis. 
Therefore, it will be interesting to measure the plasma insulin levels, as it will add an 
additional layer to defining the mechanistic role of ARNT/HIF-1β in maintaining 
normal glucose homeostasis.  
2. Examining Skeletal Muscle Glucose Uptake and Storage in β-ARNT KO Mice: 
Increased RER in β-ARNT KO mice is suggestive of higher glucose uptake and 
utilization by the muscle tissue. However, we did not investigate whether this is true 
for β-ARNT KO mice and if it is, then what would be the mechanism behind 
improved glucose uptake by the muscles in β-ARNT KO mice. Skeletal muscles 
dispose off glucose through the oxidative pathway or the non-oxidative pathway, 
where it is stored as glycogen. A very small amount of glucose is also stored as fat via 
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de novo lipogenesis in the skeletal muscles. Studies have shown that, in normal 
people, 80% of the ingested glucose is stored in the muscle as glycogen (36,277). 
Studies using hyperglycemic - hyperinsulinemic clamps in type 2 diabetic patients 
have shown that rate of glycogen synthesis in type 2 diabetic patients is 50% less than 
that observed in normal healthy individuals (278). Insulin stimulated glucose uptake 
by skeletal muscles is largely dependent on the uptake of glucose by the insulin-
responsive glucose transporter, GLUT4.  Once inside the cell, glucose is 
phosphorylated by hexokinase, converting it to hexose 6-phosphate. Hexose 6-
phosphate is then utilized to enter the oxidative pathway or the non-oxidative 
pathway where it is converted to muscle glycogen by glycogen synthase.13C magnetic 
resonance studies have shown that transport of glucose by GLUT 4 is the rate-
limiting step in glucose uptake process by the skeletal muscles (279). Studies have 
also shown that insulin-stimulated glucose uptake is dependent on the translocation of 
GLUT 4 from the endosomal compartment to the plasma membrane facilitating the 
uptake of glucose into the muscle cell for its phosphorylation by the hexokinase 
(280). Based on the increased RER values obtained from β-ARNT KO mice, it may 
be reasonable to expect muscle glucose uptake to be slightly but significantly better in 
β-ARNT KO mice compared to their controls. It will also be interesting to determine 
the level of expression of GLUT 4 in the muscles of β-ARNT KO mice as increased 
responsiveness of the muscle tissue to glucose may also be due to increased 
expression of GLUT 4. These few pieces of information will provide a more complete 
story of the observed normoglycemia in β-ARNT KO mice. 
3. β-ARNT KO Mice and High Fat Diet: A chronic high fat diet (HFD) will be an 
interesting way to investigate whether environmentally induced metabolic stress can 
impact the metabolic phenotype of β-ARNT KO mice.  With dysfunctional beta-cells, 
it will be interesting to see whether β-ARNT KO mice are protected from the adverse 
effects of HFD as observed in adipocyte-specific ARNT/HIF-1β knock-out mice 
(183) or they will be unable to cope with the increased energy demand. The adipocyte 
specific deletion of ARNT/HIF-1β and HIF-1α in mice leads to protection from the 
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consequences of HFD, which was attributed to an increase in insulin signalling in 
adipose tissue, the liver and the muscles. The adipocyte-specific HIF-1α mice also 
exhibited central effects with an increase in core temperature and energy expenditure, 
suggesting a cross-talk between the adipose tissue and the brain. On a normal chow 
diet, we did not observe a similar involvement of the central nervous system (CNS) in 
β-ARNT KO mice as there were no changes in metabolic parameters that are 
regulated by the CNS such as food intake and body weight. However, it will be 
interesting to see whether the same protection mechanisms will be activated in β-
ARNT KO mice under HFD.  
5.5 Final Remarks 
Based on our biochemical and molecular characterization of 832/13 cells treated with siRNA 
against ARNT/HIF-1β and islets from β-ARNT KO mice, we believe that ARNT/HIF-1β 
plays a central role in the maintenance of glucose-stimulated insulin secretion from the 
pancreatic beta-cells. The mechanism of insulin release mediated through ARNT/HIF-1β is 
independent of the KATP channels and increase in cellular ATP/ADP ratio, critical for the 
triggering of insulin granule exocytosis. However, ARNT/HIF-1β seems to play an important 
role in maintaining the KATP-independent or the amplifying pathway of insulin release, 
regulating glucose-stimulated anaplerosis and the key enzymes that are important to maintain 
normal substrate flow through the TCA cycle. Important stimulus-secretion coupling factors 
such as NADPH and Ca2+ seems to be impacted by the loss of ARNT/HIF1β, suggesting a 
need for the optimal expression of the transcription factor for the maintenance of metabolic 
signals critical for insulin secretion. In vivo, loss of ARNT/HIF-1β does not seem to affect 
glucose homeostasis in mice and β-ARNT KO mice seems to be protected from 
hyperglycemia through a small but significant increase in carbohydrate utilization, 
represented by the increased respiratory exchange ratios, the mechanism of which is 
currently unknown (Figure 34). Overall, our data demonstrates a critical need for the optimal 
expression of ARNT/HIF-1β in maintaining normal beta-cell function and we believe that 
our study provides significant information necessary for assessing the pharmacological 
potential of gene targets for the treatment of type 2 diabetes. 
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Figure 34: Schematics of the transcriptional network regulated by ARNT/HIF-1β and its involvement in 
GSIS. ARNT/HIF-1β regulates the expression of key enzymes in glycolysis and TCA cycle and regulates the 
expression of mitochondrial metabolite carrier proteins (denoted by green arrows and green boxes), which plays 
an important role in the generation of cytosolic second messengers such as NADPH. ARNT/HIF-1β has also 
shown to influence the expression of MODY genes, HNF-1α and HNF-4α making it a master regulator of beta-
cell transcriptional network. Metabolic processes such as anaplerosis, generation of NADPH and influx of Ca2+, 
critical for maintaining GSIS, are shown to be regulated by ARNT/HIF-1β. Insulin has been shown to regulate 
several metabolic genes through ARNT/HIF-1β-HIF-1α heterodimers, however, this has yet to be demonstrated 
in pancreatic beta-cells.
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